Nitrogen-linked benzisoxazole sulfonamide derivatives
Patent Information
- Application Number
- TW113137575
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2024-09-20
- Filing Date
- 2024-10-01
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2044-09-30
AI Technical Summary
There is a need for new inhibitors of KAT6A and KAT7 proteins, which are implicated in various cancers, to target their catalytic and non-catalytic functions for therapeutic intervention.
Development of novel nitrogen-linked benzisoxazole sulfonamide derivatives that act as inhibitors of MYST family lysine acetyltransferases (KAT) to regulate abnormal cell growth, including compounds of formula (I), (Ia), and (Ib), and their pharmaceutically acceptable salts, which can be used alone or in combination with other therapeutic agents.
These compounds effectively inhibit KAT6A and KAT7 proteins, potentially providing a therapeutic approach to treat cancers by targeting their role in abnormal cell growth and proliferation.
Smart Images

Figure TWG2TB001920325_001 
Figure TWG2TB001920325_002 
Figure TWG2TB001920325_003
Abstract
Description
Technical Field
[0001] The present invention relates to novel nitrogen-linked benzisoxazole sulfonamide derivatives that act as MYST family lysine acetyltransferase (KAT) inhibitors and are useful for treating abnormal cell growth in patients, such as cancer. The present invention also relates to pharmaceutical compositions containing the compounds and methods of using the compounds and the compositions to treat abnormal cell growth in patients. Prior Art
[0002] KAT enzymes play important regulatory functions in cancer and are therefore often targeted by mutations, translocations, and amplifications (Hu, Z. et al., Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nat Commun. 2019 Feb 13;10(1):733). KAT6A was discovered in 1996 as part of the chromosomal translocation t(8;16)(p11;p13) of CREB-binding protein (CREBBP) in a subtype of acute myeloid leukemia (AML) (Borrow, J. et al., The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 1996, 14, 33-41). Subsequently, additional KAT6A and KAT6B translocations were discovered in more AML patients, resulting in fusions with other HATs, such as adenovirus EIA-associated protein p300 (EP300), nuclear receptor coactivator 2 (NCOA2), and NCOA3 (Huang et al.).
[0003] In human cancers, especially breast cancer, KAT6A has been identified as part of a repetitively amplified region of 8p11-12 found in 10-15% of breast cancers (Adélaïde J. et al., Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer. 1998 Jul;22(3):186-99). Breast cancer cell lines containing KAT6A amplification overexpress KAT6A, suggesting that KAT6A is a putative breast cancer susceptibility gene. Turner-Ivey et al. used a genome-scale shRNA screening strategy to identify KAT6A as an important oncogene in 8p11 amplified breast cancer cell lines with KAT6A overexpression (Turner-Ivey B et al., KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia. 2014 Aug;16(8):644-55). Yu et al. subsequently demonstrated that KAT6A localizes to the estrogen receptor promoter in 8p11 amplified breast cancer cells and that shRNA-mediated attenuation of KAT6A reduces ESR1 mRNA and protein levels of ERα (Yu, L. et al., Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene 2017, 36, 2910-2918). Furthermore, they demonstrated that the growth defect caused by KAT6A depletion in 8p11 amplified breast cancer cells could be partially rescued by re-expression of ESR1. These findings suggest that KAT6A plays an important role in the genetic regulation of ERα required for the growth of ER+ breast cancer cells.
[0004] Chromosome 8p11-12 amplification and KAT6A overexpression are present in other tumor types, including ovarian cancer, cervical cancer, lung adenocarcinoma, colon and rectal adenocarcinoma, and medulloblastoma (Zack TI et al., Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013 45:1134-1140; Northcott PA et al., Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009 41:465-472). Other KAT6A-dependent tumors, including prostate cancer, have been identified (Yu C et al., High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016; Meyers RM et al., Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; and Tsherniak A et al., Defining a cancer dependency map. Cell. 2017). Overall, these data suggest that targeting KAT6A in other tumor types has broader therapeutic opportunities.
[0005] In addition to its catalytic function mediated by the histone acetyltransferase (HAT) domain, the KAT6A protein also includes other domains, such as the PHD domain, the acidic domain, and the serine / methionine domain. It has been reported that KAT6A regulates gene expression independently of its catalytic activity (Kitabayashi, I. et al., Activation of AML1 mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001, 20(24): 7184-7196). Attenuation of KAT6A protein levels using RNA interference confirmed the dependence of ER+ breast cancer cells on KAT6A (Turner-Ivey B. et al. and Yu, L. et al.). However, the requirement of KAT6A catalytic activity for ERα expression and ER+ breast cancer cell proliferation is still unclear.
[0006] KAT7 (HBO1 / MYST2) is a member of the MYST (MOZ, Ybf2 / Sas3, Sas2, and Tip60) family of histone lysine acetyltransferases that target histone and non-histone proteins for lysine acetylation (Neal, Pannuti et al., 2000, Roth, Denu et al., 2001, Yang 2004, Sapountzi and Cote 2011, Wang and Cole 2020). KAT7 exists as an enzymatic component of a four-membered protein complex that includes alternative adaptor proteins (which include JADE1 / 2 / 3 or BRPF1 / 2 / 3) as well as ING family proteins and MEAF6 (Doyon, Cayrou et al., 2006, Lalonde, Avvakumov et al., 2013). Post-translational modification of histone tails is a major mechanism for regulating chromatin structure and function and has been shown to play a key role in transcription, DNA damage repair, and DNA replication (Jenuwein and Allis 2001, Suganuma and Workman 2011, Allis and Jenuwein 2016). KAT7 enzymatically transfers the acetyl group of acetyl-CoA to the ϵ-amine group of the lysine residue CoA (Roth, Denu et al., 2001). KAT7 can accommodate other acyl-CoA cofactors to catalyze histone propionylation, butyrylation, and crotonylation, but not succinylation (Xiao, Li et al., 2021). The formation of KAT7 protein complexes with different scaffold proteins BPRF1 / 2 / 3 or JADE1 / 2 / 3 regulates the biochemical activity and substrate presence of histone H3 or histone H4, respectively (Doyon, Cayrou et al., 2006, Foy, Song et al., 2008, Kueh, Dixon et al., 2011, Mishima, Miyagi et al., 2011, Lalonde, Avvakumov et al., 2013, Tao, Zhong et al., 2017).
[0007] Other complex subunits ING4 / ING5 and MEAF6 regulate the recruitment and function of the KAT7 complex on chromatin through interactions with modified histones (Doyon, Cayrou et al., 2006, Champagne, Saksouk et al., 2008, Saksouk, Avvakumov et al., 2009, Palacios, Moreno et al., 2010, Matsuura, Tani et al., 2020, Barman, Roy et al., 2022). The combined functions of protein reader domains on KAT7 interacting proteins provide specificity for localizing the KAT7 complex on chromatin, including PHD domains (Doyon, Cayrou et al., 2006, Saksouk, Avvakumov et al., 2009, Klein, Muthurajan et al., 2016), PWWP domains (Zhang, Lei et al., 2021), and BROMO domains (Filippakopoulos and Knapp, 2012, Barman, Roy et al., 2022).
[0008] KAT7 was originally identified as a protein that binds to ORC1, the largest subunit of the initiation sequence recognition complex involved in DNA replication (Iizuka and Stillman 1999). In cervical cancer cells, the zinc finger of KAT7 interacts with MCM2, a key component of the pre-replication complex (Burke, Cook et al., 2001, Doyon, Cayrou et al., 2006). KAT7 has been reported to directly interact with CDT1, where KAT7 enhances CDT1-dependent re-replication at the origin of replicating DNA (Miotto and Struhl 2008), indicating that KAT7 plays a key role during initiation and elongation of DNA synthesis. Chromatin immunoprecipitation DNA sequencing (ChIP-seq) identified KAT7 binding at the origin of DNA replication (Feng, Vlassis et al., 2016, Xiao, Li et al., 2021). Consistent with the role of KAT7 in DNA replication, knockdown of KAT7 using siRNA caused a massive growth arrest of cancer cell lines during the S phase of the cell cycle (Doyon, Cayrou et al. 2006, Wu and Liu 2008).
[0009] In addition to its proposed role in DNA replication, there is evidence that KAT7 is involved in gene regulation through transcriptional regulation. The KAT7 complex binds to transcription start sites and gene coding regions (Saksouk, Avvakumov et al., 2009, Xiao, Li et al., 2021). When complexed with nuclear receptors, such as the progesterone receptor, the KAT7 MYST domain can act as a coactivator to increase the expression of target genes (Georgiakaki, Chabbert-Buffet et al., 2006). KAT7 also interacts with the androgen receptor in a ligand-dependent manner and can cause both activation and repression of AR target gene expression, indicating that KAT7 can act as a transcriptional activator and repressor (Sharma, Zarnegar et al., 2000, Mi, Ji et al., 2023). Expression of the N-terminal serine-rich region of KAT7 can inhibit TNFα-stimulated NF-κB activity in 293T cells through sequestration of cofactor binding, indicating that the non-catalytic function of KAT7 can also affect transcriptional regulation (Contzler, Regamey et al., 2006).
[0010] During mouse development, KAT7 acts as an essential activator of gene expression of genes that shape embryonic development after gastrulation. Knockout of the KAT7 gene in mouse embryos results in increased apoptosis, particularly affecting mesoderm organization and embryonic lethality at E10.5 (Kueh, Dixon et al., 2011). Conditional knockout of KAT7 in developing mice indicates that KAT7 functions in other tissues during development, including vascular endothelial cells (Grant, Hickey et al., 2021), bone marrow and fetal liver hematopoiesis (Mishima, Miyagi et al., 2011, Yang, Kueh et al., 2022), T cells (Newman, Voss et al., 2017), and neurons and oligodendrocytes (Kueh, Bergamasco et al., 2023). The Drosophila homolog of KAT7, chameau, is essential for larval development. Knockout of the chameau allele in developing embryos revealed a defect in homeotic transformation mediated by derepression of Hox gene expression (Grienenberger, Miotto et al., 2002).
[0011] Elevated expression of KAT7 has been found in a variety of cancers, including esophageal, bladder, testicular, breast, ovarian, and gastric cancers (Iizuka, Takahashi et al., 2009, Chen, Zhou et al., 2018, Wang, Chen et al., 2019, Guo, Li et al., 2022). In ER+ and HER2+ breast cancers, KAT7 has been identified as a common genomic amplification region on chromosome 17q21 (Hu, Stern et al., 2009). KAT7 regulates estrogen receptor-dependent transcription and can directly interact and acetylate estrogen receptor α (ERα), resulting in decreased protein stability (Iizuka, Susa et al., 2013). Inhibition of KAT7 in breast cancer cell lines results in loss of cell proliferation and blocks progression through the S phase of the cell cycle (Hu, Stern et al., 2009). Conversely, overexpression of KAT7 results in increased colony formation of breast cancer cell lines on soft agar (Hu, Stern et al., 2009). In breast cancer, CDK2 / cyclin E complex phosphorylates KAT7 in stem-like cells, which is abundant in the CD44hi / CD24lo population (Duong, Akli et al., 2013). KAT7 overexpression in breast cancer increases phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) transcription, leading to enhanced PI3K / AKT signaling and resistance to radiation therapy (Ma, Chen et al., 2023).
[0012] KAT7 acetyltransferase activity is associated with cancer pathways. KAT7 and related complex members ING4 and ING5 physically interact with the p53 tumor suppressor gene (Shiseki, Nagashima et al., 2003, Iizuka, Sarmento et al., 2008). KAT7 inhibition causes downregulation of a large number of genes involved in the p53 pathway of cell cycle control, senescence, and apoptosis (Avvakumov, Lalonde et al., 2012). KAT7 promotes bladder cancer cell proliferation by activating the Wnt / β-catenin signaling pathway (Chen, Zhou et al., 2018). In gastric cancer, KAT7 promotes the transcription and nuclear translocation of Yes-associated protein 1 (YAP1) through overexpression (Guo, Li et al., 2022).
[0013] In AML, KAT7 is overexpressed in leukemic stem cells, promoting the expression of HOXA9 and HOXA10 and maintaining the functional properties of leukemic stem cells. In MLL-rearranged AML, KAT7 acetylates histones to recruit MLL-fusion-associated adaptor proteins such as BRD4 and AF4 to gene promoters (Au, Gu et al., 2021, Takahashi, Kanai et al., 2021). In mouse models, KAT7 attenuation or small molecule inhibition reduces leukemic burden (Sauer, Arteaga et al., 2015, MacPherson, Anokye et al., 2020, Au, Gu et al., 2021). An oncogenic fusion protein, nucleoporin-98 (NUP98)-KAT7, has been identified in chronic myelomonocytic leukemia (CMML). In a mouse model, experimental overexpression of NUP98-KAT7 leads to overexpression of HOXA9 and induces leukemogenesis (Hayashi, Harada et al., 2019).
[0014] Given the established roles of KAT in general, and MYST in particular, in diseases such as cancer, there is a need for new inhibitors of these proteins. Summary of the invention
[0015] The present invention provides, in part, compounds of formula (I) and pharmaceutically acceptable salts thereof. These compounds may be useful for treating cancer. Pharmaceutical compositions are also provided, comprising a compound or salt of the present invention alone or in combination with an additional therapeutic agent. The present invention also provides, in part, methods for preparing these compounds, pharmaceutically acceptable salts and compositions of the present invention, and methods of using the foregoing. The present disclosure is provided to introduce a series of concepts in a simplified form, which will be further described in the embodiments below. The present disclosure is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used alone to help determine the scope of the claimed subject matter.
[0016] According to a first embodiment of the present invention, there is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen, methoxy or fluorine; R2 is hydrogen or methoxy, The limiting condition is that R 1 and R 2 are not both hydrogen. Its further limitation is that R 1 and R 2 are not both methoxy groups; Ring A is C 4-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or 5-10 membered heteroaryl, wherein the point of attachment is at a carbon atom; R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1.
[0017] According to a second embodiment of the present invention, a compound of formula (Ia) is provided: (Ia) or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen, methoxy or fluorine; R2 is hydrogen or methoxy, The limiting condition is that R 1 and R 2 are not both hydrogen. Its further limitation is that R 1 and R 2 are not both methoxy groups; Ring A is C 4-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or 5-10 membered heteroaryl, wherein the point of attachment is at a carbon atom; R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1.
[0018] According to a third embodiment of the present invention, a compound of formula (Ib) is provided: or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen, methoxy or fluorine; R2 is hydrogen or methoxy, The limiting condition is that R 1 and R 2 are not both hydrogen. Its further limitation is that R 1 and R 2 are not both methoxy groups; Ring A is C 4-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or 5-10 membered heteroaryl, wherein the point of attachment is at a carbon atom; R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl.
[0019] The following describes embodiments of the present invention, wherein for convenience, Embodiment 1 (E1), Embodiment 2 (E2) and Embodiment 3 (E3) are equivalent to the embodiments of Formula (I), Formula (Ia) and Formula (Ib) provided above.
[0020] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Simple diagram description
[0021] Figure 1 shows the X-ray crystal structure of 2,6-dimethoxy-4-[(2S)-oxolan-2-yl]benzene-1-sulfonyl chloride (Intermediate 140h), which reveals the absolute stereochemistry of the (S) configuration of 2,6-dimethoxy-4-[(2S)-oxolan-2-yl]benzene-1-sulfonyl chloride (Intermediate 140h). Figure 2 shows the X-ray crystal structure of (2R)-2-(4-bromo-3,5-dimethoxyphenyl)-1,4-dioxane (Intermediate 145a), which reveals the absolute stereochemistry of the (R) configuration of (2R)-2-(4-bromo-3,5-dimethoxyphenyl)-1,4-dioxane (Intermediate 145a). Figure 3 shows the X-ray crystal structure of N-{6-[(5-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-4-[(2S)-1,4-dioxane-2-yl]-2,6-dimethoxybenzene-1-sulfonamide (Example 146), which reveals the absolute stereochemistry of the (S) configuration of N-{6-[(5-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-4-[(2S)-1,4-dioxane-2-yl]-2,6-dimethoxybenzene-1-sulfonamide (Example 146). Figure 4 shows the X-ray crystal structure of N-{6-[(5-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-[(2S)-1-methylpyrrolidin-2-yl]benzene-1-sulfonamide (Example 189), which reveals the absolute stereochemistry of the (S) configuration of N-{6-[(5-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-[(2S)-1-methylpyrrolidin-2-yl]benzene-1-sulfonamide (Example 189). Implementation
[0022] This application claims the benefit of U.S. Provisional Application No. 63 / 542,051 filed on October 2, 2023, U.S. Provisional Application No. 63 / 546,442 filed on October 30, 2023, U.S. Provisional Application No. 63 / 566,213 filed on March 15, 2024, U.S. Provisional Application No. 63 / 633,660 filed on April 12, 2024, U.S. Provisional Application No. 63 / 665,990 filed on June 28, 2024, and U.S. Provisional Application No. 63 / 697,154 filed on September 20, 2024, the contents of which are incorporated herein by reference in their entirety.
[0023] [Sequence Listing] [] This application includes a sequence listing in .XML format submitted electronically. The .XML file contains a sequence listing named "PC073303A_SEQListing_ST26.xml", created on September 23, 2024, and 20 KB in size. The sequence listing contained in this .XML file is part of this specification and is incorporated herein by reference in its entirety.
[0024] The present invention may be more readily understood by reference to the following detailed description of the embodiments of the present invention and the examples included therein. It should be understood that the present invention is not limited to a particular synthetic manufacturing method, which may of course vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting.
[0025] E1 A compound of formula (I) or a pharmaceutically acceptable salt thereof, which is as defined above. E2 A compound of formula (Ia) or a pharmaceutically acceptable salt thereof, which is as defined above. E3 A compound of formula (Ib) or a pharmaceutically acceptable salt thereof, which is as defined above. E4 The compound of any one of Embodiments E1 to E3, or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from the group consisting of cyclobutyl, cyclopentyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolyl, imidazolyl, isoxazolyl, oxazolyl, 1-oxa-2,4-diazolyl, triazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrimidinyl, 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl, 5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2-b]pyrazolyl] and 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl. E5 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is cyclobutyl. E6 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is cyclopentyl. E7 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is oxetanyl. E8 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is tetrahydrofuranyl. E9 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is tetrahydropyranyl. E10 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is pyrrolyl. E11 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is imidazolyl. E12 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is isoxazolyl. E13 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is oxazolyl. E14 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is 1-oxa-2,4-oxadiazolyl. E15 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is triazolyl. E16 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is triazolyl; R6 is hydrogen or C1-3 alkyl; and each of R7, R8 and R9 is hydrogen. E17 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is pyrazolyl. E18 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is pyridinyl. E19 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is pyrimidine. E20 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is pyrimidinyl. E21 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is pyridinyl. E22 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazolyl. E23 The compound of Embodiment E4, or a pharmaceutically acceptable salt thereof, wherein Ring A is 5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2-b]pyrazolyl]. E24 The compound of Embodiment E4 or a pharmaceutically acceptable salt thereof, wherein Ring A is 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl. E25 A compound of formula (II): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E26 A compound of formula (IIa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E27 A compound of formula (IIb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; Ring B is C 3-C 6 cycloalkyl, C 6-C 10 aryl or 5-10 membered heteroaryl; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E28 A compound as described in any one of Embodiments E1 to E27, or a pharmaceutically acceptable salt thereof, wherein Ring B is cyclopropyl, 1,2,3,4-tetrahydronaphthyl, naphthyl, iodine, isoiodine, 2,3-dihydrobenzo[b][1,4]dioxinyl, pyrazolyl, pyrimidinyl, quinolyl or indazolyl. E29 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is cyclopropyl. E30 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is 1,2,3,4-tetrahydronaphthyl. E31 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is naphthyl. E32 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is alkyl. E33 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is isothiocyanate. E34 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is 2,3-dihydrobenzo[b][1,4]dioxinyl. E35 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is pyrazolyl. E36 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is pyrimidinyl. E37 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is quinolinyl. E38 The compound of Embodiment E28, or a pharmaceutically acceptable salt thereof, wherein Ring B is indazolyl. E39 A compound of formula (III): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E40 A compound of formula (IIIa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E41 A compound of formula (IIIb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with an ethoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 9 is hydrogen or fluorine; R 10 is hydrogen or C 1-3 alkyl; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E42 A compound according to any one of Embodiments E1 to E15 and E17 to E41, or a pharmaceutically acceptable salt thereof, wherein R6 is methoxy, R7 is methoxy, R8 is hydrogen, and R9 is hydrogen. E43 A compound of formula (IV): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E44 A compound of formula (V): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E45 A compound of formula (VI): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E46 A compound of formula (VIa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E47 A compound of formula (VIb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E48 A compound of formula (VII): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E49 A compound of formula (VIIa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E50 A compound of formula (VIIb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E51 A compound of formula (VIII): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E52 A compound of formula (VIIIa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E53 A compound of formula (VIIIb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E54 A compound of formula (IX): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CHR 11) n-4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, 9-10 membered heteroaryl, -C(O)NR 12R 13, -N(CH 3)(4-5 membered heterocycloalkyl) or -O-phenyl, wherein the C 1 -C 4 alkyl group is optionally substituted by one or two methoxy substituents, -N(R 14)(R 15) or one, two or three fluorine atoms, wherein the phenyl group is optionally substituted by a methoxy group, wherein the -(CHR 11) n-4-8 membered heterocycloalkyl is optionally substituted by one, two or three substituents independently selected from the following: pendant oxy groups, one or two methyl substituents, ethyl, -CHF 2, -CF 3, -CH 2CHF 2, -CH 2CF 3, methoxy, 4-6 membered heterocycloalkyl and one or two fluorine atoms, wherein the 5-8 membered heteroaryl is optionally substituted by: a pendant oxo group, a cyano group, a methyl group, -[CH(R 16)] p[N(CH 3) 2] or a 6 membered heterocycloalkyl group optionally substituted by a methyl group, wherein the 9-10 membered heteroaryl group is optionally substituted by a methyl group, wherein the -C(O)NR 12R 13 is optionally substituted by one or two fluorine atoms, and Wherein the -O-phenyl group is optionally substituted by fluorine, methyl or methoxy; R 11 is hydrogen or methyl; R 12 is hydrogen, C 1-3 alkyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 13 is hydrogen or C 1-2 alkyl; Wherein when R 12 is C 1-3 alkyl and R 13 is C 1-2 alkyl, R 12 and R 13 may be combined with the nitrogen to which they are attached to form a 4-6 membered heterocycloalkyl ring, wherein the 4-6 membered heterocycloalkyl ring is optionally substituted with one or two fluorine atoms; Each R 14 and R 15 are independently methyl or ethyl; R 16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1. E55 A compound of formula (IXa): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or one or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, -(CH 2) n-4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12 or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group, -N(R 13)(R 14) or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the -(CH 2) n-4-6 membered heterocycloalkyl and the 5-6 membered heteroaryl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, a methyl or a methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; R 12 is hydrogen or methyl; Each R 13 and R 14 is independently methyl or ethyl; and n is 0 or 1. E56 A compound of formula (IXb): or a pharmaceutically acceptable salt thereof, wherein: R 3 is hydrogen, halogen, C 1-C 4 alkyl, -CH 2OCH 3, methoxy, -C(O)OH, -C(O)OCH 3, C 3-C 5 cycloalkyl, 4-6 membered heterocycloalkyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH or one, two or three fluorine atoms, the methoxy is optionally substituted with one, two or three fluorine atoms, and the C 3-C 5 cycloalkyl is optionally substituted with methyl or two fluorine atoms; R 4 is hydrogen or optionally substituted by -OH C 1-C 3 alkyl; R 5 is hydrogen, halogen, cyano, C 1-C 3 alkyl or -C(O)NH 2; R 6 is hydrogen, halogen, C 1-C 4 alkyl, -O-(C 1-C 4 alkyl) or -O-(C 3-C 5 cycloalkyl), wherein the -O-(C 1-C 4 alkyl) is optionally substituted by one, two or three fluorine atoms; R 7 is hydrogen, C 1-C 4 alkyl or methoxy; R 8 is hydrogen, halogen, cyano, C 1-C 4 alkyl, methoxy, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, -C(O)NR 11R 12, or -O-phenyl, wherein the C 1-C 4 alkyl is optionally substituted with a methoxy group or one, two or three fluorine atoms, wherein the phenyl is optionally substituted with a methoxy group, wherein the 5-6 membered heteroaryl is optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a fluorine, methyl or methoxy group; R 11 is hydrogen, methyl, -(CH 2) 5NH 2 or -(CH 2) 5NHC(O)-phenyl-(1,2,4,5-tetrakis)-CH 3; and R12 is hydrogen or methyl. E57 A compound as described in any one of Embodiments E1 to E56, or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, chloro, C 1-C 4 alkyl, -CHF 2, -CF 3, -CF 2CH 3, -CH 2-CF 3, -CH 2OCH 3, methoxy, -O-CHF 2, -C(O)OH, -C(O)OCH 3, bicyclo[1.1.1]pent-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl or benzyl, wherein the C 1-C 4 alkyl is optionally substituted with -OH, and the cyclopropyl is optionally substituted with methyl or two fluorine atoms. E58 The compound of Embodiment E57 or a pharmaceutically acceptable salt thereof, wherein R 3 is cyclopropyl. E59 The compound according to any one of Embodiments E1 to E58, or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen, methyl, ethyl or isopropyl. E60 The compound of Embodiment E59 or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen. E61 A compound according to any one of Embodiments E1 to E60, or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen, fluoro, cyano, methyl, ethyl or -C(O)NH 2 . E62 The compound of Embodiment E61 or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen. E63 The compound of Embodiment E62 or a pharmaceutically acceptable salt thereof wherein R 3 is cyclopropyl, R 4 is hydrogen, and R 5 is hydrogen. E64 A compound as described in any one of Embodiments E1 to E15 and E17 to E62, or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, bromine, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, -O-isopropyl, -O-CH2CHF2, -O-CF3, -O-cyclobutyl or -O-cyclopropyl. E65 The compound of Embodiment E64 or a pharmaceutically acceptable salt thereof, wherein R 6 is methoxy. E66 The compound of any one of Embodiments E1 to E15 and E17 to E56, or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen, methyl, ethyl or methoxy. E67 The compound of Embodiment E66 or a pharmaceutically acceptable salt thereof, wherein R 7 is methoxy. E68 The compound of Embodiment E66 or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen. E69 A compound according to any one of Embodiments E1 to E15 and E17 to E68, or a pharmaceutically acceptable salt thereof, wherein R8 is hydrogen, chloro, fluoro, cyano, methyl, ethyl, propyl, -CHF2, -CF3, -CH2OCH3, methoxy, phenyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, oxolinyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrazolyl, -C(O)N(CH3)2, -C(O)NH(CH2)5NH2, -C(O)NH(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrahydrofuranyl)-CH 3 or -O-phenyl, wherein the phenyl is optionally substituted with a methoxy group, wherein the pyrazolyl, the imidazolyl and the thiazolyl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a methyl group, a fluoro group or a methoxy group. E70 A compound as described in any one of Embodiments E1 to E69, or a pharmaceutically acceptable salt thereof, wherein R8 is hydrogen, chloro, fluoro, cyano, methyl, ethyl, propyl, -CHF2, -CF3, -CH2OCH3, methoxy, phenyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrrolidyl, -C(O)N(CH3)2, -C(O)NH(CH2)5NH2, -C(O)NH(CH2)5NHC(O)-phenyl-(1,2,4,5-tetrahydrofuranyl)-CH3 3 or -O-phenyl, wherein the phenyl is optionally substituted with a methoxy group, wherein the pyrazolyl, the imidazolyl and the thiazolyl are each independently optionally substituted with a methyl group, and wherein the -O-phenyl is optionally substituted with a methyl group, a fluoro group or a methoxy group. E71 The compound of Embodiment E69 or Embodiment E70, or a pharmaceutically acceptable salt thereof, wherein R 8 is hydrogen. E72 A compound of formula (X): or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen or fluorine; R 3 is hydrogen, ethyl or cyclopropyl; R 6 is methoxy, ethoxy, O-cyclopropyl or O-cyclobutyl; R 7 is hydrogen, fluorine or methoxy; R8 is hydrogen, fluorine, methyl or -CHF2. E73 The compound of any one of embodiments E1 to E24 and E72, or a pharmaceutically acceptable salt thereof, wherein R 1 is fluoro, and R 2 is methoxy. E74 The compound of any one of embodiments E1 to E24 and E72, or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, and R 2 is methoxy. E75 A compound according to any one of embodiments E72 to E74, or a pharmaceutically acceptable salt thereof, wherein R 3 is cyclopropyl. E76 A compound selected from the group consisting of , or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E77 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E78 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E79 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E80 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E81 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E82 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E83 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E84 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E85 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E86 The compound of Example E76, which is or its tautomer, or a pharmaceutically acceptable salt of the compound or its tautomer. E87 The compound of Example E76, which is , or a pharmaceutically acceptable salt thereof. E88 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E89 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E90 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E91 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E92 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E93 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E94 The compound of Example E76, which is or a pharmaceutically acceptable salt thereof. E95 The compound of Example E76, which is , or a pharmaceutically acceptable salt thereof. E96 A pharmaceutical composition comprising a compound according to any one of embodiments E1 to E94 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. E97 A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of Embodiments E1 to E95 or a pharmaceutically acceptable salt thereof. E98 The method of embodiment E96, wherein the cancer is breast cancer. E99 The method of embodiment E97, wherein the breast cancer is ER+ breast cancer. E100 The method of embodiment E98, wherein the ER+ breast cancer is ER+ HER2- breast cancer. E101 A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Embodiments E1 to E99 or a pharmaceutically acceptable salt thereof, and the method further comprises administering an amount of an additional therapeutic agent. E102 The method of embodiment E100, wherein the cancer is breast cancer. E103 The method of embodiment E101, wherein the breast cancer is ER+ breast cancer. E104 The method of embodiment E102, wherein the ER+ breast cancer is ER+ HER2- breast cancer. E105 The compound according to any one of Embodiments E1 to E103 or a pharmaceutically acceptable salt thereof, which is suitable for use as a medicament. E106 The compound according to any one of Embodiments E1 to E104 or a pharmaceutically acceptable salt thereof, for use in treating cancer. E107 Use of a compound according to any one of Embodiments E1 to E105 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating cancer.
[0026] Each embodiment described herein may be combined with any other embodiment described herein, and the (s) any other embodiment is consistent with the embodiment with which it is combined. In addition, for any of the embodiments described herein, any of the compounds described in the examples or their pharmaceutically acceptable salts may be claimed alone, or may be combined with one or more other compounds or their pharmaceutically acceptable salts in the examples.
[0027] Additionally, each of the embodiments described herein contemplates within its scope the pharmaceutically acceptable salts of the compounds described herein.
[0028] [definition] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention have the same meanings as commonly understood by one of ordinary skill in the art.
[0029] The invention described herein may suitably be practiced in the absence of any element not specifically disclosed herein.
[0030] As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. For example, "a" or "an" substituent includes one or more substituents.
[0031] As used herein, the term "about" when used to modify a parameter whose value is defined (e.g., a dose of 5 mg) means that the parameter may vary by up to 10% below or above the specified value of the parameter. For example, a dose of about 5 mg means 5 mg ± 10%, i.e., it may vary between 4.5 mg and 5.5 mg.
[0032] If a substituent is described as being "independently selected" from a group, each substituent is selected independently of the others. Thus, each substituent may be the same as or different from the other substituents.
[0033] The words “subject to” or “subject to” mean that the event or circumstance described subsequently may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0034] The term "optionally substituted" is used to indicate that the particular group being described may have no non-hydrogen substituents (i.e., unsubstituted), or that the group may have one or more non-hydrogen substituents (i.e., substituted). If not otherwise specified, the total number of substituents that may be present is equal to the number of H atoms present in the unsubstituted form of the group being described. When an optional substituent is attached via a double bond, such as a pendant oxy (=0) substituent, the group occupies two available valencies, so the total number of other substituents included is reduced by two. In the case where the optional substituents are independently selected from a range of alternative substituents, the selected groups may be the same or different. Throughout this disclosure, it is understood that the number and nature of the optional substituents will be limited to the extent that such substitution is chemically reasonable to one of ordinary skill in the art.
[0035] "Halogen" or "halo" refers to fluorine, chlorine, bromine and iodine (F, Cl, Br, I).
[0036] "Cyano" refers to a substituent in which a carbon atom is bonded to a nitrogen atom via a paraffin bond, i.e., -C≡N.
[0037] "Hydroxyl" refers to an -OH group.
[0038] "Oxy" refers to a double-bonded oxygen (=O).
[0039] "Alkyl" refers to a saturated monovalent aliphatic hydrocarbon radical having a specified number of carbon atoms, including straight or branched chain groups. Alkyl groups may contain, but are not limited to, 1 to 4 carbon atoms ("C1-C4 alkyl"), 1 to 3 carbon atoms ("C1-C3 alkyl"), or 1 to 2 carbon atoms ("C1-C2 alkyl"). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl, tertiary butyl, and the like. In one embodiment, the alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, secondary butyl, isobutyl, or tertiary butyl. Alkyl groups may be substituted, unsubstituted, or substituted, as further defined herein.
[0040] "Cycloalkyl" refers to a fully saturated hydrocarbon ring system having the specified number of carbon atoms, which may be a monocyclic or bridged ring system attached to the base molecule through a carbon atom of the cycloalkyl ring. Cycloalkyl may contain, but is not limited to, 3 to 6 carbon atoms ("C3-C6 cycloalkyl"), 3 to 5 carbon atoms ("C3-C5 cycloalkyl"), 4 to 5 carbon atoms ("C4-C5 cycloalkyl"), or 3 to 4 carbon atoms ("C3-C4 cycloalkyl"). Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pent-1-yl, cyclohexyl, and the like. In one embodiment, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or bicyclo[1.1.1]pent-1-yl. Cycloalkyl may be optionally substituted, unsubstituted, or substituted, as further defined herein.
[0041] "Heterocycloalkyl" refers to a fully saturated ring system containing the specified number of ring atoms and containing at least one heteroatom selected from nitrogen and oxygen as a ring member, and wherein the heterocycloalkyl ring is attached to the base molecule via a ring atom which may be C or N. A heterocycloalkyl ring may contain 1 to 2 heteroatoms selected from N and O as ring members, provided that such heterocycloalkyl ring does not contain two consecutive nitrogen or oxygen atoms. Heterocycloalkyl rings include spiro rings, wherein the spiro ring is saturated, provided that the point of attachment to the base molecule is an atom of the heterocycloalkyl portion of the ring system. "4-8 membered heterocycloalkyl" contains four to eight ring atoms, "4-6 membered heterocycloalkyl" contains four to six ring atoms, "6 membered heterocycloalkyl" contains six ring atoms, and "4-5 membered heterocycloalkyl" contains four to five ring atoms. Heterocycloalkyl rings may be optionally substituted, unsubstituted or substituted, as further defined herein. Examples of heterocycloalkyl include, but are not limited to: Azetidine (azetidinyl) Oxetane (oxetane) Pyrrolidine (pyrrolidyl) Tetrahydrofuran (tetrahydrofuranyl) Piperidine (piperidinyl) Isopropylamine (Isopropylamine) Piperidinium (piperidinyl) Tetrahydropyran (tetrahydropyranyl) 1,4-Dioxane (1,4-dioxane) 5-Azaspiro[3.4]octane(5-Azaspiro[3.4]octyl)
[0042] "Aryl" or "aromatic" refers to a monocyclic or bicyclic (e.g., biaryl, fused) ring system containing the specified number of ring atoms, wherein all carbon atoms in the ring are sp2 hybridized and wherein the π electrons are conjugated. Aryl groups may contain, but are not limited to, 6 to 10 carbon atoms ("C6-C10 aryl"). Fused aryl groups may include an aromatic ring (e.g., a benzene ring) fused to another aromatic ring. Examples include, but are not limited to, phenyl and naphthyl. As used herein, also included within the scope of the term "aryl" are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as dihydroindanyl (2,3-dihydro-1H-indene) and tetrahydronaphthyl (also known as 1,2,3,4-tetrahydronaphthyl), wherein the radical or point of attachment is on the aromatic ring. Aryl groups may be optionally substituted, unsubstituted, or substituted, as further defined herein.
[0043] "Heteroaryl" or "heteroaromatic" refers to a monocyclic, bicyclic (e.g., heterobiaryl, fused) or polycyclic ring system containing the specified number of ring atoms and including at least one heteroatom selected from N, O and S as a ring member in the ring, wherein all carbon atoms in the ring are sp2 hybridized and wherein the π electrons are conjugated. Heteroaryl rings include spiro rings, rings bridged or fused to one or more other cycloalkyl or heterocycloalkyl rings, wherein such spiro rings, bridged rings or fused rings may themselves be saturated, partially unsaturated or aromatic, the degree of unsaturation or aromaticity being chemically reasonable, provided that the point of attachment to the base molecule is an atom of the heterocycloalkyl portion of the ring system.
[0044] The heteroaryl group may contain, but is not limited to, 5 to 10 ring atoms ("5-10 membered heteroaryl"), 5 to 8 ring atoms ("5-8 membered heteroaryl"), 9 to 10 ring atoms ("9-10 membered heteroaryl"), or 5 to 6 ring atoms ("5-6 membered heteroaryl"). The heteroaryl ring is attached to the base molecule via the ring atoms of the aromatic ring. Thus, a 5- or 6-membered heteroaryl ring (alone or in a fused or polycyclic structure) may be attached to the base molecule via a ring C or N atom. Also included within the scope of the term "heteroaryl" as defined herein are 5- or 6-membered monocyclic heteroaryl rings, which may be fused with a cycloalkyl or heterocycloalkyl group to form a fused or polycyclic structure. As defined herein, examples of heteroaryl include, but are not limited to, pyrrolyl (1H-pyrrolyl), pyrazolyl (1H-pyrazolyl), imidazolyl (1H-imidazolyl), isoxazolyl, oxadiazolyl, oxadiazolyl (1-oxa-2,4-oxadiazolyl), thiazolyl, triazolyl (1H-1,2,3-triazole, 1H-1,2,4-triazole), pyridinyl, pyrimidinyl, pyridinyl, indazolyl (2 In one preferred embodiment, the heteroaryl group is pyrazolyl. The heteroaryl group may be substituted, unsubstituted or substituted as further defined herein.
[0045] Illustrative examples of monocyclic heteroaryl groups include, but are not limited to, the following monovalent groups: Pyrrole (pyrrolyl) Furan (furanyl) Thiophene (Thienyl) Pyrazole (pyrazolyl) Imidazole (Imidazole) Isoazole (isoxazolyl) Azoles (Azoles) Isothiazol (isothiazolyl) Thiazole (thiazolyl) 1,2,3-Triazole (1,2,3-triazolyl) 1,3,4-Triazole (1,3,4-triazolyl) 1-Oxa-2,3-diazole (1-Oxa-2,3-diazole) 1-Oxa-2,4-diazole (1-Oxa-2,4-diazole) 1-Oxa-2,5-diazole (1-Oxa-2,5-diazole) 1-Oxa-3,4-diazole (1-Oxa-3,4-diazole) 1-Thia-2,3-diazole (1-thia-2,3-diazole) 1-Thia-2,4-diazole (1-Thia-2,4-diazole) 1-Thia-2,5-diazole (1-Thia-2,5-diazole) 1-Thiadiazole-3,4-diazole (1-Thiazolyl-3,4-diazole) Tetrazolyl Pyridine (pyridyl) Da 𠯤 (Da 𠯤 base) Pyrimidine (pyrimidinyl) Pyridine (pyridine)
[0046] Illustrative examples of fused ring heteroaryl groups include, but are not limited to: Benzofuran (Benzofuryl) Benzothiophene (benzothiophene) Indole (Indolyl) Benzimidazole (benzimidazole) Indazole (Indazolyl) Benzotriazole (Benzotriazolyl) Pyrrolo[2,3-b]pyridine(Pyrrolo[2,3-b]pyridinyl) Pyrrolo[2,3-c]pyridine(pyrrolo[2,3-c]pyridinyl) Pyrrolo[3,2-c]pyridine (Pyrrolo[3,2-c]pyridinyl) Pyrrolo[3,2-b]pyridine (Pyrrolo[3,2-b]pyridinyl) Imidazolo[4,5-b]pyridine (Imidazolo[4,5-b]pyridinyl) Imidazolo[4,5-c]pyridine(Imidazolo[4,5-c]pyridinyl) Pyrazolo[4,3-d]pyridine (Pyrazolo[4,3-d]pyridinyl) Pyrazolo[4,3-c]pyridine (Pyrazolo[4,3-c]pyridinyl) Pyrazolo[3,4-c]pyridine (Pyrazolo[3,4-c]pyridinyl) Pyrazolo[3,4-b]pyridine (Pyrazolo[3,4-b]pyridinyl) Isoindole (isoindolyl) Indazole (Indazolyl) Purine (purine base) Indole(Indoleyl) Imidazolo[1,2-a]pyridine(Imidazolo[1,2-a]pyridinyl) Imidazolo[1,5-a]pyridine(Imidazolo[1,5-a]pyridinyl) Pyrazolo[1,5-a]pyridine(Pyrazolo[1,5-a]pyridinyl) Pyrrolo[1,2-b]py ... Imidazolo[1,2-c]pyrimidine (Imidazolo[1,2-c]pyrimidinyl) Quinoline(Quinoline) Isoquinoline (isoquinolyl) Arphyrin (arphyrinyl) Quinazoline (Azaquinazoline) Quinoxaline (quinoxaline) Tie 𠯤 (Tie 𠯤 base) 1,6-Hexadine (1,6-Hexadine) 1,7-Hexadine (1,7-Hexadine) 1,8-Hexidine (1,8-Hexidine) 1,5-Hexidine (1,5-hexidine) 2,6-Hexidine (2,6-hexidine) 2,7-Hexadine (2,7-Hexadine) Pyrido[3,2-d]pyrimidine (pyrido[3,2-d]pyrimidinyl) Pyrido[4,3-d]pyrimidine (Pyrido[4,3-d]pyrimidinyl) Pyrido[3,4-d]pyrimidine (pyrido[3,4-d]pyrimidinyl) Pyrido[2,3-d]pyrimidine (Pyrido[2,3-d]pyrimidinyl) Pyrido[2,3-b]pyrroline(Pyrido[2,3-b]pyrroline) Pyrido[3,4-b]pyrroline(Pyrido[3,4-b]pyrroline) Pyrimido[5,4-d]pyrimidine (pyrimido[5,4-d]pyrimidinyl) Pyrro[2,3-b]py ... Pyrimido[4,5-d]pyrimidine (pyrimido[4,5-d]pyrimidinyl) Hexahydropyrido[3,4-d]pyrimidine(Hexahydropyrido[3,4-d]pyrimidinyl) Alkane (Alkyl) Isothane (isothiazolidine) 2,3-Dihydrobenzo[b][1,4]dioxadicyclohexene(2,3-Dihydrobenzo[b][1,4]dioxadicyclohexene) 5,6-Dihydro-4H-pyrrolo[1,2- b]pyrazole(5,6-Dihydro-4H-pyrrolo[1,2- b]pyrazolyl) 5',6'-Dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2- b]pyrazolyl](5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2- b]pyrazolyl]) 2,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazole(2,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazolyl) 6,7-Dihydro-4H-pyrazolo[5,1-c][1,4]oxathiocarbyl
[0047] The term "pharmaceutically acceptable" means that the substance (e.g., the compounds described herein) and any salts thereof, or compositions containing the substance or salt of the invention are suitable for administration to an individual or patient.
[0048] "Compounds of the present invention" include compounds of formula (I)-(X), (Ia)-(VIIa), (Ib)-(VIIb) and examples used in their preparation. Those skilled in the art will appreciate that the compounds of the present invention and their novel intermediates include possible configurational isomers (e.g., cis- and trans-isomers) and all optical isomers (e.g., mirror isomers and non-mirror isomers), racemates, non-mirror isomers and mixtures of other such isomers, and tautomers thereof. Those skilled in the art will also appreciate that the compounds of the present invention and their novel intermediates include possible solvates, hydrates, isomorphs, polymorphs, esters, salt forms, prodrugs and isotope-labeled forms thereof (including deuterium substitution).
[0049] The compounds of the present invention act as KAT6 / 7 inhibitors that selectively target KAT5 and KAT8. The MYST family of histone lysine acetyltransferases KAT5, KAT6A, KAT6B, KAT7 and KAT8 regulate gene transcription that is critical for cellular function. These enzymes share a common MYST domain, but exist in a unique complex that dictates their function. According to the Cancer Dependency Map (DepMap) ( [https: / / depmap.org / portal]), predicted by the loss of histone acetylation at H3K23, H3K14 and H4K12, the combined inhibition of KAT6A / B and KAT7 can drive selective dependence in cancer cells. In contrast, KAT5 and KAT8 are classified as essential genes in DepMap, and knockout mouse models exhibit embryonic lethality (Thomas, Tim et al., "Mof (MYST1 or KAT8) is essential for progression of embryonic development past the blastocyst stage and required for normal chromatin architecture." Molecular and cellular biology 28.16 (2008): 5093-5105; Hu, Yaofei et al., "Homozygous disruption of the Tip60 gene causes early embryonic lethality." Developmental dynamics: an official publication of the American Association of Anatomists 238.11 (2009): 2912-2921).KAT8, as the catalytic component of the NSL complex, is required for cell survival and regulates the transcription of essential genes (Radzisheuskaya A, Shliaha PV, Grinev VV, Shlyueva D, Damhofer H, Koche R, Gorshkov V, Kovalchuk S, Zhan Y, Rodriguez KL, Johnstone AL, Keogh MC, Hendrickson RC, Jensen ON, Helin K. Complex-dependent histone acetyltransferase activity of KAT8 determines its role in transcription and cellular homeostasis. Mol Cell. 2021 Apr 15;81(8):1749-1765.e8. doi: 10.1016 / j.molcel.2021.02.012. Epub 2021 Mar 2. PMID: 33657400; PMCID: PMC8056186).
[0050] The compounds of the present invention include but are not limited to:
[0051] "Pharmaceutical composition" refers to a mixture of the compound of the present invention, or one or more of its pharmaceutically acceptable salts, solvates, hydrates or prodrugs as an active ingredient, and at least one pharmaceutically acceptable excipient.
[0052] As used herein, "deuterium enrichment factor" means the ratio between the abundance of deuterium and the natural abundance of deuterium, each relative to the abundance of hydrogen. In particular embodiments, the deuterium enrichment factor for an atomic position designated as having deuterium is typically at least 1000 (15% deuterium incorporation), at least 2000 (30% deuterium incorporation), at least 3000 (45% deuterium incorporation), at least 3500 (52.5% deuterium incorporation), at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporated).
[0053] As used herein, "excipient" describes any ingredient other than a compound of the invention. The choice of excipient will to a large extent depend on factors such as the mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
[0054] As used herein, "excipients" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, carriers, diluents, and the like that are physiologically compatible. Examples of excipients include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, and combinations thereof, and may include isotonic agents in the composition, such as sugars, sodium chloride, or polyols such as mannitol or sorbitol. Examples of excipients also include various organic solvents (such as hydrates and solvates). If necessary, the pharmaceutical composition may contain additional excipients, such as flavor enhancers, binders / adhesives, lubricants, disintegrants, sweeteners or flavoring agents, colorants or dyes, and the like. For example, for oral administration, tablets containing various excipients such as citric acid may be used together with various disintegrants such as starch, alginic acid and certain complex silicates and binders such as sucrose, gelatin and acacia. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc are often suitable for tableting purposes. Solid compositions of similar types may also be used in the form of soft and hard-filled gelatin capsules. Thus, non-limiting examples of excipients also include lactose or milk sugar and high molecular weight polyethylene glycols. When an aqueous suspension or elixir is required for oral administration, the active compound therein may be combined with various sweeteners or flavoring agents, coloring matter or dye and, if necessary, an emulsifier or suspending agent, as well as additional excipients such as water, ethanol, propylene glycol, glycerol or a combination thereof.
[0055] Examples of excipients also include pharmaceutically acceptable substances such as wetting agents or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the compound.
[0056] As used herein, unless otherwise indicated, the term "treating" means reversing, alleviating or inhibiting the progression of the disease, disorder or condition to which such term applies, or one or more symptoms of such disease, disorder or condition. As "treating" is defined immediately above, as used herein, unless otherwise indicated, the term "treatment" refers to the act of treating.
[0057] As used herein, the terms "subject", "individual" or "patient" are used interchangeably and refer to any animal, including mammals. Mammals according to the present invention include dogs, cats, cows, goats, horses, sheep, pigs, rodents, lagomorphs, primates, humans and the like, and include unborn mammals. In one embodiment, humans are preferred subjects. Human subjects can be of any gender and at any stage of development.
[0058] As used herein, the phrase "therapeutically effective amount" or "effective amount" refers to the amount of an active compound or pharmaceutical agent that elicits the biological or medical response sought by a researcher, veterinarian, physician or other clinician in a tissue, system, animal, individual or human, and may include one or more of the following: (1) Prevention of disease; for example, prevention of a disease, condition or disorder in an individual who may be susceptible to the disease, condition or disorder but who does not yet experience or display the pathology or symptoms of the disease; (2) inhibiting a disease; for example, inhibiting a disease, condition or disorder in a subject who is experiencing or displaying pathology or symptoms of the disease, condition or disorder (i.e., arresting (or slowing) the further development of the pathology or symptoms or both); and (3) Ameliorating a disease; e.g., ameliorating a disease, condition, or disorder in a subject experiencing or displaying pathology or symptoms of the disease, condition, or disorder (i.e., reversing the pathology or symptoms or both).
[0059] [Salt] Salts encompassed within the term "pharmaceutically acceptable salts" refer to compounds of the invention which are generally prepared by reacting a free base or free acid with a suitable organic or inorganic acid, or a suitable organic or inorganic base, respectively, to provide a salt of the compound of the invention suitable for administration to a subject or patient.
[0060] In addition, the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb) may also include other salts of such compounds, which may not necessarily be pharmaceutically acceptable salts, and which may be useful as intermediates for one or more of the following: 1) preparing the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); 2) purifying the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); 3) separating the mirror image isomers of the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); or 4) separating the diastereoisomers of the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb).
[0061] Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include, but are not limited to, acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthalene dicarboxylate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, glucarate, stearate, succinate, tannate, tartrate, toluenesulfonate, trifluoroacetate, 1,5-naphthalene disulfonic acid, and hydroxynaphthoate.
[0062] Suitable base salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycine, lithium, lysine, magnesium, meglumine, ethanolamine, piperidine, potassium, sodium, tromethamine, and zinc salts.
[0063] It can also form hemisalts of acids and bases, such as hemisulphate and hemicalcium salts.
[0064] For a review of suitable salts, see Paulekun, GS et al., Trends in Active Pharmaceutical Ingredient Salt Selection Based on Analysis of the Orange Book Database, J. Med. Chem. 2007; 50(26), 6665-6672.
[0065] Pharmaceutically acceptable salts of the compounds of the present invention can be prepared by methods well known to those skilled in the art, including but not limited to the following procedures: (i) reacting a compound of the present invention with a desired acid or base; (ii) using a desired acid or base to remove an acid- or base-labile protecting group from a suitable precursor of the compound of the invention, or to ring-open a suitable cyclic precursor (e.g., a lactone or lactam); or (iii) converting one salt of a compound of the invention into another salt. This can be achieved by reaction with an appropriate acid or base or by means of a suitable ion exchange procedure.
[0066] These procedures are generally carried out in solution. The resulting salt may precipitate and be collected by filtration or may be recovered by evaporation of the solvent.
[0067] [Solvate] The compounds of the present invention and their pharmaceutically acceptable salts may exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of the present invention or its pharmaceutically acceptable salt and one or more pharmaceutically acceptable solvent molecules, such as ethanol. When the solvent is water, the term "hydrate" is used.
[0068] In addition, the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb) may also include other solvates of such compounds, which may not necessarily be pharmaceutically acceptable solvates, and which may be useful as intermediates for one or more of the following: 1) preparing the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); 2) purifying the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); 3) separating the mirror image isomers of the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb); or 4) separating the diastereoisomers of the compounds of formula (I)-(X), (Ia)-(VIIa) and (Ib)-(VIIb).
[0069] The currently accepted classification system for organic hydrates is a system that defines isolated site hydrates, channel hydrates, or metal ion coordinated hydrates. See KR Morris, [Polymorphism in Pharmaceutical Solids] (HG Brittain, ed., Marcel Dekker, 1995). An isolated site hydrate is a hydrate in which water molecules are separated from each other by the insertion of organic molecules and are not in direct contact. In a channel hydrate, a water molecule is in a lattice channel in close proximity to other water molecules. In a metal-ion coordination hydrate, a water molecule is bound to a metal ion.
[0070] When the solvent or water is tightly bound, the complex can have a well-defined stoichiometry that is independent of humidity. However, when the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water / solvent content can depend on humidity and drying conditions. In these cases, non-stoichiometry will be the norm.
[0071] [Compound] [] Also included within the scope of the present invention are multi-component complexes (in addition to salts and solvates) in which the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. Complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals. The latter are generally defined as crystalline complexes of neutral molecular components held together by non-covalent interactions, for example, hydrogen-bonded complexes (co-crystals) can be formed with neutral molecules or with salts. Co-crystals can be prepared by melt crystallization, by recrystallization from solvents, or by physically grinding the components together, see O. Almarsson and MJ Zaworotko, Chem Commun, 17, 1889-1896 (2004). For a general review of multi-component complexes, see Haleblian, J Pharm Sci, 64(8), 1269-1288 (August 1975).
[0072] [Solid form] The compounds of the present invention may exist in a continuum of solid forms ranging from amorphous to crystalline. The term 'amorphous' refers to a state in which a material lacks long-range order at the molecular level and may exhibit the physical properties of a solid or a liquid, depending on the temperature. Such materials generally do not produce a distinctive X-ray diffraction pattern and are more formally described as liquids while exhibiting the properties of a solid. Upon heating, a change from solid properties to liquid properties occurs, characterized by a change of state, typically a second order change ('glass transition'). The term 'crystalline' refers to a solid phase in which the material has a regularly ordered internal structure at the molecular level and produces a distinctive X-ray diffraction pattern with defined peaks. Such materials will also exhibit the properties of a liquid when heated sufficiently, but the change from solid to liquid is characterized by a phase transition, typically a first order change ('melting point').
[0073] The compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between the true crystalline state and the true liquid state (melt or solution) and consists of a two-dimensional arrangement at the molecular level. Mesomorphism that occurs as a result of a change in temperature is described as "thermotropic," while mesomorphism that occurs as a result of the addition of a second component (such as water or another solvent) is described as "lyotropic." Compounds that have the potential to form lyotropic mesophases are described as "amphiphilic," and consist of molecules with either ionic polar head groups (such as -COO-Na+, -COO-K+, or -SO3-Na+) or nonionic polar head groups (such as -N-N+(CH3)3). For more information, see Crystals and the Polarizing Microscope, 4th edition, by NH Hartshorne and A. Stuart (Edward Arnold, 1970).
[0074] [Stereoisomers] The compounds of the present invention may exist in the form of two or more stereoisomers. Stereoisomers of a compound may include cis and trans isomers (geometric isomers), optical isomers (such as R and S mirror image isomers), diastereomers, rotational isomers, asymmetric isomers, and conformational isomers. For example, compounds of the present invention containing one or more asymmetric carbon atoms may exist in the form of two or more stereoisomers. Saturated rings may also exist as cis / trans isomers.
[0075] Pharmaceutically acceptable salts of the compounds of the present invention may also contain an optically active counter ion (eg, d-lactate or l-lysine) or a racemic counter ion (eg, dl-tartrate or dl-arginine).
[0076] Cis / trans isomers can be separated by conventional techniques well known to those skilled in the art (eg, chromatography and fractional crystallization).
[0077] Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of racemates (or racemates of salts or derivatives) using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or racemic precursor) can be reacted with a suitable optically active compound (e.g., an alcohol, or, in the case of compounds of the invention containing an acidic or basic moiety, a base or acid, such as 1-phenylethylamine or tartaric acid). The resulting diastereomeric mixture can be separated by chromatography, fractional crystallization, or by using both of these techniques, and one or both of the diastereomeric isomers can be converted to the corresponding pure enantiomer by means well known to those skilled in the art. The chiral compounds of the invention (and their chiral precursors) can be obtained in an enantiomerically enriched form using chromatography (usually HPLC). Concentrating the solvent yields an enriched mixture. Chiral chromatography using subcritical and supercritical fluids can be employed. Methods for chiral chromatography suitable for use in some embodiments of the present invention are known in the art (see, e.g., Smith, Roger M., Loughborough University, Loughborough, UK; Chromatographic Science Series (1998), 75 (Supercritical Fluid Chromatography with Packed Columns), pp. 223-249 and references cited therein).
[0078] When any racemate is crystallized, there may be two different types of crystals. The first type is the racemic compound (true racemate) mentioned above, in which a homogeneous crystal form containing two mirror image isomers in equimolar amounts is produced. The second type is a racemic mixture or agglomerate, in which two crystal forms each containing a single mirror image isomer are produced in equimolar amounts. Although the two crystal forms present in the racemic mixture may have the same physical properties, they may have different physical properties compared to the true racemate. The racemic mixture can be separated by conventional techniques known to those skilled in the art, see, for example, Stereochemistry of Organic Compounds, EL Eliel and SH Wilen (Wiley, 1994).
[0079] [Tautomerism] When structural isomers are interconvertible via a low energy barrier, tautomerism ("tautomerism") may occur. This may occur as proton tautomerism in compounds of the invention containing, for example, imine / amine, keto / enol or oxime / nitroso, lactamide / lactimide, or as so-called valence tautomerism in compounds containing aromatic moieties. Thus a single compound may exhibit more than one type of isomerism.
[0080] It must be emphasized that, although the compounds of the present invention have been drawn herein in a single tautomeric form for the sake of brevity, all possible tautomeric forms are included within the scope of the present invention.
[0081] Tautomerism in the compounds of the present invention can be depicted as shown in the following structures.
[0082] The dotted lines in the above structure mean that the tautomeric forms are in resonance, which simply depicts the movement of electrons. Resonance is the presence of more than one form (of the same compound), which determines the actual structure of the compound.
[0083] structure: Equivalent to and .
[0084] With substituent and The tautomers of the compounds of the present invention.
[0085] [isotope] The present invention includes all pharmaceutically acceptable isotopically labeled compounds of the present invention in which one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number that predominates in nature.
[0086] Examples of isotopes suitable for inclusion in the compounds of the present invention may include isotopes of hydrogen, such as 2H (D, deuterium) and 3H (T, tritium); isotopes of carbon, such as 11C, 13C and 14C; isotopes of chlorine, such as 36Cl; isotopes of fluorine, such as 18F; isotopes of iodine, such as 123I and 125I; isotopes of nitrogen, such as 13N and 15N; isotopes of oxygen, such as 15O, 17O and 18O; isotopes of phosphorus, such as 32P; and isotopes of sulfur, such as 35S.
[0087] Certain isotopically labeled compounds of the invention (e.g., compounds incorporating a radioisotope) are useful in either or both drug or substrate tissue distribution studies. Radioisotopes such as tritium and 14C are particularly useful for this purpose in view of their ease of incorporation and simple means of detection. Substitution with positron emitting isotopes such as 11C, 18F, 15O, and 13N may be useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Deuterium substitution may provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, reduced CYP450 inhibition (competitive or time-dependent), or improved therapeutic index or tolerability.
[0088] In some embodiments, the present disclosure provides deuterium-labeled (or deuterated) compounds and salts, wherein the chemical formulae and variables of such compounds and salts are each independently as described herein. "Deuterated" means that at least one of the atoms in the compound is deuterium, with an abundance greater than the natural abundance of deuterium (typically about 0.015%). One skilled in the art recognizes that in a compound having a hydrogen atom, the hydrogen atom actually represents a mixture of H and D, of which about 0.015% is D. The concentration of deuterium incorporated into the deuterium-labeled compounds and salts of the present invention can be defined by a deuterium enrichment factor. It is understood that one or more deuteriums can be exchanged for hydrogen under physiological conditions.
[0089] In some embodiments, one or more hydrogen atoms on certain metabolic sites of the compounds of the invention are deuterated. Certain metabolic sites on the compounds of the invention are depicted below.
[0090] In some embodiments, the deuterium compound is selected from [surface] As described in [1-12] Any of the compounds shown in [Examples section]. [surface] [1] [Instance Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] 145-D1 D H H H H H H 145-D2 H D H H H H H 145-D3 H H H H D H H 145-D4 H H H H H D H 145-D5 H H H H H H D 145-D6 H H D H H H H 145-D7 H H H D H H H [Table] [2] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] 146-D1 D H H H H H H 146-D2 H D H H H H H 146-D3 H H H H D H H 146-D4 H H H H H D H 146-D5 H H H H H H D 146-D6 H H D H H H H 146-D7 H H H D H H H [Table] [3] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 152-D1 H H H H H H H D 152-D2 D H H H H H H H 152-D3 H D H H H H H H 152-D4 H H H D H H H H 152-D5 H H H H D H H H 152-D6 H H H H H D H H 152-D7 H H H H H H D H [Table] [4] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 174-D1 H D H H H H H 174-D2 H H H D H H H 174-D3 H H H H D H H 174-D4 D H H H H H H 174-D5 H H H H H D H 174-D6 H H D H H H H 174-D7 H H H H H H D [Table] [5] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 179-D1 H H H H H H H D 179-D2 D H H H H H H H 179-D3 H H H H D H H H 179-D4 H H H H H D H H 179-D5 H D H H H H H H 179-D6 H H H H H H D H 179-D7 H H D H H H H H 179-D8 H H H D H H H H [Table] [6] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 181-D1 H D H H H H H H 181-D2 H H H H D H H H 181-D3 H H H H H D H H 181-D4 D H H H H H H H 181-D5 H H H H H H D H 181-D6 H H H D H H H H [, , ] [] [Table] [7] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 188-D1 H D H H H H H H 188-D2 D H H H H H H H 188-D3 H H H H D H H H 188-D4 H H H H H D H H 188-D5 H H H H H H D H 188-D6 H H H D H H H H [Table] [8] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 189-D1 H D H H H H H H 189-D2 D H H H H H H H 189-D3 H H H H D H H H 189-D4 H H H H H D H H 189-D5 H H H H H H D H 189-D6 H H H D H H H H [Table] [9] [Instance Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 195-D1 D H H H H H H H 195-D2 H H H D H H H H 195-D3 H H H H D H H H 195-D4 H H H H H D H H 195-D5 H H D H H H H H 195-D6 H D H H H H H H [Table]
[10] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 199-D1 H H H D H H H H 199-D2 H H D H H H H H 199-D3 H H H H D H H H 199-D4 H H H H H D H H 199-D5 H D H H H H H H 199-D6 H H H H H H D H 199-D7 H H H H H H H D [Table]
[11] [Example No.] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y , 6, ] [Y , 7, ] [Y , 8, ] 201-D1 H H H D H H H H 201-D2 H H H H D H H H 201-D3 H H H H H D H H 201-D4 D H H H H H H H 201-D5 H D H H H H H H 201-D6 H H H H H H D H 201-D7 H H H H H H H D [Table]
[12] [Example Number] [Y, 1, ] [Y, 2, ] [Y, 3, ] [Y, 4, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 203-D1 H H H D H H H H 203-D2 D H H H H H H H 203-D3 H D H H H H H H 203-D4 H H H H D H H H 203-D5 H H H H H D H H 203-D6 H H H H H H D H 203-D7 H H H H H H H D [Table]
[13] [Example Number] [Y, 1, ] [Y, 5, ] [Y, 6, ] [Y, 7, ] [Y, 8, ] 213-D1 D H H H H 213-D2 D H H H H 213-D3 H H H H H 213-D4 H D H H H 213-D5 H H D H H 213-D6 H H H D H 213-D7 H H H H D
[0091] Isotopically-labeled compounds of this invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[0092] Pharmaceutically acceptable solvates according to the present invention include those wherein the solvent of crystallization may be isotopically substituted, for example D 2 O, d 6 -acetone, d 6 -DMSO.
[0093] [Prodrug] The compounds of the present invention may be administered in the form of prodrugs. Thus, certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity may be converted, when administered into or onto the body, into compounds of the present invention that have the desired activity, for example by hydrolytic cleavage, particularly hydrolytic cleavage promoted by esterases or peptidases. Such derivatives are referred to as "prodrugs". Further information on the use of prodrugs can be found in "The Expanding Role of Prodrugs in Contemporary Drug Design and Development", Nature Reviews Drug Discovery, 17, 559-587 (2018) (J. Rautio et al.).
[0094] Prodrugs according to the invention can be produced, for example, by replacing appropriate functional groups present in the compounds of the invention with certain moieties known to those skilled in the art as "promoieties", for example as described in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).
[0095] Thus, the prodrugs according to the present invention may be (a) ester or amide derivatives of carboxylic acids when present in the compounds of the present invention; (b) ester, carbonate, carbamate, phosphate or ether derivatives of hydroxy groups when present in the compounds of the present invention; or (c) amide, imine, carbamate or amine derivatives of amino groups when present in the compounds of the present invention.
[0096] Some specific examples of prodrugs according to the present invention include: (i) When the compounds of the present invention contain a carboxylic acid functional group (-COOH), esters thereof, such as compounds wherein the hydrogen of the carboxylic acid functional group of the compound is replaced by a C1-C8 alkyl group (e.g., ethyl) or a (C1-C8 alkyl)C(=O)OCH2- (e.g., tBuC(=O)OCH2-); (ii) when the compounds of the present invention contain an alcohol functional group (-OH), esters thereof, such as compounds wherein the hydrogen of the alcohol functional group of the compound is replaced by -CO(C1-C8 alkyl) (e.g. methylcarbonyl) or the alcohol is esterified by an amino acid; (iii) when the compounds of the present invention contain an alcohol functional group (-OH), ethers thereof, such as compounds wherein the hydrogen of the alcohol functional group of the compound is replaced by (C1-C8 alkyl)C(=O)OCH2- or -CH2OP(=O)(OH)2; (iv) when the compound of the present invention contains an alcohol functional group (-OH), its phosphate ester, such as a compound in which the hydrogen of the alcohol functional group of the compound is replaced by -P(=O)(OH)2 or -P(=O)(O-Na+)2 or -P(=O)(O-)2Ca2+; (v) when the compounds of the present invention contain a primary or secondary amino functional group (-NH2 or -NHR, wherein R ≠ H), the amides thereof, for example compounds wherein, as the case may be, one or both hydrogen atoms of the amino functional group of the compound are replaced by a (C1-C10) alkyl group, -COCH2NH2 or the amino group is derivatized by an amino acid; (vi) When the compounds of the present invention contain a primary or secondary amine functional group (-NH2 or -NHR, wherein R≠H), the amine, for example, a compound wherein one or both hydrogen atoms of the amine functional group of the compound are replaced by -CH2OP(=O)(OH)2, as the case may be.
[0097] Certain compounds of the invention may themselves act as prodrugs of other compounds of the invention. It is also possible for two compounds of the invention to be joined together in prodrug form. In certain cases, a prodrug of a compound of the invention may be produced by internally linking two functional groups in a compound of the invention, for example by forming a lactone.
[0098] [Pharmaceutical composition] In another embodiment, the present invention includes a pharmaceutical composition. For the purpose of the pharmaceutical composition, the compound itself or its pharmaceutically acceptable salt will be referred to as the compound of the present invention.
[0099] The compositions of the present invention may be in a variety of forms. Such forms include, for example, semi-solid and solid dosage forms, such as dispersions or suspensions, tablets, capsules, and pills. The form depends on the intended mode of administration and therapeutic application.
[0100] Oral administration of solid dosage forms can be presented, for example, in the form of discrete units such as hard or soft capsules, pills, cachets, lozenges or tablets, each of which contains a predetermined amount of at least one compound of the invention. In such solid dosage forms, the compounds of the invention are usually combined with one or more adjuvants. Such capsules or tablets may contain controlled release formulations. In the case of capsules, tablets and pills, the dosage form may also contain a buffer or may be prepared with an enteric coating.
[0101] Other excipients and modes of administration known in the pharmaceutical art may also be used. The pharmaceutical compositions of the present invention may be prepared by any of the well-known pharmaceutical techniques, such as effective formulation and administration procedures. The above considerations regarding effective formulation and administration procedures are well known in the art and are described in standard textbooks. The formulation of drugs is discussed, for example, in Ansel, Howard C. et al., [Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems]. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R. et al., [Remington: The Science and Practice of Pharmacy]. Philadelphia: Lippincott, Williams & Wilkins, 2000; Rowe, Raymond C. [Handbook of Pharmaceutical Excipients]. Chicago, Pharmaceutical Press, 2005; edited by Stahl, P. Heinrich and Camilli G. Wermuth. [Handbook of Pharmaceutical Salts: Properties, Selection, and Use]. New York: Wiley-VCH, 2011; and Brittain, Harry G., eds. [Polymorphism in Pharmaceutical Solids]. New York: Informa Healthcare USA, Inc., 2016.
[0102] Acceptable excipients are nontoxic to the subject at the dosages and concentrations used, and may include one or more of the following: 1) buffers, such as phosphates, citrates, or other organic acids; 2) salts, such as sodium chloride; 3) antioxidants, such as ascorbic acid or methionine; 4) preservatives, such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, chloride), phenol, butyl alcohol or benzyl alcohol; 5) alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol or m-cresol; 6) low molecular weight (less than about 10 residues) polypeptides; 7) proteins such as serum albumin, gelatin or immunoglobulins; 8) hydrophilic polymers such as polyvinylpyrrolidone; 9) amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; 10) monosaccharides, disaccharides or other carbohydrates, including glucose, mannose or dextrin; 11) chelating agents, such as EDTA; 12) sugars, such as sucrose, mannitol, trehalose or sorbitol; 13) salt-forming counterions, such as sodium, metal complexes (e.g., Zn-protein complexes), or 14) non-ionic surfactants, such as polysorbates (e.g., polysorbate 20 or polysorbate 80), poloxamer or polyethylene glycol (PEG).
[0103] For oral administration, the composition can be provided in the form of tablets or capsules containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 75.0, 100, 125, 150, 175, 200, 250 or 500 mg of active ingredient to adjust the dosage to the patient. The medicament usually contains about 0.01 mg to about 500 mg of active ingredient, or in another embodiment, about 1 mg to about 100 mg of active ingredient. The dosage regimen can depend on the route of administration, the schedule of administration and the use of fixed doses, the body surface area or the administration based on weight. For example, for intravenous administration based on weight, the dosage can be in the range of about 0.01 to about 10 mg / kg / minute during infusion at a constant rate.
[0104] Liposomes containing the compounds of the invention can be prepared by methods known in the art (see, e.g., Chang, HI; Yeh, MK; Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy; Int J Nanomedicine 2012; 7; 49-60). Particularly suitable liposomes can be produced by reverse phase evaporation using a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). The liposomes are extruded through a filter with a defined pore size to produce liposomes with the desired diameter.
[0105] The compounds of the invention may also be embedded in microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively) prepared, for example, by coacervation techniques or by interfacial polymerization, colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or macroemulsions. Such techniques are disclosed in Remington, The Science and Practice of Pharmacy, 20th edition, Mack Publishing (2000).
[0106] Sustained-release formulations may be used. Suitable examples of sustained-release formulations include semipermeable matrices of solid hydrophobic polymers containing the compounds of the invention, which matrices are in the form of shaped articles, such as films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactic acid, copolymers of L-glutamic acid and 7-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers (such as the copolymers used in leuprolide acetate for depot suspensions) (injectable microspheres composed of lactic acid-glycolic acid copolymers and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.
[0107] A drug intermediate (DPI) is a partially processed material that must undergo additional processing steps before it becomes a bulk drug product. The compounds of the present invention may be formulated into a drug intermediate DPI, which contains the active ingredient in a higher free energy form than the crystalline form. One reason for using a DPI is to improve oral absorption characteristics due to low solubility, slow dissolution, increased mass transport through the mucus layer adjacent to epithelial cells, and in some cases, due to limitations of biological barriers such as metabolism and transport proteins. Other reasons may include improved solid-state stability and downstream manufacturability. In one embodiment, the drug intermediate contains a compound of the present invention isolated and stabilized in an amorphous state (e.g., an amorphous solid dispersion (ASD)). Many techniques for making ASDs are known in the art, which produce materials suitable for integration into bulk drug products, such as spray dried dispersions (SDDs), melt extrudates (commonly referred to as HMEs), coprecipitations, amorphous drug nanoparticles, and nanoadsorbates. In one embodiment, the amorphous solid dispersion comprises a compound of the present invention and a polymer excipient. Other excipients and concentrations of such excipients and compounds of the invention are well known in the art and described in standard textbooks. See, for example, Navnit Shah et al., "Amorphous Solid Dispersions Theory and Practice".
[0108] [Dosage and administration] Typically, the compounds of the present invention are administered in an amount effective to treat the conditions described herein. The compounds of the present invention can be administered as the compounds themselves or alternatively as pharmaceutically acceptable salts. For the purpose of dosing and administration, the compounds themselves or their pharmaceutically acceptable salts will be referred to simply as the compounds of the present invention.
[0109] The compounds of the present invention are administered by any appropriate route, in the form of pharmaceutical compositions suitable for such route, and in dosages effective to achieve the desired treatment.
[0110] The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, whereby the compound enters the bloodstream directly from the mouth.
[0111] The dosing regimen of the compounds of the present invention or compositions containing such compounds is based on various factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the specific compound employed. Therefore, the dosing regimen can vary widely. In one embodiment, the total daily dose of the compounds of the present invention is generally about 0.01 to about 100 mg / kg (i.e., milligrams of the compounds of the present invention per kilogram of body weight) for the treatment of the specified conditions discussed herein. In another embodiment, the total daily dose of the compounds of the present invention is about 0.1 to about 50 mg / kg, and in another embodiment, about 0.5 to about 30 mg / kg. It is not uncommon for the compounds of the present invention to be administered multiple times (usually no more than 4 times) in one day. If necessary, multiple doses per day can usually be used to increase the total daily dose.
[0112] [Treatment methods and uses] The compounds of the present invention act as MYST family lysine acetyltransferase (KAT) inhibitors and may be useful in treating abnormal cell growth, such as cancer. Specifically, these compounds act as KAT6 and / or KAT7 inhibitors.
[0113] References to methods of treatment by the therapies of this specification should be construed as also referring to the compounds, pharmaceutical compositions and medicaments of the invention for use in such methods, including for the manufacture of medicaments used in such methods.
[0114] As used herein, "abnormal cell growth" or "cancer" refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition), unless otherwise indicated. This includes abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing mutant tyrosine kinases or overexpressing receptor tyrosine kinases; (2) benign and malignant cells of other proliferative diseases with aberrant tyrosine kinase activation; (3) any tumor that proliferates by receptor tyrosine kinases; (4) any tumor that proliferates by aberrant serine / threonine kinase activation; (5) benign and malignant cells of other proliferative diseases with aberrant serine / threonine kinase activation; (6) any tumor that proliferates by aberrant signaling, metabolic, epigenetic, and transcriptional mechanisms; and (7) benign and malignant cells of other proliferative diseases with aberrant signaling, metabolic, epigenetic, and transcriptional mechanisms.
[0115] For convenience, certain well-known abbreviations may be used herein, including: estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), non-small cell lung cancer (NSCLC), and castration-resistant prostate cancer (CRPC).
[0116] Other embodiments relate to methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound described herein that is effective to treat the cancer.
[0117] In another embodiment, the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, liver cancer, colon cancer, breast cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, hematological malignancies, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphomas, spinal axis tumors, glioblastomas, brain stem gliomas, and pituitary adenomas, or a combination of two or more of the foregoing cancers.
[0118] In another embodiment, the cancer is breast cancer, lung cancer, colon cancer, brain cancer, prostate cancer, stomach cancer, pancreatic cancer, ovarian cancer, melanoma, endocrine cancer, uterine cancer, testicular cancer, or bladder cancer.
[0119] In another embodiment, the cancer is breast cancer, lung cancer, prostate cancer, pancreatic cancer, or ovarian cancer.
[0120] In another embodiment, the cancer is breast cancer.
[0121] In another embodiment, the breast cancer is ER+ breast cancer.
[0122] In another embodiment, the breast cancer is ER+ HER2- breast cancer.
[0123] In another embodiment, the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.
[0124] In another embodiment, the lung cancer is non-small cell lung cancer.
[0125] In another embodiment, the lung cancer is locally advanced or metastatic non-small cell lung cancer.
[0126] In another embodiment, the prostate cancer is castration-resistant prostate cancer.
[0127] In another embodiment, the prostate cancer is locally advanced or metastatic castration-resistant prostate cancer.
[0128] Other embodiments relate to methods of treating a blood tumor in a subject. Some embodiments relate to treating a blood tumor in a subject in need thereof, comprising administering to the subject an amount of a compound described herein that is effective in treating the blood tumor.
[0129] In another embodiment, the hematological tumor is leukemia, lymphoma or multiple myeloma.
[0130] In another embodiment, the hematological tumor is a leukemia or a lymphoma.
[0131] Other embodiments relate to methods of treating cancer in a patient comprising administering to the patient an amount of a compound described herein effective to treat the cancer in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxic agents, anti-hormones, and anti-androgens.
[0132] Further embodiments relate to pharmaceutical compositions for treating cancer in a patient, comprising an amount of a compound described herein effective to treat the cancer and a pharmaceutically acceptable carrier.
[0133] Still further embodiments relate to methods of treating angiogenesis-related disorders in patients (including humans), comprising administering to the patient an amount effective to treat the disorder of a compound as defined herein or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof and a combination of one or more anti-tumor agents listed above. Such conditions include cancerous tumors, such as melanoma; ocular conditions, such as age-related macular degeneration, presumed ocular histoplasmosis syndrome, and retinal neovascularization due to proliferative diabetic retinopathy; rheumatoid arthritis; bone loss conditions, such as osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, hypercalcemia due to tumor metastasis to bone, and osteoporosis induced by glucocorticoid therapy; coronary artery restenosis; and certain microbial infections, including infections associated with microbial pathogens selected from adenovirus, hantavirus, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and Group A Streptococcus.
[0134] Some embodiments relate to methods (and pharmaceutical compositions) for treating cancer in a patient, comprising an amount of a compound described herein, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and an amount of one or more agents selected from anti-angiogenic agents, signal transduction inhibitors (e.g., agents that inhibit the way regulatory molecules that control fundamental processes of cell growth, differentiation and survival communicate within a cell), and anti-proliferative agents, which together are effective to treat the abnormal cell growth.
[0135] Anti-angiogenic agents, such as matrix metalloproteinase 2 (MMP-2) inhibitors, matrix metalloproteinase 9 (MMP-9) inhibitors, and cyclooxygenase II (COX-II) inhibitors, can be used in combination with the compounds described in the methods herein and in the pharmaceutical compositions described herein.
[0136] Tyrosine kinase inhibitors may also be combined with the compounds described herein.
[0137] VEGF inhibitors, such as sutent and axitinib, can also be combined with the compounds described herein.
[0138] ErbB2 receptor inhibitors can be administered in combination with the compounds described herein. Various other compounds, such as styrene derivatives, have also been shown to have tyrosine kinase inhibitory properties, and some tyrosine kinase inhibitors have been identified as erbB2 receptor inhibitors.
[0139] Epidermal growth factor receptor (EGFR) inhibitors may be administered in combination with the compounds of the invention.
[0140] PI3K inhibitors, such as PI3K alpha or PI3K beta inhibitors, may be administered in combination with the compounds of the invention.
[0141] Mammalian target of rapamycin (mTOR) inhibitors may be administered in combination with the compounds of the invention.
[0142] c-MET inhibitors may be administered in combination with the compounds of the invention.
[0143] CDK inhibitors may be administered in combination with the compounds of the invention.
[0144] MEK inhibitors may be administered in combination with the compounds of the invention.
[0145] PARP inhibitors may be administered in combination with the compounds of the invention.
[0146] JAK inhibitors may be administered in combination with the compounds of the invention.
[0147] Antagonists of the programmed death 1 protein (PD-1) may be administered in combination with the compounds of the invention.
[0148] Antagonists of programmed death-ligand 1 (PD-L1) may be administered in combination with the compounds of the invention.
[0149] Other antiproliferative agents that may be used with the compounds described herein include inhibitors of the enzyme farnesyl protein transferase and inhibitors of the receptor tyrosine kinase PDGFr.
[0150] The compounds described herein may also be used with other agents useful for treating abnormal cell growth or cancer, including but not limited to agents capable of enhancing anti-tumor immune responses, such as cytotoxic lymphocyte antigen 4 (CTLA4) antibodies and other agents capable of blocking CTLA4; and anti-proliferative agents, such as other farnesyl protein transferase inhibitors, e.g., farnesyl protein transferase.
[0151] The compounds described herein may be administered as a sole therapy or may be combined with one or more other anti-tumor substances, such as substances selected from, for example, mitotic inhibitors, alkylating agents, antimetabolites, growth factor inhibitors, cell cycle inhibitors, intercalating antibiotics, enzymes, and anti-hormones.
[0152] The compounds described herein may be used alone or in combination with one or more of a variety of anticancer agents or supportive care agents. For example, the compounds described herein may be used with a cytotoxic agent. Some embodiments also contemplate the use of the compounds described herein with hormone therapy. In addition, some embodiments provide a compound described herein alone or in combination with one or more supportive care products, such as a product selected from the group consisting of: Filgrastim (Neupogen), ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or a combination thereof. Such combination therapy may be achieved by simultaneous, sequential, or separate administration of the individual components of the treatment.
[0153] The compounds described herein can be used together with the following: anti-tumor agents, alkylating agents, antimetabolites, antibiotics, botanical anti-tumor agents, camptothecin derivatives, tyrosine kinase inhibitors, antibodies, interferons and / or biological response modifiers. In this regard, the following is a non-limiting list of examples of second agents that can be used together with the compounds described herein.
[0154] [Co-investment] The compounds of the present invention may be used alone or in combination with one or more other therapeutic agents. The present invention provides any of the uses, methods or compositions defined herein, wherein the compounds of the present invention or their pharmaceutically acceptable salts are used in combination with one or more other therapeutic agents discussed herein.
[0155] Administration of two or more compounds "in combination" means that all compounds are administered close enough in time to achieve treatment of the individual. Depending on the treatment regimen, two or more compounds may be administered simultaneously or sequentially, via the same or different routes of administration, in the same or different administration schedules and with or without specific time limits. In addition, simultaneous administration may be performed by mixing the compounds prior to administration, or by administering the compounds as separate dosage forms at the same time point but at the same or different sites of administration. Examples of "combination" include, but are not limited to, "concurrent administration," "co-administration," "simultaneous administration," "sequential administration," and "administered simultaneously."
[0156] The compounds of the invention and one or more other therapeutic agents may be administered as a fixed or non-fixed combination of active ingredients. The term "fixed combination" means that the compound of the invention, or a pharmaceutically acceptable salt thereof, and the one or more therapeutic agents are both administered to a subject simultaneously in a single composition or dosage. The term "non-fixed combination" means that the compound of the invention, or a pharmaceutically acceptable salt thereof, and the one or more therapeutic agents are formulated as separate compositions or dosages so that they can be administered to a subject in need thereof simultaneously or at different times with variable time intervals, wherein such administration provides an effective amount of the two or more compounds in the subject.
[0157] These agents and compounds of the invention may be combined with pharmaceutically acceptable vehicles such as saline, Ringer's solution, dextrose solution, and the like. The specific dosage regimen, i.e., dosage, timing, and repetition will depend on the particular individual and that individual's medical history.
[0158] [Set] Another aspect of the present invention provides a kit comprising a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention. In addition to the compound of the present invention or its pharmaceutical composition, the kit may also include a diagnostic agent or a therapeutic agent. The kit may also include instructions for use of the diagnostic or therapeutic method. In some embodiments, the kit includes a compound or its pharmaceutical composition and a diagnostic agent.
[0159] In yet another embodiment, the invention comprises a kit suitable for performing the methods of treatment described herein. In one embodiment, the kit contains a first dosage form comprising one or more of the compounds of the invention in an amount sufficient to perform the methods of the invention. In another embodiment, the kit comprises an amount of one or more compounds of the invention sufficient to perform the methods of the invention and a container for dosage.
[0160] [Synthesis method] The compounds of the invention can be synthesized by synthetic routes including methods analogous to those well known in the chemical arts, particularly in accordance with the description contained herein. Starting materials are generally available from commercial sources or can be prepared using methods well known to those skilled in the art. Many of the compounds used herein relate to or can be derived from compounds of general scientific interest or previously identified as meeting commercial needs. Thus, such compounds can be one or more of the following: 1) commercially available; 2) reported in the literature; or 3) prepared by one skilled in the art from other commonly available substances using materials reported in the literature.
[0161] For illustrative purposes, the reaction schemes depicted below provide possible pathways for synthesizing the compounds of the present invention and key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic pathways may also be used to synthesize the compounds of the present invention. Although specific starting materials and reagents are discussed below, other starting materials and reagents may be substituted to provide one or more of the various derivatives or reaction conditions. In addition, many compounds prepared by the methods described below may be further modified according to the present disclosure using conventional chemical methods well known to those skilled in the art.
[0162] It will be appreciated by those skilled in the art that the experimental conditions set forth in the schemes below are illustrative of conditions suitable for achieving the transformations shown, and that it may be necessary or desirable to vary the precise conditions used to prepare the compounds of the invention. It will be further appreciated that it may be necessary or desirable to perform the transformations in an order different from that described in the schemes, or to modify one or more transformations, in order to provide the desired compounds of the invention.
[0163] In preparing the compounds of the present invention, it should be noted that some preparation methods suitable for preparing the compounds described herein may require protection of remote functional groups (e.g., primary amines, secondary amines, carboxyl groups, etc. in precursors of the compounds of the present invention). The need for such protection will vary depending on the nature of the remote functional group and the conditions of the preparation method. The need for such protection is easily determined by those skilled in the art. The use of such protection / deprotection methods is also within the skill of the art. For a general description of protecting groups and their uses, see March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 8th Edition.
[0164] For example, if the compound contains an amine or carboxylic acid functional group, such functional groups, if not protected, may interfere with reactions at other sites of the molecule. Therefore, such functional groups may be protected by an appropriate protecting group (PG) that can be removed in a subsequent step. Suitable protecting groups for protecting amines and carboxylic acids include those commonly used in peptide synthesis (such as N-tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and 9-fluorenylmethyleneoxycarbonyl (Fmoc) for amines and lower alkyl groups, or benzyl esters for carboxylic acids), which are generally chemically unreactive under the reaction conditions described and can generally be removed without chemically altering other functional groups in the compounds of the invention.
[0165] [General Experimental Details] In illustrating the present invention and in the non-limiting examples and preparations set forth in the specification, as well as in the following general methods and schemes, reference may be made to the following abbreviations, definitions and analytical procedures:
[0166] Unless otherwise stated, materials were obtained from commercial suppliers and used without further purification. Removal of solvents under reduced pressure or concentration refers to distillation using a Büchi rotary evaporator connected to a vacuum pump (3 mm Hg). Products obtained as solids or high boiling oils were dried under vacuum (1 mm Hg). Silica gel chromatography was performed by CombiFlash ® (Teledyne ISCO), SP4 or Isolera ™ (Biotage) purification systems. Unless otherwise indicated, all reactions were performed in anhydrous solvents under a positive pressure of nitrogen, argon, or with a drying tube at ambient temperature (unless otherwise specified).
[0167] Analytical thin layer chromatography was performed on glass-backed silica 60_F 254 plates (Analtech, 0.25 mm) and eluted with appropriate solvent ratios (v / v). Reactions were analyzed by high performance liquid chromatography-mass spectrometry (LCMS) or thin layer chromatography (TLC), and termination was judged based on consumption of starting material. TLC plates were visualized by UV, anisaldehyde, phosphomolybdic acid, or iodine staining. Microwave-assisted reactions were performed in Biotage initiator.
[0168] 1H NMR spectra were recorded on a Bruker XWIN-NMR (400 MHz) spectrometer. Proton resonances are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). 1H NMR data are reported as multiplets (s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sept, septet; dd, doublet of doublet; ddd, meaning doublet of doublets; dt, doublet of triplet; td, meaning triplet of doublets; tt, meaning triplet of triplets; dq, meaning doublet of quartets; qd, meaning quadruple of doublets; bs, broad singlet). Exchangeable protons were not always observed. In the NMR spectra, "br" means broad, "m" means multiplet, and "J" means coupling constant. For spectra obtained in CDCl3, DMSO-d6, and CD3OD, residual protons (7.27, 2.50, and 3.31 ppm, respectively) were used as internal references. The progress of the reactions and the purity of the products were measured using LCMS at 254 and 220 nm wavelengths and electrospray ionization (ESI) positive mode or atmospheric pressure chemical ionization (APCI) in positive mode.
[0169] [Purification instructions] All final compounds were purified to ≥95% purity. For most compounds, purity was determined by an Agilent 1200 or 1260 series HPLC coupled to an Agilent 6120 or 6140 Quadrupole LC / MS with simultaneous UV (220 nm and 254 nm) and TIC detection (APCI or ESI), or using a Shimadzu LC-20 HPLC with UV 220 nm detection, or using an Agilent 1260 Infinity Hybrid HPLC / SFC with an Aurora A5 SFC control module, DAD, Leap PAL autosampler, and 6120 single quadrupole MS detection. Chiral purity was analyzed using chiral SFC analysis, utilizing an Agilent 1260 Infinity Hybrid HPLC / SFC, and by screening multiple chiral columns.
[0170] [abbreviation] Ab is absolute; Ac is acetyl; ACN or CH3CN is acetonitrile; AcOH is acetic acid; approx. is approximately; aq is an aqueous solution; ArX is an aryl bromide, aryl chloride or aryl iodide; Boc is a tertiary butoxycarbonyl group; BPin is Acid pinacol ester; B 2Pin 2 is bis(pinacolyl)diboron; ℃ is degrees Celsius; cat is catalytic; CDCl 3 is deuterated chloroform; CN is cyano; δ is the chemical shift; D 2O is deuterated water; DABSO is 1,4-diazabicyclo[2.2.2]octane bis(sulfur dioxide) adduct; DAST is diethylaminosulfur trifluoride; DBU is 1,8-diazabicyclo[5.4.0]undec-7-ene; DCC is N,N-dicyclohexylcarbodiimide; DCM is dichloromethane; methyl chloride; DIEA is N,N-diisopropylethylamine; DHP is dihydro-2H-pyran; DIAD is diisopropyl azodicarboxylate; DIPEA is N-ethyldiisopropylamine, also known as N,N-diisopropylethylamine; DMA is dimethylacetamide; DMAD is dimethyl acetylene dicarboxylate; DMAP is 4-(dimethylamino)pyridine; DMB is 2,4-dimethoxybenzyl; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; DMSO-d6 is deuterated dimethyl sulfoxide; DPPA is diphenylphosphoryl azide; Et is ethyl; EtOAc is ethyl acetate; EtOH is ethanol; F / mol is the number of faradays per mole; g is gram; HATU is 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; Het(Ar) and Ar(Het) used in the process mean heteroaryl or aryl, as defined in this specification and the scope of the patent application; HFIP is hexafluoroisopropanol; HPLC is high pressure liquid chromatography; HSPMB is 4-methoxy-α-toluenethiol; hr is hours; L is liter; LCMS is liquid chromatography mass spectrometry; LDA is lithium diisopropylamine; LiHMDS is lithium hexamethyldisilazide; M is mole; mA is milliampere or one thousandth of an ampere; MeOH is methanol; mg is milligram; MHz is million Hertz; MIDA is N-methyliminodiacetic acid; min is minutes; mL means milliliter; mmol is millimole; Mol means mole; MPa is megapascal; MS (m / z) is the mass spectrum peak; MsOH is methanesulfonic acid; MTBE is tertiary butyl methyl ether; NaOtPn is sodium 2-methylbutan-2-ol; nBuLi is n-butyllithium; n-Bu 2Mg is di-n-butylmagnesium; NCS is N-chlorobutane diimide; N / D means not determined; NMR is nuclear magnetic resonance spectroscopy; Pd / C is palladium / carbon; Pd 2(dba) 3 is di(benzhydryl)acetone dipalladium(0); Pd(dppf)Cl 2 is [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II); Pd(OAc) 2 is palladium(II) acetate; Pd(PPh 3) 4 is tetrakis(triphenylphosphine)palladium(0); Pet ether is petroleum ether, and is a petroleum fraction composed of aliphatic hydrocarbons and boiling in the range of 35-60°C; PG is a protecting group; pH is the power or potential of hydrogen; Ph 3P is triphenylphosphine; PMB is p-methoxybenzyl or 4-methoxybenzyl; ppm is parts per million; rt is room temperature; R f is the retention factor; R t is the residence time; sat. is saturated; SEM is 2-(trimethylsilyl)ethoxymethyl; SEM-Cl is 2-(trimethylsilyl)ethoxymethyl chloride or [2-(chloromethoxy)ethyl](trimethyl)silane; SFC is supercritical fluid chromatography; SiO 2 is silicon dioxide; SM is the starting material; STAB is sodium triacetoxyborohydride; tBu is tertiary butyl; TEA is triethylamine; TFA is trifluoroacetic acid; TFAA is trifluoroacetic anhydride; THF is tetrahydrofuran; THP is tetrahydropyran; TLC is thin layer chromatography; TMPLi is tetramethylpiperidinium lithium; TMS stands for trimethylsilyl and tetramethylsilane; Turbo grignard is a composite solution of isopropyl magnesium chloride and lithium chloride; µL means microliter; µmol is micromole; Xantphos is 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran; and XPhos is 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl.
[0171] The reaction schemes described below are intended to provide a general description of methods for preparing compounds of the present invention. Some of the compounds of the present invention contain one or two chiral centers. In the following schemes, general methods for preparing compounds are shown in racemic or enantiomerically enriched form. It is obvious to those skilled in the art that all synthetic transformations can be carried out in a very similar manner, whether the material is enantiomerically enriched or racemic. In addition, the resolution of the desired optically active material can be carried out at any desired position in the sequence using well-known methods such as those described herein and in the chemical literature.
[0172] [General method] Unless otherwise indicated, the variables in Scheme IX have the same meanings as defined herein. Process I: Process II: Process III: Process IV: Process V: Process VI: Process VII: Process VIII: Process IX: Process X:
[0173] In some cases, the compounds described in Schemes I-VIII may contain protecting groups, which can be added or removed by additional steps in the synthetic sequence using conditions known in the art (March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 8th Edition, or Protecting Groups, 10 Georg Thieme Verlag, 1994). The compounds at each step can be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Ring A, Ring B, R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9R 10, R 13 and R 14 are defined as in the embodiments, schemes, examples and claims herein.
[0174] [Example] [] In order to better understand the present invention, the following examples are described. These examples are only for the purpose of illustration and should not be interpreted as limiting the scope of the present invention in any way.
[0175] The compounds and intermediates described below are named using the nomenclature provided by ACD / Spectrus Processor 2019.1.1, Version S05S41; 2020.2.1.1, Version C25H41; or 2022.2.0, Version C45H41 (Advanced Chemistry Development, 8 King Street East, Suite 107, Toronto, Ontario, M5C 1B5, Canada). The naming conventions provided by ACD / Spectrus Processor 2019.1.1, Version S05S41; 2020.2.1.1, Version C25H41; or 2022.2.0, Version C45H41 are well known to those skilled in the art and are believed to be generally consistent with the International Union for Pure and Applied Chemistry (IUPAC) recommendations for organic chemical nomenclature and CAS index rules unless otherwise stated. All reactants were obtained commercially without further purification or prepared using methods known in the literature.
[0176] [Preparation of synthetic intermediates] [Intermediate] [A] [:] [6-] [bromine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine]
[0177] [4-] [bromine] [-2-] [fluorine] [-6-] [Methoxybenzonitrile] [(A1)] [:] To a cooled (0 °C) solution of 4-bromo-2,6-difluorobenzonitrile (100 g, 459 mmol) in THF (1000 mL) was added sodium methoxide (65 g, 360 mmol) in portions. When the addition was complete, stirring was continued at room temperature (30 °C) for 16 hours. The mixture was quenched with H 2 O (600 mL) and extracted with EtOAc (2×400 mL). The combined organic extracts were concentrated under reduced pressure, and the residue was then recrystallized from DCM (100 mL) and petroleum ether (300 mL) to give 4-bromo-2,6-difluorobenzonitrile as a white solid. [A1](64.5 g,61%). 1H NMR (400 MHz, CHLOROFORM- d) δ 7.10-6.99 (m, 1H), 6.99-6.93 (m, 1H), 3.98 (br s, 3H).
[0178] [6-] [bromine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine] [(] [Intermediate] [A)] [:]Heat 4-bromo-2-fluoro-6-methoxybenzonitrile ( A mixture of [A1]) (26.0 g, 90 mmol), N-hydroxyacetamide (20.4 g, 271 mmol) and 1,1,3,3-tetramethylguanidine (62.5 g, 543 mmol) in ACN (240 mL) and H 2 O (30 mL) was added for 16 hours. After cooling to room temperature, the solvent was removed under vacuum. H 2 O (50 mL) was added to the residue, resulting in the formation of a white precipitate. The precipitate was collected by filtration and dried to give [Intermediate] [A] (17.0 g, 77% yield). 1H NMR (400 MHz, DMSO-d 6) δ 7.32 (d, J=0.9 Hz, 1H), 6.91 (s, 1H), 6.05 (s, 2H), 3.93 (s, 3H).
[0179] [Intermediate] [B] [:] [6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine]
[0180] [4-] [bromine] [-2-] [fluorine] [-5-] [Methoxybenzamide] [(B1)] [:] DIPEA (17.1 g, 133 mmol) was added to a solution of 4-bromo-2-fluoro-5-methoxybenzoic acid (11.0 g, 44.2 mmol) and ammonium chloride (3.58 g, 66.9 mmol) in DMF (100 mL) at room temperature (15 °C). Next, HATU (25.2 g, 66.3 mmol) was added portionwise, slowly enough to maintain the internal temperature below 20 °C. When the addition was complete, stirring was continued at room temperature (15 °C) for two hours. The reaction mixture was poured into cold H 2 O (200 mL) with stirring, causing a precipitate to form. The solid was collected by filtration, washed with H 2 O and dried to give [B1](9.3 g,85%). 1H NMR (400 MHz, DMSO- d 6) δ 7.75 (br s, 2H), 7.67 (d, J=9.5 Hz, 1H), 7.31 (d, J=6.2 Hz, 1H), 3.87 (s, 3H).
[0181] [4-] [bromine] [-2-] [fluorine] [-5-] [Methoxybenzonitrile] [(B2)] [:] 4-Bromo-2-fluoro-5-methoxybenzamide ( ) was treated dropwise with TFAA (11.8 g, 56 mmol) at 15 °C. [B1]) (9.3 g, 37.5 mmol) and TEA (11.4 g, 112 mmol) in DCM (180 mL). The resulting clear solution was stirred at 15 °C for two hours. The mixture was poured into H 2 O (200 mL), the layers were separated and the aqueous layer was extracted with DCM (100 mL). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated to give [B2](10 g,>100%). 1H NMR (400 MHz, chloroform- d) δ 7.48 (d, J=7.8 Hz, 1H), 7.04 (d, J=5.3 Hz, 1H), 3.92 (s, 3H).
[0182] [6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine] [(] [Intermediate] [B)] [:] At room temperature (20°C), 4-bromo-2-fluoro-5-methoxybenzonitrile ( [B2]) (6.00 g, 23 mmol) and potassium carbonate (18.8 g, 136 mmol) were suspended in DMF (140 mL) and H 2 O (20 mL). N-Hydroxyacetamide (5.11 g, 68 mmol) was added and the mixture was heated at 60° C. for three hours. After cooling to room temperature, the crude reaction mixture was poured into ice water (250 mL), and the resulting precipitate was collected by filtration. The filter cake was washed with H 2 O (50 mL) and dried to give the first batch of product. The aqueous filtrate was extracted with EtOAc (2×100 mL). The combined organic extracts were washed with brine (3×50 mL), dried over sodium sulfate, concentrated, and the residue (900 mg) was recrystallized from 20 mL 1:4 EtOAc / petroleum ether to give the second batch of product. The two batches of product were combined and dried under vacuum to give [Intermediate] [B](4.7 g,85%). LCMS m / z242.8 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.83 (s, 1H), 7.52 (s, 1H), 6.40 (s, 2H), 3.86 (s, 3H).
[0183] [intermediate] [C] [:] [6-] [bromine] [-5-] [fluorine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine]
[0184] [4-] [bromine] [-2,3,6-] [Trifluorobenzaldehyde] [(C1)] [:] To a solution of 1-bromo-2,3,5-trifluorobenzene (200 g, 948 mmol, 114 mL) in THF (2000 mL) was added TMPLi (1 M, 1422 mmol, 1.42 L) dropwise at -65°C and stirred at 25°C for one hour. DMF (83.2 g, 1.14 mol, 87.5 mL) was then added dropwise at 25°C and the crude reaction mixture was stirred at 25°C for one hour. LCMS showed that the starting material was completely consumed and the desired product was formed. The process was repeated and the two batches were combined. The reaction was quenched with saturated NH 4 Cl (2000 mL) at 0~5°C and adjusted to pH=5 with 2 N HCl aqueous solution. The aqueous layer was extracted with EtOAc (2000 mL×2). The combined organic layers were washed with brine (2000 mL), dried over MgSO 4 , filtered, and the filtrate was concentrated. The crude product was purified by silica gel chromatography and eluted with petroleum ether-THF (1:0-97:3) to obtain a yellow solid. [C1](158 g,34%). 1H NMR (400 MHz, chloroform- d) δ 10.21 (s, 1H), 7.22-7.19 (m, 1H).
[0185] [4-] [bromine] [-2,3,6-] [Trifluorobenzonitrile] [(C2)] [:] to 4-bromo-2,3,6-trifluorobenzaldehyde ( [C1]) (108 g, 452 mmol) in H 2 O (1000 mL) was added hydroxylamine-O-sulfonic acid (66.4 g, 588 mmol), and then the reaction was stirred at 105 ° C for four hours. TLC (petroleum ether-EtOAc=10:1, R f=0.5) showed that the starting material was completely consumed. The reactant was extracted with EtOAc (1000 mL×2). The combined organic layers were washed with brine (1000 mL), dried over MgSO 4, filtered, and the filtrate was concentrated to give a crude product. TFAA (113.1 g, 539 mmol, 74.9 mL) was added to a solution of the crude product (114 g, 449 mmol) and TEA (136.2 g, 1.4 mol, 187 mL) in THF (1200 mL) at 0~5 ° C, and then the reactant was stirred at 25 ° C for 2 hours. TLC (petroleum ether-EtOAc=10:1, R f=0.4) showed that the starting material was completely consumed. The reactant was added to H 2O (1000 mL) and the aqueous layer was extracted with EtOAc (1000 mL×2). The combined organic layers were washed with brine (1000 mL), dried over MgSO 4, filtered, and the filtrate was concentrated to give a crude product. The crude product was mixed with the crude product 4-bromo-2,3,6-trifluorobenzaldehyde ( [C1]) (50 g, 209 mmol) were combined and purified by silica gel chromatography and eluted with petroleum ether-THF (1:0-98:2) to obtain a yellow solid. [C2] (115 g, 74% yield). 1H NMR (400 MHz, DMSO-d 6) δ 8.11-8.07 (m, 1H).
[0186] [4-] [bromine] [-3,6-] [Difluoro] [-2-] [Methoxybenzonitrile] [(C3)] [:] At 0~5℃, 4-bromo-2,3,6-trifluorobenzonitrile ( [C2]) (94.3 g, 400 mmol) in methanol (1000 mL) was added sodium methoxide (72 g, 400 mmol) dropwise and then the reaction was stirred at 0-5 °C for one hour. LCMS showed that the starting material was completely consumed. The reactant was added to H 2O (1000 mL) and the aqueous layer was extracted with EtOAc (1000 mL×2). The combined organic layers were washed with brine (1000 mL), dried over MgSO 4, filtered, and the filtrate was concentrated to give the crude product. The crude product was purified by silica gel chromatography and eluted with petroleum ether-THF (1:0-99:1) to give [C3] (84.3 g, 85%). 1H NMR (400 MHz, DMSO- d 6) δ 7.78 (dd, J=8.5, 4.9 Hz, 1H), 4.16 (d, J=3.4 Hz, 3H).
[0187] [6-] [bromine] [-5-] [fluorine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [amine] [(] [Intermediate] [C)] [:] to 4-bromo-3,6-difluoro-2-methoxybenzonitrile ( [C3]) (84.3 g, 340 mmol), N-hydroxyacetamide (76.5 g, 1.02 mol) in DMF (800 mL) and H 2O (100 mL) were added K 2CO 3 (281.8 g, 2.04 mol), and then the reaction was stirred at 60°C for two hours. LCMS showed that the starting material was completely consumed and the desired product was formed. The reactant was added to H 2O (1000 mL) and extracted with EtOAc (1000 mL×2). The combined organic layers were washed with brine (1000 mL), dried over MgSO 4, filtered, and the filtrate was concentrated to give the crude product. The crude product was triturated with petroleum ether-EtOAc=10:1 (250 mL) at 25°C for one hour. The mixture was filtered and the filter cake was washed with petroleum ether (20 mL×2). The filter cake was collected and concentrated under reduced pressure to give an off-white solid. [Intermediate] [C](53.5 g,60%). LCMS m / z261 / 263 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.58 (d, J=4.2 Hz, 1H), 6.19 (s, 2H), 4.10 (d, J=3.8 Hz, 3H).
[0188] [Intermediate] [D] [:] [3-] [Methoxy] [-5,6,7,8-] [Tetralin] [-2-] [Sulfonyl chloride]
[0189] [3-] [Methoxy] [-5,6,7,8-] [Tetralin] [-2-] [Sulfonyl chloride] [(] [Intermediate] [D)] [:] Chlorosulfonic acid (338 mg, 0.22 mL, 3.33 mmol) was added dropwise to a cooled (0°C) solution of 6-methoxy-1,2,3,4-tetrahydronaphthalene (200 mg, 1.1 mmol) in DCM (3.0 mL) under nitrogen. The solution was stirred at 0°C for 1 hour, during which time the color changed from gray to purple. The mixture was slowly poured into ice water and extracted with DCM (2×30 mL). The combined organic extracts were washed with H 2 O (2×30 mL) and brine (30 mL), dried over sodium sulfate, filtered and concentrated to give 6-methoxy-1,2,3,4-tetrahydronaphthalene (200 mg, 1.1 mmol) as a white solid. [Intermediate] [D](230 mg,80%). 1H NMR (400 MHz, chloroform-d) δ 7.65 (s, 1H), 6.79 (s, 1H), 4.01 (s, 3H), 2.84 (br s, 2H), 2.75 (br s, 2H), 1.82 (td, J=3.4, 6.4 Hz, 4H).
[0190] according to [Intermediate] General method preparation of [D] [surface]
[14] as the sulfonyl chloride intermediate. [ , , ] [] [surface]
[14] [Intermediate Name] [Structure / IUPAC] [name] [Analysis data] [D] [a] 2-Ethoxy-5-fluoro-4-methylbenzene-1-sulfonyl chloride 1H NMR (400 MHz, CDCl 3) d 7.62 (δ, J=8.3 Hz, 1H), 6.91 (d, J=5.8 Hz, 1H), 4.24 (q, J=7.0 Hz, 2H), 2.38 (d, J=2.0 Hz, 3H), 1.55 (t, J=7.0 Hz, 3H) [Db] 4-Bromo-2,6-dimethoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, CDCl 3) δ 6.83 (s, 2 H) 3.99 (s, 6 H)
[0191] [Intermediate] [E] [:] [2-] [Ethoxy] [-4-] [Methylbenzene] [-1-] [Sulfonyl chloride]
[0192] [5-] [bromine] [-2-] [Ethoxy] [-4-] [Methylbenzene] [-1-] [Sulfonic acid] [(E1)] [:] To an ice-bath cooled flask containing concentrated sulfuric acid (300 mL) was added 1-bromo-4-ethoxy-2-methylbenzene (158 g, 732 mmol) dropwise over 10 minutes. The resulting light brown mixture was stirred overnight and then quenched by the addition of crushed ice (750 mL), resulting in the formation of a white precipitate. The solid was collected by filtration and dried to give [E1](180 g,83%).
[0193] [2-] [Ethoxy] [-4-] [Methylbenzene] [-1-] [Sulfonic acid] [(E2)] [:] 5-bromo-2-ethoxy-4-methylbenzene-1-sulfonic acid ( [E1]) (150 g, 508 mmol) and 10% Pd / C (27 g) in ethanol (1000 mL) were reacted under 0.4 MPa hydrogen at 60 °C overnight. The mixture was filtered through a powdered cellulose pad to remove the solids, and the filtrate was concentrated to dryness to leave a white solid. [E2](96.6 g,88%).
[0194] [2-] [Ethoxy] [-4-] [Methylbenzene] [-1-] [Sulfonyl chloride] [(] [Intermediate] [E)] [:] containing 2-ethoxy-4-methylbenzene-1-sulfonic acid ( [E2]) (46.2 g, 214 mmol) was cooled in an ice bath. Thionyl chloride (240 mL, 3.3 mol) and DMF (30 drops) were added over 30 minutes. The mixture was heated at reflux for two hours and then allowed to stir at room temperature overnight. The mixture was concentrated to dryness to leave a white solid. [Intermediate] [E](33.6 g,67%). GCMS m / z234 M +; 1H NMR (400 MHz, chloroform- d) δ 7.81 (d, J=8.5 Hz, 1H), 6.87-6.85 (m. 2H), 4.25 (q, J=7.0 Hz, 2H), 2.44 (s, 3H), 1.54 (t, J=7.0 Hz, 3H).
[0195] [Intermediate] [F] [:] [2-] [Ethoxy] [-6-] [Methoxybenzene] [-1-] [Sulfonyl chloride]
[0196] [2-(] [Benzylthio] [)-1-] [Methoxy] [-3-(] [Methoxymethoxy] [)] [benzene] [(F1)] [:] To a cooled (0°C) solution of 1-methoxy-3-(methoxymethoxy)benzene (6.00 g, 35.7 mmol) in anhydrous THF (150 mL) was added n-butyllithium (2.5 M in THF, 17.8 mL, 44.6 mmol) dropwise under a dry nitrogen atmosphere. After the addition was complete, stirring was continued at 0°C for one hour, followed by the addition of diphenylmethyl disulfide (10.5 g, 42.8 mmol) in portions. Stirring was continued at 0°C for two hours, then at room temperature overnight. The reaction was quenched with methanol, directly adsorbed onto silica gel, and purified by silica gel chromatography (eluting with 0-50% EtOAc in petroleum ether) to give [F1](7.7 g,74%). 1H NMR (400 MHz, chloroform- d) δ 7.24-7.14 (m, 6H), 6.77 (d, J=8.3 Hz, 1H), 6.60 (d, J=8.3 Hz, 1H), 5.09 (s, 2H), 4.02 (s, 2H), 3.85 (s, 3H), 3.44 (s, 3H).
[0197] [2-(] [Benzylthio] [)-3-] [Methoxyphenol] [(F2)] [:] 2-(Benzylthio)-1-methoxy-3-(methoxymethoxy)benzene ( A solution of [F1]) (7.70 g, 26.5 mmol) in acetone (330 mL) was treated with sodium iodide (4.77 g, 31.8 mmol) and stirred until all dissolved. The solution was cooled to 0 °C, and then a solution of HCl in methanol (4.0 M in dioxane, 166 mL, 664 mmol) was added dropwise. The cloudy yellow mixture was stirred at 0 °C for 10 minutes, and then poured into saturated aqueous NaHCO 3 solution (500 mL). Solid NaHCO 3 was added until pH = 7. The mixture was extracted with EtOAc (300 mL). The organic layer was washed with brine (200 mL), dried over sodium sulfate and concentrated to give the crude product as a yellow oil. [F2](7.0 g,100%). 1H NMR (400 MHz, chloroform- d) δ 7.30-7.15 (m, 4H), 7.15-7.08 (m, 2H), 6.74 (s, 1H), 6.57 (dd, J=1.1, 8.3 Hz, 1H), 6.47 (d, J=8.3 Hz, 1H), 3.88 (s, 2H), 3.87 (s, 3H).
[0198] [2-(] [Benzylthio] [)-1-] [Ethoxy] [-3-] [Methoxybenzene] [(F3)] [:] 2-(Benzylthio)-3-methoxyphenol ( [F2]) (1.0 g, 3.78 mmol), iodoethane (807 mg, 5.18 mmol) and cesium carbonate (2.81 g, 8.63 mmol) in anhydrous DMF (20.0 mL) were added for 16 h. The mixture was poured into brine (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (30 mL), dried over sodium sulfate, concentrated and purified by silica gel chromatography (eluting with 0-50% EtOAc in petroleum ether) to give [F3](900 mg,86%). LCMS m / z275 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 7.26-7.10 (m, 6H), 6.52 (d, J=8.4 Hz, 2H), 4.07-3.98 (m, 4H), 3.85-3.77 (m, 3H), 1.44 (t, J=6.9 Hz, 3H).
[0199] [2-] [Ethoxy] [-6-] [Methoxybenzene] [-1-] [Sulfonyl chloride] [(] [Intermediate] [F)] [:] To 2-(Benzylthio)-1-ethoxy-3-methoxybenzene ( To a cooled (0 °C) solution of [F3]) (900 mg, 3.28 mmol) in acetic acid (27 mL) and H2O (9.0 mL) was added N-chlorobutanediimide (482 mg, 3.61 mmol). Stirring was continued at 0 °C for several minutes, then a second portion of NCS (482 mg, 3.61 mmol) was added and the mixture was stirred at 20 °C for 30 minutes, but no further conversion was observed. A third portion of NCS (482 mg, 3.61 mmol) was added and stirring was continued at 15 °C for 2.5 hours. The reaction mixture was poured into saturated aqueous NaHCO3 (100 mL) and solid NaHCO3 was carefully added to basify the solution. The mixture was extracted with EtOAc (2×50 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, concentrated and immediately purified by silica gel chromatography (eluting with 0-50% EtOAc in petroleum ether) to give [Intermediate] [F] (700 mg, 85%), which solidified upon standing. The product was stored at 0°C to delay decomposition. 1H NMR (400 MHz, chloroform-d) δ 7.53 (t, J=8.5 Hz, 1H), 6.65 (d, J=8.5 Hz, 2H), 4.73 (s, 1H), 4.22 (q, J=7.0 Hz, 2H), 3.99 (s, 3H), 1.54 (t, J=7.0 Hz, 3H).
[0200] according to [Intermediate] [F], prepared by using a specified alkyl halide instead of iodoethane in the ether formation step [surface]
[15] is a sulfonyl chloride intermediate. [surface]
[15] [Intermediate Name] [Structure / IUPAC] [name] [Analysis data] [Used] [Alkyl halide] [F] [a] 2-(2,2-Difluoroethoxy)-6-methoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform- d) δ 7.58 (t, J=8.5 Hz, 1H), 6.77 (d, J=8.3 Hz, 1H), 6.64 (d, J=8.0 Hz, 1H), 6.22 (tt, J=4.0, 55.0 Hz, 1H), 4.33 (dt, J=4.1, 12.5 Hz, 2H), 4.01 (s, 3H) 1,1-Difluoro-2-iodoethane [Fb] 2-Methoxy-6-[(propan-2-yl)oxy]benzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform-d) δ 7.42 (t, J=8.5 Hz, 1H), 6.57 (d, J=8.1 Hz, 1H), 6.52 (d, J=8.5 Hz, 1H), 4.70-4.59 (m, 1H), 3.89 (s, 3H), 1.37 (d, J=6.0 Hz, 6H) 2-Iodopropane [Fc] 2-(Cyclobutyloxy)-6-methoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform-d) δ 7.48 (t, J=8.5 Hz, 1H), 6.62 (d, J=8.5 Hz, 1H), 6.47 (d, J=8.5 Hz, 1H), 4.78 (quin, J=7.1 Hz, 1H), 3.97 (s, 3H), 2.55-2.44 (m, 2H), 2.41-2.27 (m, 2H), 1.99-1.88 (m, 1H), 1.79-1.65 (m, 1H) Bromocyclobutane
[0201] [Intermediate] [G] [:] [2-(2,2-] [Difluoroethoxy] [)-4-] [Methylbenzene] [-1-] [Sulfonyl chloride:] [1-] [bromine] [-2-(2,2-] [Difluoroethoxy] [)-4-] [Methylbenzene] [(G1)] [:] A mixture of 2-bromo-5-methylphenol (1.0 g, 5.3 mmol), 1,1-difluoro-2-iodoethane (2.0 g, 10.7 mmol) and potassium carbonate (2.2 g, 16 mmol) in DMF (10 mL) was heated at 80 °C for 16 h. The mixture was diluted with H 2 O (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to give 4-(2-bromo-5-methylphenol) as a brown solid. [G1] (1.4 g, quantitative). TLC (1 / 4 petroleum ether / EtOAc) R f 0.3.
[0202] [2-(2,2-] [Difluoroethoxy] [)-1-{[(4-] [Methoxyphenyl] [)] [methyl] []] [Thio] [}-4-] [Methylbenzene] [(G2)] [:] 1-Bromo-2-(2,2-difluoroethoxy)-4-methylbenzene ( A solution of [G1]) (700 mg, 2.8 mmol), Pd2(dba)3 (102 mg, 0.11 mmol), Xantphos (129 mg, 0.22 mmol) and (4-methoxyphenyl)methanethiol (1.3 g, 8.4 mmol) in dioxane (16 mL) was degassed and purged three times with nitrogen, followed by the addition of diisopropylamine (2.4 mL, 13.9 mmol). The crude reaction mixture was heated at 105 °C for 16 hours. The crude reaction mixture was concentrated under reduced pressure, and the residue was purified using silica gel chromatography and eluted with 0-40% EtOAc-petroleum ether to give [G2](400 mg,44%). TLC (1 / 4 petroleum ether / EtOAc) R f0.2; 1H NMR (400 MHz, chloroform- d) δ 7.24-7.15 (m, 3H), 6.85-6.75 (m, 3H), 6.69 (s, 1H), 6.35-5.96 (m, 1H), 4.23 (dt, J=4.3, 13.1 Hz, 2H), 4.04 (s, 2H), 3.80 (s, 3H), 2.42-2.26 (m, 3H).
[0203] [2-(2,2-] [Difluoroethoxy] [)-4-] [Methylbenzene] [-1-] [Sulfonyl chloride] [(] [Intermediate] [G)] [:] To 2-(2,2-difluoroethoxy)-1-{[(4-methoxyphenyl)methyl]thio}-4-methylbenzene ( To a solution of [G2]) (400 mg, 1.2 mmol) in ACN (16 mL) were added acetic acid (0.7 mL), H2O (0.5 mL) and 1,3-dichloro-5,5-dimethyllactone (486 mg, 2.5 mmol). The latter was added portionwise at 0°C. After the addition, the crude reaction mixture was stirred at 0-10°C for 1 hour. The crude reaction mixture was diluted with EtOAc (20 mL) and washed with aqueous sodium bicarbonate solution (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated. The crude product was purified by silica gel chromatography eluting with 0-40% EtOAc-petroleum ether and obtained as a white solid. [Intermediate] [G] (250 mg, 75%). For the starting material, TLC (1 / 2 EtOAc / petroleum ether) R f0.1 and R f0.3; 1H NMR (400 MHz, chloroform- d) δ 7.88 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8.3 Hz, 1H), 6.92 (s, 1H), 6.38-6.08 (m, 1H), 4.41 (dt, J = 4.3, 12.4 Hz, 2H), 2.49 (s, 3H).
[0204] according to [Intermediate] General method preparation of [G] [surface]
[16] as the sulfonyl chloride intermediate. [surface]
[16] [Intermediate Name] [Structure / IUPAC] [name] [Analysis data] [Ga] [2-] [Ethoxy-4-] [Fluorobenzene-1-] [Sulfonyl chloride] 1H NMR (400 MHz, chloroform- d) δ 8.02-7.95 (m, 1H), 6.84-6.75 (m, 2H), 4.27 (q, J=7.0 Hz, 2H), 1.58 (t, J=7.0 Hz, 3H) [Gb] 2-Fluoro-6-methoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform- d) δ 7.65-7.60 (m, 1H), 6.94-6.82 (m, 2H), 4.06 (s, 3H) [Gc] 4-Fluoro-2-methoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform- d) δ 8.00 (dd, J=8.7, 5.9 Hz, 1H), 6.90 (d, J=8.6 Hz, 1H), 6.85-6.82 (m, 1H) 4.07 (s, 3H) [Gd] 4,5-Difluoro-2-methoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform- d) δ 7.87 (t, J=8.7 Hz, 1H), 6.96 (dd, J=11.3, 5.9 Hz, 1H), 4.05 (s, 3H) [Ge] 4-(Difluoromethyl)-2-ethoxybenzene-1-sulfonyl chloride 1H NMR (400 MHz, chloroform- d) δ 8.07 (d, J=8.2 Hz, 1H), 7.36-7.30 (m, 1H), 6.96-6.87 (m, 1H), 6.70 (t, J=55.8 Hz, 1H), 4.36 (q, J=7.0 Hz, 2H), 1.60 (t, J=7.0 Hz, 3H)
[0205] [intermediate] [H] [:] [2-(] [Cyclopropyloxy] [)-6-] [Methoxybenzene] [-1-] [Sulfonyl chloride]
[0206] [2-(] [Benzylthio] [)-1-(] [Cyclopropyloxy] [)-3-] [Methoxybenzene] [(H1)] [:] 2-(Benzylthio)-3-methoxyphenol ( A mixture of [F2]) (1.50 g, 6.09 mmol), potassium cyclopropyltrifluoroborate (2.30 g, 15.5 mmol), 1,10-phenanthroline (274 mg, 1.52 mmol), copper(II) acetate (277 mg, 1.52 mmol) and potassium carbonate (1.68 g, 12.2 mmol) in toluene (12.0 mL) and H 2 O (4.0 mL) was gassed with oxygen and then stirred at 70° C. under an oxygen balloon for 16 hours. The mixture was diluted with EtOAc (50 mL) and the aqueous layer was separated. The organic layer was concentrated and purified by silica gel chromatography (eluting with 0-10% EtOAc in petroleum ether) to give [H1](700 mg,40%). 1H NMR (400 MHz, chloroform-d) δ 7.27-7.10 (m, 6H), 6.88 (dd, J=0.9, 8.3 Hz, 1H), 6.55 (d, J=8.6 Hz, 1H), 3.95 (s, 2H), 3.83 (s, 3H), 3.71 (br d, J=3.1 Hz, 1H), 0.81-0.72 (m, 2H), 0.72-0.63 (m, 2H).
[0207] [2-(] [Cyclopropyloxy] [)-6-] [Methoxybenzene] [-1-] [Sulfonyl chloride] [(] [Intermediate] [H)] [:] by and through [G2] converted to [Intermediate] [G] The same method was used, using 2-(benzylthio)-1-(cyclopropyloxy)-3-methoxybenzene ( [H1]) (900 mg, 3.14 mmol) was prepared as a colorless oil [Intermediate] [H] (700 mg, 85%), which solidified upon standing. 1H NMR (400 MHz, chloroform-d) δ 7.61-7.51 (m, 1H), 7.05 (dd, J=0.9, 8.4 Hz, 1H), 6.68 (d, J=8.6 Hz, 1H), 4.73 (s, 1H), 4.04-3.96 (m, 3H), 3.96-3.88 (m, 1H), 0.99-0.83 (m, 4H).
[0208] [Intermediate] [I] [:] [3-(1,1-] [Difluoroethyl] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-5-] [amine] A mixture of potassium (E)-1-cyano-3,3-difluorobut-1-en-2-olate (171 mg, 1.0 mmol) and (4-methoxybenzyl)hydrazine hydrochloride (225 mg, 1.00 mmol) in ethanol (3.3 mL) was heated at 80 °C for six hours. The crude reaction mixture was analyzed by LCMS and gave a ca. 3:2 mixture of isomers (R t 1.2 min and R t 1.5 min). The crude reaction mixture was concentrated to a solid and partitioned between EtOAc and H 2 O. The EtOAc layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to an oil. The crude product was purified by silica gel chromatography and eluted with 0-100% EtOAc-heptane. The two isomers were separated on silica gel and the isomer (189 mg, 71%) was isolated as a light amber oil with R t 1.2 min. LCMS m / z268 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 7.13 (d, J=8.6 Hz, 2H), 6.88 (d, J=8.6 Hz, 2H), 5.75 (s, 1H), 5.17 (s, 2H), 3.80 (s, 3H), 3.39 (br s, 2H), 2.00 (t, J=18.4 Hz, 3H).
[0209] [] [Intermediate] [J] [:] [5-(] [Difluoromethoxy] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [amine]
[0210] [5-] [Hydroxy] [-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [Ethyl formate] [(J1)] [:] To a mixture of diethyl but-2-ynedioate (1.70 g, 10.0 mmol) and (4-methoxybenzyl)hydrazine (1.89 g, 10.0 mmol) in ethanol (20 mL) was added TEA (1.1 g, 11.0 mmol, 1.5 mL) at room temperature. Two days later, LCMS gave an 86:13 mixture of isomers (R t 1.2 min (most) and R t 1.4 min (minor)). The crude reaction mixture was concentrated and the crude product was partitioned between EtOAc and H 2 O. The EtOAc layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to an oil. The crude product was purified by silica gel chromatography (40 g) and eluted with 0-100% EtOAc-heptane to give 4-(4-methoxybenzyl)-2 ... [J1](1.5 g,54%). LCMS m / z277 [M+H]+.
[0211] [5-(] [Difluoromethoxy] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [Ethyl formate] [(J2)] [:] Heating 5-hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester ( [J1]) (276 mg, 1.0 mmol) and sodium carbonate (116 mg, 1.1 mmol) in ACN (3.3 mL). After 20 min, (bromodifluoromethyl)trimethylsilane (203 mg, 1.0 mmol, 155 µL) was added and a white precipitate formed. LCMS of the crude reaction mixture gave 36% conversion to product. More (bromodifluoromethyl)trimethylsilane (203 mg, 1.0 mmol, 155 µL) was added and after 45 min, 57% conversion to product was observed. More (bromodifluoromethyl)trimethylsilane (203 mg, 1.0 mmol, 155 µL) was added. After 15 min, the crude reaction mixture was cooled to room temperature and stirred overnight. The crude reaction mixture was analyzed by LCMS and gave about 11% starting material remaining, 61% product and 27% unknown byproduct. The crude reaction mixture was diluted with EtOAc and H 2 O. The EtOAc layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to an oil. The crude product was purified by silica gel chromatography (12 g) and eluted with 0-100% EtOAc-heptane to give [J2](176 mg,54%). LCMS m / z349 [M+Na] +; 1H NMR (400 MHz, chloroform- d) δ 7.23 (d, J=8.8 Hz, 2H), 6.91-6.81 (m, 2H), 6.42 (s, 1H), 6.61-6.15 (m, 1H), 5.25 (s, 2H), 4.41 (q, J=7.1 Hz, 2H), 3.79 (s, 3H) 1.40 (t, J=7.1 Hz, 3H).
[0212] [5-(] [Difluoromethoxy] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [Formic acid] [(J3)] [:] At room temperature, 5-(difluoromethoxy)-1-[(4-methoxyphenyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester ( A mixture of [J2]) (153 mg, 0.47 mmol) and hydrated lithium hydroxide (98.5 mg, 2.34 mmol) in methanol (1.56 mL) was stirred for 20 minutes and then heated at 60°C. After one hour, LCMS gave no starting material and mainly product. The crude reaction mixture was concentrated to a white solid and partitioned between EtOAc and 1 N aqueous HCl (3 mL). The EtOAc layer was washed with brine, dried over Na2SO4, filtered and concentrated to give [J3] (141 mg, quantitative). LCMS m / z 321 [M+Na] +; 1H NMR (400 MHz, chloroform- d) δ 7.24 (d, J=8.7 Hz, 2H), 6.91-6.84 (m, 2H), 6.66-6.23 (m, 2H), 5.25 (s, 2H), 3.80 (s, 3H).
[0213] [{5-(] [Difluoromethoxy] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [base] [}] [Tributyl carbamate] [(J4)] [:] At room temperature, 5-(difluoromethoxy)-1-[(4-methoxyphenyl)methyl]-1H-pyrazole-3-carboxylic acid ( [J3]) (137 mg, 0.46 mmol) in toluene (1.53 mL) was added TEA (51 mg, 0.5 mmol, 70 µL). A paste formed that stuck to the side of the flask. Next, DPPA (139 mg, 0.50 mmol, 109 µL) was added and the mixture was heated at 90 °C for 16 h. LCMS gave a 2:1 mixture of urea and product. The crude reaction mixture was diluted with EtOAc and H 2 O. The EtOAc layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to an oil. The crude product was purified by silica gel chromatography (12 g) and eluted with 0-100% EtOAc-heptane to give [J4](36 mg,22%). LCMS m / z370 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 7.49 (br s, 1H), 7.15 (d, J=8.7 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 6.66-6.26 (m, 1H), 6.22 (br s, 1H), 5.04 (s, 2H), 4.57-4.13 (m, 1H), 3.78 (s, 3H), 1.49 (s, 9H).
[0214] [5-(] [Difluoromethoxy] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [amine] [(] [Intermediate] [J)] [:] Tributyl {5-(difluoromethoxy)-1-[(4-methoxyphenyl)methyl]-1H-pyrazol-3-yl}carbamate ( [J4]) (36 mg, 0.10 mmol) and TFA (445 mg, 3.90 mmol, 0.3 mL) in DCM (0.3 mL) for five hours. The crude reaction mixture was concentrated to an oil (37 mg, quantitative), and H-NMR showed the presence of a TFA salt. [Intermediate] [J]. 1H NMR (400 MHz, chloroform- d) δ 7.23 (d, J=8.6 Hz, 2H), 6.93-6.81 (m, 2H), 6.73-6.35 (m, 1H), 6.26 (br s, 3H), 5.30 (s, 1H), 4.99 (s, 2H), 3.80 (s, 3H).
[0215] [Intermediate] [K] [:] [5-(2,2-] [Difluorocyclopropyl] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [amine]
[0216] [2,2-] [Difluorocyclopropane] [-1-] [Butyl formate] [(K1)] [:] To a solution of 2,2-difluorocyclopropane-1-carboxylic acid (610 mg, 5.0 mmol) in ACN (10.0 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 837 mg, 5.5 mmol, 0.81 mL) at room temperature. The mixture was cooled in an ice-water bath before adding iodobutane (1.0 g, 5.5 mmol, 0.63 mL). After two days, the reaction mixture was concentrated to give a solid. The solid was partitioned between EtOAc and H 2 O, and the EtOAc layer was washed with brine, dried over Na 2 SO 4, filtered and concentrated to give an amber oil. [K1](499 mg,56%). 1H NMR (400 MHz, chloroform- d) δ 4.16 (t, J=6.7 Hz, 2H), 2.45-2.41 (m, 1H), 2.11-2.03 (m, 1H), 1.84-1.70 (m, 1H), 1.67-1.57 (m, 2H), 1.40 (dq, J=15.0, 7.4 Hz, 2H), 0.95 (t, J=7.4 Hz, 3H).
[0217] [3-(2,2-] [Difluorocyclopropyl] [)-3-] [Oxopropionitrile] [(K2)] [:] 2,2-difluorocyclopropane-1-carboxylic acid butyl ester ( A solution of [K1]) (342 mg, 1.92 mmol) and ACN (158 mg, 3.84 mmol, 0.158 mL) in THF (0.91 mL) was cooled to -70 °C in a dry ice acetone bath. To the solution was added LDA (452 mg, 4.22 mmol, 2.11 mL, 2.0 M). A dark brown solution was formed. After 30 minutes, the crude reaction mixture was allowed to warm to room temperature. Saturated aqueous NH4Cl was added to the crude reaction mixture. The aqueous layer was partitioned between EtOAc and H2O, and the EtOAc layer was washed with brine, dried over Na2SO4, filtered and concentrated to an oil, and the crude product was purified by HPLC. [K2] is used in the next step.
[0218] [5-(2,2-] [Difluorocyclopropyl] [)-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-3-] [amine] [(] [Intermediate] [K)] [:] The crude β-ketonitrile 3-(2,2-difluorocyclopropyl)-3-oxopropionitrile ( [K2]) was dissolved in isopropanol (2.0 mL) and (4-methoxybenzyl)hydrazine (362 mg, 1.9 mmol) was added followed by TEA (194 mg, 1.92 mmol, 0.27 mL). The mixture was heated at 60 °C for 4 h and cooled to room temperature. The crude reaction mixture was concentrated to a solid. The solid was suspended in DCM and loaded onto a 5 g silica gel pre-column cartridge. LCMS of the solid confirmed that the solid was the TEA-HCl salt and it was discarded. The crude product was purified by silica gel chromatography (pre-column in series with a 12 g silica gel column) and eluted with 0-100% EtOAc-heptane to give [Intermediate] [K](76 mg,14%). LCMS m / z280 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 7.11 (d, J=8.6 Hz, 2H), 6.90-6.84 (m, 2H), 5.42 (d, J=1.1 Hz, 1H), 5.11 (s, 2H), 3.79 (s, 3H), 3.55-3.08 (m, 2H), 2.69 (td, J=12.2, 8.0 Hz, 1H), 1.83-1.74 (m, 1H), 1.70-1.62 (m, 1H).
[0219] according to [Intermediate] [K] is prepared by using a commercially available acid or ester and an excess of hydrazine in an alcohol solvent or (4-methoxybenzyl)hydrazine [surface]
[17] An aminopyrazole intermediate. [surface]
[17] [Intermediate Name] [Structure / IUPAC] [name] [Analysis data] [Ka] 3-(1-{[tributyl(dimethyl)silyl]oxy}ethyl)-1H-pyrazol-5-amine LCMS m / z 242 [M+H] +; 1H NMR (400 MHz, chloroform- d) δ 7.27 (s, 1H), 5.43 (s, 1H), 4.92 (q, J=6.5 Hz, 1H), 1.43 (d, J=6.5 Hz, 3H), 0.92 (m, 9H), 0.07 (s, 3H), 0.01 (s, 3H) [Kb] 3-(3-amino-1H-pyrazol-5-yl)butan-1-ol LCMS m / z 156 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.94-8.87 (m, 1H), 5.17 (s, 1H), 4.36 (br s, 3H), 3.38-3.26 (m, 2H), 2.79-2.71 (m, 1H), 1.71-1.64 (m, 1H), 1.60-1.52 (m, 1H), 1.12 (d, J=7.1 Hz, 3H)
[0220] [Intermediate] [L] [:] [4-] [methyl] [-5,6-] [Dihydrogen] [-4 , H , - ] [Pyrrolo] [[1,2- , b , ] ] [Pyrazole] [-2-] [amine]
[0221] [5-(4-] [Chloroprene] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [amine] [(L1)] [:] Add 3-(3-amino-1H-pyrazol-5-yl)butan-1-ol ( [Intermediate] [Kb]) (183 mg, 1.18 mmol) and THF (7.8 mL) were added, followed by thionyl chloride (701 mg, 5.9 mmol, 0.43 mL). The resulting milky white mixture was stirred at room temperature for two hours. LCMS showed [L1] and [Intermediate] [L] was a 1:1 mixture, LCMS m / z were 174 [M+H] + and 138 [M+H] +, respectively.
[0222] [4-] [methyl] [-5,6-] [Dihydrogen] [-4 , H , - ] [Pyrrolo] [[1,2- , b , ] ] [Pyrazole] [-2-] [amine] [(] [Intermediate] [L)] [:] Condensed from [L1] was added to the crude reaction mixture prepared by DMF (6.6 mL) and cesium carbonate (576 mg, 1.8 mmol). The mixture was placed on a preheated hot plate at 100°C and stirred at 100°C for one hour. LCMS showed complete conversion to product. The crude reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated and triturated with EtOAc and methanol (about 5:1) to give [Intermediate] [L](68 mg,42%). LCMS m / z138 [M+H]+.
[0223] [Intermediate] [M] [:] [5',6'-] [Dihydrospiro] [[] [Cyclopropane] [-1,4'-] [Pyrrolo] [[1,2- , b , ] ] [Pyrazole] []-2'-] [amine]
[0224] [3-[1-(2-] [Hydroxyethyl] [)] [Cyclopropyl] []-3-] [Oxopropionitrile] [(M1)] [:] To a sealed, oven-dried vial flushed with nitrogen was added LDA (0.49 mL, 0.98 mmol) and anhydrous THF (1 mL). The solution was degassed, backfilled with nitrogen three times and cooled to -78 °C. A degassed and nitrogen-flushed solution of 5-oxaspiro[2.4]heptan-4-one (42 µL, 0.45 mmol) in anhydrous THF (1.4 mL) and anhydrous ACN (47 µL, 0.89 mmol) was added dropwise to a solution of LDA in THF. The solution was stirred at -78 °C for 15 minutes, then the vial was allowed to warm to room temperature and stirred for two hours to give a light yellow mixture. The crude reaction mixture was diluted with saturated aqueous ammonium chloride and the aqueous layer was extracted three times with EtOAc. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated to give an orange oil. [M1]. The crude product was used in the next step.
[0225] [2-[1-(3-] [Amine] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Cyclopropyl] []] [Second] [-1-] [alcohol] [(M2)] [:] Add 3-[1-(2-hydroxyethyl)cyclopropyl]-3-oxopropionitrile ( [M1]) (68 mg, 0.44 mmol) and methanol (0.63 mL). To the solution was added hydrazine monohydrate (32 µL, 0.67 mmol) and the yellow solution was stirred at 80 °C overnight. LCMS gave the product. The crude reaction mixture was cooled to room temperature and concentrated to an orange oil. The crude product was purified using silica gel chromatography (4 g) and eluted with 0-20% methanol-DCM to give [M2](26 mg,35%). 1H NMR (methanol-d 4, 400 MHz) δ 5.31 (s, 1H), 3.50 (t, J=7.3 Hz, 2H), 1.70 (t, J=7.3 Hz, 2H), 0.80-0.70 (m, 2H), 0.69-0.60 (m, 2H).
[0226] [5-[1-(2-] [Chloroethyl] [)] [Cyclopropyl] []-1 , H , - ] [Pyrazole] [-3-] [amine] [(M3)] [:] Add 2-[1-(3-amino-1H-pyrazol-5-yl)cyclopropyl]ethan-1-ol ( [M2]) (26 mg, 0.16 mmol) in anhydrous THF (86 mL) and thionyl chloride (58 µL, 0.78 mmol). The crude reaction mixture was stirred at room temperature for two hours. The yellow solution quickly turned into a turbid mixture and then a thick yellow solution. LCMS gave a 2:1 ratio of 5-[1-(2-chloroethyl)cyclopropyl]-1H-pyrazol-3-amine ( [M3]) than 5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2- b ]pyrazole]-2'-amine ( [Intermediate] [M]). After 18 hours, the LCMS trace gave the same conclusion as after two hours. The crude reaction mixture was concentrated and a dark orange oil was obtained and used in the next step.
[0227] [Intermediate] [M] [:] [5',6'-] [Dihydrospiro] [[] [Cyclopropane] [-1,4'-] [Pyrrolo] [[1,2- , b , ] ] [Pyrazole] []-2'-] [amine] The crude product was dissolved in DMF (0.86 mL) and Cs 2CO 3 (76 mg, 0.23 mmol) was added. The crude reaction mixture was heated at 100 °C for one hour. LCMS of the resulting orange mixture gave 5-[1-(2-chloroethyl)cyclopropyl]-1H-pyrazol-3-amine ( [M3]) was completely converted to 5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2- b ]pyrazole]-2'-amine ( [Intermediate] [M]). The crude reaction mixture was cooled to room temperature and added dropwise to H 2 O (75 mL). The aqueous layer was extracted three times with DCM. An emulsion was formed, which was separated by breaking the emulsion by adding a spoonful of LiCl. LCMS of the aqueous layer showed that the product remained in the aqueous layer even after three extractions with EtOAc. Therefore, the organic and aqueous layers were combined and lyophilized for one week, which gave an orange solid. The crude product was purified by reverse phase HPLC (5-45% ACN-H 2 O gradient over 25 minutes) to give [Intermediate] [M](6 mg,25%). 1H NMR (methanol-d 4, 400 MHz) δ 4.94 (s, 1H), 3.91 (t, J=7.2 Hz, 2H), 2.38 (dt, J=7.3, 1.0 Hz, 2H), 0.86 (s, 4H).
[0228] [Intermediate] [N] [:] [5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [amine]
[0229] [2-(5-] [Cyclopropyl] [-1 , H , - ] [Pyrazole] [-3-] [base] [)-1 , H , - ] [Isoindole] [-1,3(2 , H , )- ] [Diketone] [(N1)] [:] A mixture of 5-cyclopropyl-1H-pyrazol-3-amine (10 g, 81 mmol) and 2-benzofuran-1,3-dione (12 g, 81 mmol) in acetic acid was heated at 100°C for two hours and at 120°C for six hours. The crude reaction mixture was concentrated under reduced pressure and H 2 O was added. A white solid (19 g, 92%) was collected by filtration. LCMS m / z 254 [M+H] +.
[0230] [2-[5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [base] []-1 , H , - ] [Isoindole] [-1,3(2 , H , )- ] [Diketone] [(N2)] [:] To a suspension of 2-(5-cyclopropyl-1H-pyrazol-3-yl)-1H-isoindole-1,3(2H)-dione (N1) (17.9 g, 71 mmol) in ACN (353 mL) was added pyridinium p-toluenesulfonate (2.7 g, 11 mmol) and dihydro-2H-pyran (12 g, 141 mmol). The reaction was stirred at 60 °C for 16 h. The crude reaction mixture was mixed with a smaller batch (using 1 g [N1]) and concentrated under reduced pressure. The crude product was triturated with H 2 O (300 mL) and EtOAc (50 mL) and filtered. The solid was washed with H 2 O and EtOAc (50 mL×3) and dried to give [N2] (19.8 g, 83.0%). The filtrate was extracted with EtOAc (100 mL×2), washed with brine (200 mL), concentrated at 66°C under house vacuum and then concentrated under high vacuum to give a crude product as a light red oil, which was triturated with petroleum ether:EtOAc=3:1 (100 mL) for 2 hours, filtered, and the collected solid was washed with H 2 O and petroleum ether:EtOAc=3:1 (10 mL×3) and dried to give additional off-white solid. [N2](2.9 g,12%). LCMS m / z260 [M+Na] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.99-7.89 (m, 4H), 6.06 (s, 1H), 5.64 (dd, J=9.9, 2.3 Hz, 1H), 3.98-2.94 (m, 1H), 3.75-3.63 (m, 1H), 2.33-2.19 (m, 1H), 2.09-1.96 (m, 2H), 1.96-1.87 (m, 1H), 1.77-1.61 (m, 1H), 1.61-1.48 (m, 2H), 1.07-0.96 (m, 2H), 0.79-0.64 (m, 2H).
[0231] [5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [amine] [(] [Intermediate] [N)] [:] 2-[5-cyclopropyl-1-(oxacyclohexane-2-yl)-1H-pyrazol-3-yl]-1H-isoindole-1,3(2H)-dione ( A solution of [N2]) (22.7 g, 67 mmol) in THF (336 mL) was treated with hydrazine monohydrate (9.5 g, 150 mmol) and stirred at 70°C for 4 hours. After cooling to ambient temperature, the suspension was filtered. The filtrate was extracted with EtOAc (200 mL×6), and the combined organic phases were washed with saturated sodium bicarbonate (200 mL×2) and brine (200 mL×2), dried over sodium sulfate and concentrated under reduced pressure to give a yellow oil. [Intermediate] [N] (9.8 g, 70%). The combined aqueous phases were extracted again with EtOAc (200 mL×6). The combined organic phases were washed with saturated sodium bicarbonate (100 mL) and brine (200 mL×2), dried over sodium sulfate and concentrated under reduced pressure to give more as a yellow oil. [Intermediate] [N](2.84 g,20%). LCMS m / z208 [M+H] +; 1H NMR (400 MHz, CDCl 3) δ 5.35 (dd, J=2.4, 10.5 Hz, 1H), 5.28 (s, 1H), 4.15-4.04 (m, 1H), 3.92-3.20 (m, 3H), 2.47-2.30 (m, 1H), 2.17-2.00 (m, 1H), 1.91-1.82 (m, 1H), 1.81-1.64 (m, 3H), 1.58-1.51 (m, 1H), 0.93-0.90 (m, 2H), 0.78-0.69 (m, 1H), 0.65-0.55 (m, 1H).
[0232] [Example] [] [method] [A] [Example]
[01] [:] [2,6-] [Dimethoxy] [- , N , -{4- ] [Methoxy] [-6-[(1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide]
[0233] [ , N , ] [-(6-] [bromine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(1a)] [:]Heat 6-bromo-4-methoxy-1,2-benzoxazol-3-amine ( [Intermediate] [A]) (17 g, 70 mmol) and 2,6-dimethoxybenzene-1-sulfonyl chloride (24.8 g, 105 mmol) in pyridine (170 mL) for two hours. After cooling to room temperature, the solvent was evaporated under reduced pressure and the residue was purified by silica gel chromatography (eluting with 100% EtOAc) to give [1a](26.5 g,85%). LCMS m / z443 / 445 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.78 (s, 1H), 7.56-7.45 (m, 2H), 7.05 (d, J=1.1 Hz, 1H), 6.78 (d, J=8.4 Hz, 2H), 3.93 (s, 3H), 3.77 (s, 6H).
[0234] [ , N , ] [-(6-] [bromine] [-4-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)- , N , -[(2,4- ] [Dimethoxyphenyl] [)] [methyl] []-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(1b)] [:] N-(6-bromo-4-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide ( [1a]) (28.0 g, 63 mmol), (2,4-dimethoxyphenyl)methanol (15.9 g, 94.8 mmol) and triphenylphosphine (41.4 g, 158 mmol) in THF (300 mL) were cooled to 0°C, followed by the dropwise addition of DIAD (25.5 g, 126 mmol). After stirring at room temperature (15°C) for 16 h, the pale yellow solution was concentrated under reduced pressure and purified by silica gel chromatography (eluting with 60-70% EtOAc in petroleum ether) to give about 25 g of the product, which was mixed with triphenylphosphine oxide. Recrystallization from methanol gave [1b] (7.0 g, 19%). The mother liquor was concentrated and purified by reverse phase preparative HPLC (YMC-Triart Prep C18 250×50 mm, 10 µm column, eluted with 50-70% H 2O + ACN containing 0.1% TFA). The fraction containing the product was concentrated to remove ACN, extracted with EtOAc, washed with brine, dried over sodium sulfate and concentrated to give a second batch of [1b](8.30 g,22%). 1H NMR (400 MHz, DMSO- d 6) δ 7.64 (d, J=1.1 Hz, 1H), 7.56 (t, J=8.4 Hz, 1H), 7.22 (d, J=8.4 Hz, 1H), 7.03 (d, J=1.0 Hz, 1H), 6.77 (d, J=8.6 Hz, 2H), 6.45 (d, J=8.0 Hz, 1H), 6.39 (s, 1H), 4.78 (s, 2H), 3.70 (s, 3H), 3.65 (s, 3H), 3.52 (s, 6H), 3.39 (s, 3H).
[0235] [3-[(3-{(2,6-] [Dimethoxybenzene] [-1-] [Sulfonyl] [)[(2,4-] [Dimethoxyphenyl] [)] [methyl] []] [Amine] [}-4-] [Methoxy] [-1,2-] [Benzoazole] [-6-] [base] [)] [Amine] []-1 , H , - ] [Pyrazole] [-1-] [Tributyl formate] [(1c)] [:] To N-(6-bromo-4-methoxy-1,2-benzoxazol-3-yl)-N-[(2,4-dimethoxyphenyl)methyl]-2,6-dimethoxybenzene-1-sulfonamide ( To a solution of [1b]) (100.0 mg, 0.169 mmol) and tributyl 3-amino-1H-pyrazole-1-carboxylate (92.6 mg, 0.506 mmol) in 1,4-dioxane (2 mL) were added cesium carbonate (165 mg, 0.506 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran (Xantphos, 29.3 mg, 0.051 mmol) and tris(diphenylacetone)dipalladium (0) (23.1 mg, 0.025 mmol). The suspension was stirred at 100°C for 16 hours and then concentrated under vacuum to give a crude brown gel. [1c] (150 mg, >100%), which was used in the next step without further purification. LCMS m / z 696 [M+H] +.
[0236] [2,6-] [Dimethoxy] [- , N , -{4- ] [Methoxy] [-6-[(1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide] [(] [Example] [01)] [:] The crude 3-[(3-{(2,6-dimethoxybenzene-1-sulfonyl)[(2,4-dimethoxyphenyl)methyl]amino}-4-methoxy-1,2-benzoxazol-6-yl)amino]-1H-pyrazole-1-carboxylic acid tertiary butyl ester ( [1c]) (100 mg, maximum 0.113 mmol) was dissolved in DCM (2 mL) and TFA (2 mL) and stirred at room temperature (20°C) for 15 hours. The resulting pink solution was concentrated to dryness, the residue was dissolved in methanol (2 mL) and DMSO (2 mL), the solution was filtered and purified by preparative reverse phase HPLC (YMC Triart C18, 250×50 mm×7 µm column, eluted with 11-51% H 2O + ACN containing 0.2% formic acid). The fraction containing the product was lyophilized to give [Example]
[01] (40 mg, 80%). LCMS m / z446.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.18 (s, 1H), 9.10 (s, 1H), 7.62 (d, J=2.2 Hz, 1H), 7.50 (t, J=8.5 Hz, 1H), 7.25 (s, 1H), 6.78 (d, J=8.4 Hz, 2H), 6.63 (s, 1H), 5.90 (d, J=2.1 Hz, 1H), 3.88 (s, 3H), 3.79 (s, 6H).
[0237] [method] [B] [Example]
[02] [:] [ , N, ] [-{6-[(3-] [Ethyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide]
[0238] [ , N , ] [-(6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(2a)] [:] Place 6-bromo-5-methoxy-1,2-benzoxazol-3-amine ( [intermediate] [B]) (1.50 g, 6.17 mmol) and 2,6-dimethoxybenzene-1-sulfonyl chloride (1.75 g, 7.41 mmol). A 0.05 M solution of DMSO in ACN (6.17 mL, 0.309 mmol DMSO) was added, followed by a solution of 3,5-lutidine (1.98 g, 2.11 mmol) in ACN (15.0 mL). The vessel was sealed and stirred at 23 °C for 20 h. A solid precipitate formed during this time. According to LCMS, because there was still unreacted [Intermediate] [B], so a second portion of 2,6-dimethoxybenzene-1-sulfonyl chloride (906 mg, 3.83 mmol) and 3,5-lutidine (992 mg, 9.26 mmol) were added, the vessel was resealed and stirring was continued again at 23 °C for 20 h. The reaction mixture was then diluted with DCM (100 mL) and washed with 2 N aqueous HCl (35 mL). The organic layer was washed with saturated aqueous NaHCO 3 (50 mL) and a white solid precipitate formed. The suspension was filtered and the filter cake was washed with H 2 O (3×10 mL) and DCM (3×5 mL). The precipitate was dried under vacuum overnight, then suspended in ACN (5 mL) and H 2 O (30 mL) and lyophilized to dryness, leaving a white solid. [2a](2.1 g,77%). LCMS m / z443 / 445 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.65 (s, 1H), 7.28 (s, 1H), 7.24 (t, J=8.3 Hz, 1H), 6.61 (d, J=8.4 Hz, 2H), 3.83 (s, 3H), 3.59 (s, 6H).
[0239] Alternatively, a reaction vessel is charged with 6-bromo-5-methoxy-1,2-benzoxazol-3-amine ( [Intermediate] [B]) (0.70 g, 2.88 mmol) and 2,6-dimethoxybenzene-1-sulfonyl chloride (1.02 g, 4.32 mmol) in ACN (15.0 mL). The vessel was stirred at 23 °C and a 2.0 M solution of sodium tert-butoxide in THF (5.0 mL, 10.1 mmol) was added dropwise. A solid precipitate formed during this time. The reaction mixture was stirred for two hours, then diluted with EtOAc (50 mL) and washed with 1 N aqueous HCl (35 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate and concentrated. The solid residue was slurried in heptane, filtered under vacuum and washed with heptane to leave a white solid. [2a](1.3 g,99%). LCMS m / z443 / 445 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.35 (s, 1H), 8.00 (s, 1H), 7.73 (s, 1H), 7.48 (t, J=8.4 Hz, 1H), 6.74 (d, J=8.5 Hz, 2H), 3.87 (s, 3H), 3.74 (s, 6H).
[0240] [ , N , ] [-(6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-2,6-] [Dimethoxy] [- , N , -[(4- ] [Methoxyphenyl] [)] [methyl] []] [benzene] [-1-] [Sulfonamide] [(2b)] [:] Stir N-(6-bromo-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide ( [2a]) (2.78 g, 6.17 mmol), 4-methoxybenzyl chloride (1.06 g, 6.79 mmol) and potassium carbonate (1.02 g, 7.40 mmol) in DMF (30.0 mL) for 16 h. The mixture was poured into H 2 O (100 mL) and stirred for 20 min. The resulting suspension was filtered and the filter cake was washed with H 2 O (5 mL). The solid was dissolved in ACN (50 mL) and evaporated to dryness (three cycles) to give [2b] (3.0 g, 86%). LCMS m / z563 / 565 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.09 (s, 1H), 7.57 (t, J=8.4 Hz, 1H), 7.30 (d, J=8.7 Hz, 2H), 7.24 (s, 1H), 6.88-6.83 (m, 2H), 6.81 (d, J=8.6 Hz, 2H), 4.98 (s, 2H), 3.78 (s, 3H), 3.72 (s, 6H), 3.69 (s, 3H).
[0241] [ , N , ] [-{6-[(3-] [Ethyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxy] [- , N , -[(4- ] [Methoxyphenyl] [)] [methyl] []] [benzene] [-1-] [Sulfonamide] [(2c)] [:] N-(6-bromo-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxy-N-[(4-methoxyphenyl)methyl]benzene-1-sulfonamide ( A yellow suspension of [2b]) (150 mg, 0.266 mmol), 5-ethyl-1H-pyrazol-3-amine (188 mg, 1.69 mmol), cesium carbonate (260 mg, 0.799 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran (Xantphos, 108 mg, 0.186 mmol) and tris(dibenzylideneacetone)dipalladium(0) (48.8 mg, 0.0532 mmol) in 1,4-dioxane (6.0 mL) was aerated with dry argon for one minute, and then the mixture was heated at 100°C for 16 hours. After cooling to room temperature, the reaction mixture was diluted with H2O (30 mL) and stirred for 30 minutes. The resulting solid was collected by filtration. The filter cake was washed with H2O (2×5 mL) and then suspended in DCM (100 mL) with stirring for 10 minutes. The suspension was filtered and the solid was washed with methanol (4 x 1 mL). The filtrate was concentrated in vacuo and purified by silica gel chromatography (eluting with 0-100% EtOAc in petroleum ether) to give [2c](130 mg,82%). LCMS m / z594 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.89 (s, 1H), 8.16 (d, J=12.5 Hz, 2H), 7.54 (t, J=8.4 Hz, 1H), 7.32 (d, J=8.5 Hz, 2H), 6.97 (s, 1H), 6.87 (d, J=8.8 Hz, 2H), 6.79 (d, J=8.5 Hz, 2H), 5.88 (d, J=1.8 Hz, 1H), 4.99 (s, 2H), 3.77 (s, 3H), 3.75 (s, 6H), 3.70 (s, 3H), 2.56 (q, J=7.7 Hz, 2H), 1.18 (t, J=7.5 Hz 3H).
[0242] [ , N , ] [-{6-[(3-] [Ethyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(] [Example] [02)] [:] TFA (1 mL) was added to N-{6-[(3-ethyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-N-[(4-methoxyphenyl)methyl]benzene-1-sulfonamide ( [2c]) (130 mg, 0.219 mmol) in a cooled (0 °C) solution of DCM (4 mL). After stirring at room temperature (25 °C) for five hours, the solvent was evaporated and the residue was suspended in methanol (2 mL) and ACN (2 mL) and stirred for five minutes. The solid was collected by filtration and washed with ACN (3×1 mL). The filter cake was dissolved in H 2 O (20 mL) and DCM (20 mL), stirred for 10 minutes, and adjusted to pH 10 with saturated aqueous NaHCO 3 solution. The layers were separated and the aqueous layer was extracted with DCM / methanol (10:1, 4×25 mL). The combined organic layers were dried over sodium sulfate, filtered, concentrated, and purified by reverse phase preparative HPLC (YMC Triart C18; 250×50 mm, 7 µm column, eluted with 0-40% H 2 O + ACN containing 0.05% NH 4 OH) to obtain [Example]
[02] (55 mg, 53%). LCMS m / z474.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.89 (s, 1H), 10.97 (br s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.46 (t, J=8.4 Hz, 1H), 7.40 (s, 1H), 6.74 (d, J=8.6 Hz, 2H), 5.89 (s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 2.57 (q, J=7.7 Hz, 2H), 1.18 (t, J=7.6 Hz, 3H).
[0243] [method] [C] [Example]
[03] [:] [2,6-] [Dimethoxy] [- , N , -{5- ] [Methoxy] [-6-[(1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide]
[0244] N-(6-bromo-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide ( [2a], prepared as in Method B) (50.0 mg, 0.11 mmol), 3-amino-1H-pyrazole-1-carboxylic acid tributyl ester (62.0 mg, 0.338 mmol), cesium carbonate (110 mg, 0.338 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran (Xantphos, 19.6 mg, 0.0338 mmol) and tris(dibenzylideneacetone)dipalladium(0) (15.5 mg, 0.0169 mmol) in 1,4-dioxane (2.0 mL) for 16 hours. A yellow precipitate formed. The suspension was diluted with EtOAc (10 mL), filtered to remove the solids, and the filtrate was concentrated to dryness under vacuum. The residue was purified by reverse phase preparative HPLC (YMC Triart C18; 250×50 mm, 7 μm column, eluted with 17-57% H 2 O + ACN containing 0.05% NH 4 OH) to give [Example]
[03] (20 mg, 40%). LCMS m / z446.1 [M+H] +, 468 [M+Na] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.17 (br s, 1H), 8.21 (s, 1H), 8.15 (br d, J=4.6 Hz, 1H), 7.59 (d, J=2.3 Hz, 1H), 7.46 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.11 (d, J=2.3 Hz, 1H), 3.89 (s, 3H), 3.76 (s, 6H).
[0245] [Example]
[04] [:] [2,6-] [Dimethoxy] [- , N , -{5- ] [Methoxy] [-6-[(1-] [methyl] [-1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide]
[0246] N-(6-bromo-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide ( [2a], prepared according to method B) (50.0 mg, 0.11 mmol), 1-methyl-1H-pyrazol-3-amine (32.9 mg, 0.338 mmol), cesium carbonate (110 mg, 0.338 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran (Xantphos, 19.6 mg, 0.0338 mmol) and tris(dibenzylideneacetone)dipalladium(0) (15.5 mg, 0.0169 mmol) in 1,4-dioxane (2.0 mL) was stirred for 16 hours. After cooling to room temperature, the mixture was diluted with EtOAc (10 mL), the solid was filtered off, the filtrate was concentrated to dryness, and the residue was purified by reverse phase preparative HPLC (YMC Triart C18; 250×50 mm, 7 μm column, eluted with 24-64% H 2 O + ACN containing 0.2% formic acid) to give [Example]
[04] (30 mg, 52%). LCMS m / z460.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.92 (br s, 1H), 8.23 (s, 1H), 8.15 (s, 1H), 7.53 (d, J=2.3 Hz, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.06 (d, J=2.4 Hz, 1H), 3.88 (s, 3H), 3.79 (s, 3H), 3.76 (s, 6H).
[0247] [Example]
[05] [:] [3-] [Methoxy] [- , N , -{5- ] [Methoxy] [-6-[(1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}-5,6,7,8-] [Tetralin] [-2-] [Sulfonamide]
[0248] [ , N , ] [-(6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-3-] [Methoxy] [-5,6,7,8-] [Tetralin] [-2-] [Sulfonamide] [(5a)] [:]Through and synthesis [2a] Using the same method, 6-bromo-5-methoxy-1,2-benzoxazol-3-amine ( [Intermediate] [B]) (257 mg, 1.06 mmol) and 3-methoxy-5,6,7,8-tetrahydronaphthalene-2-sulfonyl chloride ( [Intermediate] [D]) (230 mg, 0.882 mmol) was obtained as a white solid after purification by reverse phase preparative HPLC. [5a](165 mg,40%). 1H NMR (400 MHz, chloroform-d) δ 7.70 (s, 1H), 7.54 (s, 1H), 7.42 (s, 1H), 6.72 (s, 1H), 3.99 (d, J=1.7 Hz, 6H), 2.76 (br t, J=5.3 Hz, 2H), 2.62 (br t, J=5.0 Hz, 2H), 1.83-1.68 (m, 5H).
[0249] [3-] [Methoxy] [- , N , -{5- ] [Methoxy] [-6-[(1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}-5,6,7,8-] [Tetralin] [-2-] [Sulfonamide] [(] [Example] [05)] [:]Through and synthesis [Example]
[03] The same method was used, but 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl (BrettPhos) was used instead of Xantphos to make N-(6-bromo-5-methoxy-1,2-benzoxazol-3-yl)-3-methoxy-5,6,7,8-tetrahydronaphthalene-2-sulfonamide ( [5a]) (165 mg, 0.353 mmol) and 3-amino-1H-pyrazole-1-carboxylic acid tributyl ester (129 mg, 0.706 mmol) were reacted to give a white solid [Example]
[05] (15 mg,9%). LCMS m / z470.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (br s, 1H), 11.19 (br s, 1H), 8.25 (s, 1H), 8.16 (br d, J=5.5 Hz, 1H), 7.59 (d, J=2.3 Hz, 1H), 7.36 (s, 1H) 7.53 (s, 1H), 6.84 (s, 1H), 6.11 (d, J=2.3 Hz, 1H), 3.90 (s, 3H), 3.76 (s, 3H), 2.76-2.65 (m, 4H), 1.70 (br s, 4H).
[0250] [method] [D] [Example]
[06] [:] [2-] [Methoxy] [- , N , -{5- ] [Methoxy] [-6-[(3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide]
[0251] [step] [1] [:] [1-[(4-] [Methoxyphenyl] [)] [methyl] []-3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [amine] [(6a)] [:] A solution of 3-oxobutyronitrile (5.0 g, 60.2 mmol) and [(4-methoxyphenyl)methyl]hydrazine (11.9 g, 78.2 mmol) in ethanol (50 mL) was stirred at 50° C. for three hours. The crude reaction mixture was concentrated under reduced pressure and diluted with EtOAc (50 mL). The organic layer was washed with saturated sodium bicarbonate (10 mL), H 2 O (40 mL), brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated, and the resulting residue was purified by silica gel (Combi-flash, 40 g) and eluted with 0-60% EtOAc-petroleum ether to give 4-(4-methoxyphenyl)methyl)-1-(4-methoxyphenyl ... [6a] (4 g, 49% yield). LCMS m / z 218 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.09 (d, J=8.6 Hz, 2H), 6.89-6.81 (m, 2H), 5.08 (d, J=8.1 Hz, 3H), 4.91 (s, 2H), 3.74-3.62 (m, 3H), 1.94 (s, 3H).
[0252] [step] [2] [:] [2-] [fluorine] [-5-] [Methoxy] [-4-({1-[(4-] [Methoxyphenyl] [)] [methyl] []-3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [}] [Amine] [)] [Benzonitrile] [(6b)] [:] 4-bromo-2-fluoro-5-methoxybenzonitrile ( [B2]) (100 mg, 0.4 mmol), 1-[(4-methoxyphenyl)methyl]-3-methyl-1H-pyrazol-5-amine A yellow suspension of [(6a)] (115 mg, 0.5 mmol) and cesium carbonate (425 mg, 1.3 mmol) in dioxane (6 mL) was degassed and purged with argon followed by the addition of Pd2(dba)3 (40 mg, 0.04 mmol) and Xantphos (75 mg, 0.13 mmol). LCMS provided mostly product after heating the mixture at 80 °C for 18 h. [B2]) (1.5 g, 6.6 mmol), 1-[(4-methoxyphenyl)methyl]-3-methyl-1H-pyrazol-5-amine The process was repeated with [(6a)] (1.7 g, 8.0 mmol), cesium carbonate (6.5 g, 20 mmol), Pd 2(dba) 3 (609 mg, 0.7 mmol) and Xantphos (1.1 g, 2.0 mmol) in dioxane (30 mL). After 18 h at 80 °C, the crude reaction mixture was cooled to room temperature and diluted with EtOAc (50 mL) and filtered. The filtrates from both reactions were combined and purified over silica gel (Combi-flash, 40 g) and eluted with 0-45% EtOAc-petroleum ether to give a yellow solid [6b] (3 g, 56% purity by LCMS). LCMS m / z 367 [M+H] +.
[0253] [step] [3] [:] [5-] [Methoxy] [- , N , , 6 , -{1-[(4- ] [Methoxyphenyl] [)] [methyl] []-3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [}-1,2-] [Benzoazole] [-3,6-] [Diamine] [(6c)] [:] A solution of N-hydroxyacetamide (1.8 g, 25 mmol) and sodium tert-butoxide (2.8 g, 25 mmol) in DMF (75 mL) was stirred for 30 minutes. To the resulting white mixture was added 2-fluoro-5-methoxy-4-({1-[(4-methoxyphenyl)methyl]-3-methyl-1H-pyrazol-5-yl}amino)benzonitrile ( [6b]) (3.0 g, 8.2 mmol) in DMF (5 mL). The mixture was stirred at 80 °C for 16 h. LCMS indicated starting material and product. Another portion of N-hydroxyacetamide (1.8 g, 25 mmol) and sodium tert-butoxide (2.8 g, 25 mmol) were added to the crude reaction mixture. The resulting mixture was stirred at 80 °C for 16 h. LCMS indicated more product, but starting material was still present. The process of adding additional N-hydroxyacetamide (1.8 g, 25 mmol) and sodium tert-butoxide (2.8 g, 25 mmol) to the crude reaction mixture followed by heating at 80 °C for 16 h was repeated three more times. The crude reaction mixture was concentrated to remove DMF and the mixture was diluted with EtOAc (250 mL). The organic layer was washed with H 2 O (250 mL) and the aqueous layer was extracted with EtOAc (3×250 mL). The combined organic extracts were washed with brine, dried over Na 2 SO 4 and filtered. The filtrate was concentrated and the crude product was purified over silica gel (Combi-flash, 40 g) and eluted with 0-60% EtOAc-petroleum ether to give the compound as a brown oil. [6c](2 g,64%). LCMS m / z380 [M+H]+.
[0254] [Steps] [4] [:] [2-] [Methoxy] [- , N , -[5- ] [Methoxy] [-6-({1-[(4-] [Methoxyphenyl] [)] [methyl] []-3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [}] [Amine] [)-1,2-] [Benzoazole] [-3-] [base] []] [benzene] [-1-] [Sulfonamide] [(6d)] [:] 5-methoxy-N 6-{1-[(4-methoxyphenyl)methyl]-3-methyl-1H-pyrazol-5-yl}-1,2-benzoxazole-3,6-diamine ( [6c]) (200 mg, 0.5 mmol) and 2-methoxybenzene-1-sulfonyl chloride (163 mg, 0.79 mmol) in pyridine (2 mL) for six hours. The crude reaction mixture was concentrated and purified over silica gel (12 g) and eluted with 0-80% EtOAc-petroleum ether to give the compound as a brown oil. [6d](50 mg,17%). LCMS m / z550 [M+H]+.
[0255] [Steps] [5] [:] [2-] [Methoxy] [- , N , -{5- ] [Methoxy] [-6-[(3-] [methyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-1,2-] [Benzoazole] [-3-] [base] [}] [benzene] [-1-] [Sulfonamide] [(] [Example] [06)] [:] 2-methoxy-N-[5-methoxy-6-({1-[(4-methoxyphenyl)methyl]-3-methyl-1H-pyrazol-5-yl}amino)-1,2-benzoxazol-3-yl]benzene-1-sulfonamide ( [6d]) in TFA (2 mL) for 16 h. The crude reaction mixture was concentrated and the residue was diluted with methanol (5 mL) and saturated sodium bicarbonate (1 mL). The mixture was concentrated and dissolved in DMSO (3 mL), and the crude product was purified by reverse phase chromatography using a Phenomenex C18 column (75×30 mm; 3 μm) and eluted with aqueous ammonium hydroxide-ACN to give [Example]
[06] (6 mg, 25%). LCMS m / z430.2[M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.89 (dd, J=1.6, 7.8 Hz, 1H), 7.65-7.52 (m, 2H), 7.26 (s, 1H), 7.13 (d, J=8.4 Hz, 1H), 7.03 (t, J=7.6 Hz, 1H), 5.88 (s, 1H), 3.97 (s, 3H), 3.87 (s, 3H), 2.27 (s, 3H).
[0256] [method] [E] [Example]
[07] [:] [ , N , ] [-{6-[(3-] [Cyclopropyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxy] [-4-(] [Pyridine] [-3-] [base] [)] [benzene] [-1-] [Sulfonamide]
[0257] [] [step] [1] [:synthesis] [ , N , ] [ , 6 , ] [-{3-] [Cyclopropyl] [-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-5-] [base] [}-5-] [Methoxy] [-1,2-] [Benzoazole] [-3,6-] [Diamine] [(7a)] [7a] [6c] In a similar manner, 3-cyclopropyl-3-oxopropionitrile was used instead of 3-oxobutyronitrile in the first step. 1H NMR (400 MHz, DMSO- d 6 ) δ ppm 0.63 - 0.68 (m, 2 H) 0.82 - 0.86 (m, 2 H) 1.81 - 1.88 (m, 1 H) 3.66 - 3.70 (m, 3 H) 3.87 (s, 3 H) 5.05 (s, 2 H) 5.87 - 5.92 (m, 1 H) 6.02 - 6.08 (m, 2 H) 6.39 - 6.42 (m, 1 H) 6.81 (d, J=8.63 Hz, 2 H) 7.04 (d, J=8.63 Hz, 2 H) 7.26 (s, 1 H) 7.51 (s, 1 H); []LCMS m / z 406.1 (M+H).
[0258] [step] [2] [:synthesis] [4-] [bromine] [- , N , -[6-({3- ] [Cyclopropyl] [-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-5-] [base] [}] [Amine] [)-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] []-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(7b)] To N 6-{3-cyclopropyl-1-[(4-methoxyphenyl)methyl]-1H-pyrazol-5-yl}-5-methoxy-1,2-benzoxazole-3,6-diamine [7a] (900 mg, 2.22 mmol) and 4-bromo-2,6-dimethoxybenzene-1-sulfonyl chloride ( [Intermediate] To a solution of [Db]) (1.1 g, 3.6 mmol) in ACN (5 mL) was added 0.05 N DMSO in ACN (9 mg, 0.1 mmol) and 3,5-lutidine (714 mg, 6.66 mmol). The suspension was stirred at 60 °C for 16 h. The solvent color changed from yellow to red. The solvent was removed under reduced pressure and the resulting residue was purified on silica gel and eluted with 0-54% EtOAc in petroleum ether to give [7a] (810 mg, 53% yield). LCMS m / z 685 (M+H).
[0259] [step] [3] [:synthesis] [ , N , ] [-[6-({3-] [Cyclopropyl] [-1-[(4-] [Methoxyphenyl] [)] [methyl] []-1 , H , - ] [Pyrazole] [-5-] [base] [}] [Amine] [)-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] []-2,6-] [Dimethoxy] [-4-(] [Pyridine] [-3-] [base] [)] [benzene] [-1-] [Sulfonamide] [(7c)] 4-Bromo-N-[6-({3-cyclopropyl-1-[(4-methoxyphenyl)methyl]-1H-pyrazol-5-yl}amino)-5-methoxy-1,2-benzoxazol-3-yl]-2,6-dimethoxybenzene-1-sulfonamide ( To a solution of 1,4-dioxaborolan-2-ylpyridine (60 mg, 0.29 mmol) and 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (7b) (100 mg, 0.15 mmol) in dioxane (2.0 mL) and H2O (0.7 mL) was added potassium phosphate (93 mg, 0.44 mmol) and Pd(dppf)Cl2 (2.4 mg, 0.003 mmol). The mixture was stirred under nitrogen at 80 °C for 1 hour. LCMS showed that the reaction was complete and the desired product was observed. The crude reaction mixture was combined with a batch from another experiment (using 25 mg of the aryl bromide) and diluted with H2O (10 mL). The aqueous layer was extracted with EtOAc (10×3 mL), and the combined organic extracts were washed with brine, dried over Na 2 SO 4 , filtered and concentrated to give a brown solid. [7c](158 mg). LCMS m / z683 [M+H]+.
[0260] [Steps] [4] [:synthesis] [ , N , ] [-{6-[(3-] [Cyclopropyl] [-1 , H, - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxy] [-4-(] [Pyridine] [-3-] [base] [)] [benzene] [-1-] [Sulfonamide] [(] [Example] [07)] The crude product [7c] was dissolved in TFA (5 mL) and stirred at 80 °C for 18 hours. LCMS showed the starting material [7c] was exhausted and the desired product was observed. The crude reaction mixture was concentrated under reduced pressure and diluted with H2O. The aqueous layer was extracted with EtOAc (50 mL×2), and the combined extracts were washed with saturated aqueous NaHCO3 solution (15 mL), brine (30 mL), dried over Na2SO4 and concentrated under reduced pressure to give the crude product (150 mg) as a brown solid. The crude product was diluted into DMF (2 mL) and purified by reverse phase chromatography using a Phenomenex Gemini NX column (150×20 mm, 5 microns) and eluted with aqueous ammonium hydroxide buffer and ACN at a gradient of 60 mL min-1 to give the crude product as a white solid. [Example]
[07] (31 mg). LCMS m / z563.3 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 11.06 (s, 1H), 9.01 (s, 1H), 8.68-8.60 (m, 1H), 8.23-8.18 (m, 1H), 8.14 (s, 1H), 8.07 (d, J=1.1 Hz, 1H), 7.54-7.49 (m, 1 H), 7.44 (s, 1H), 7.05 (d, J=2.0 Hz, 2H), 5.78 (s, 1H), 3.91-3.87 (m, 9H), 1.91-1.80 (m, 1H) 0.96-0.89 (m, 2H), 0.69-0.63 (m, 2H).
[0261] [method] [F] [Example]
[08] [:] [ , N , ] [-{6-[(3-] [Cyclopropyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxy] [-4-(1,3-] [Zazoline] [-2-] [base] [)] [benzene] [-1-] [Sulfonamide]
[0262] [step] [1] [:] [ , N , ] ['-(6-] [bromine] [-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)- , N , , , N , - ] [Dimethylformamidine] [(8-1a)] Will [Intermediate] A solution of [B] (125 g, 514.28 mmol) in N,N-dimethylformamide dimethyl acetal (462.69 g, 3.88 mol, 515.82 mL) was heated to 90°C for 30 min. H 2O (3 L) was added to the crude reaction at 15°C-25°C, and the mixture was stirred at 25°C for 2 hours, then filtered and washed with H 2O (500 mL×6). The filter cake was dried at 50°C for 24 hours to obtain an off-white solid. [8-1a] (151.2 g, 98% yield). 1H NMR (400 MHz, CDCl 3) δ 8.24 (s, 1H), 7.67 (s, 1H), 7.12 (s, 1H), 3.95 (s, 3H), 3.16 (s, 3H), 3.12 (s, 3H); LCMS m / z 299.8 (M+H) +.
[0263] [step] [2] [:synthesis] [ , N , ] ['-(6-{[5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [base] []] [Amine] [}-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)- , N , , , N , - ] [Dimethylformamidine] [(8-2a)] The reaction was carried out in 2 batches. To a mixture of [8-1a] (80 g, 268.33 mmol), tBuBrettPhos Pd G3 (27.51 g, 32.20 mmol) and Cs 2CO 3 (122.40 g, 375.67 mmol) in 2-methylbutan-2-ol (2.2 L) was added [Intermediate] [N] (66.74 g, 322.00 mmol) in dioxane (160 mL). The reaction mixture was heated to 100 ° C for 16 hours, then diluted with water (3 L) and brine (1 L), then extracted with EtOAc (3 L×3). The two combined organic layers were washed with brine (1 L×2), dried over MgSO 4, filtered and concentrated. The crude material was purified by silica gel column chromatography (0-85% EtOAc / DCM) to give [8-2a] (210 g, 66% yield). 1H NMR (400 MHz, CDCl 3) δ 8.21 (s, 1H), 7.79 (s, 1H), 7.00 - 6.88 (m, 2H), 5.69 (s, 1H), 5.37 - 5.24 (m, 1H), 3.98 - 3.86 (m, 3H), 3.70 - 3.55 (m, 2H), 3.14 (s, 3H), 3.08 (s, 3H), 2.64 - 2.29 (m, 2H), 2.15 (br dd, J= 3.7, 9.6 Hz, 1H), 1.79 - 1.61 (m, 4H), 0.99 - 0.90 (m, 2H), 0.81 - 0.45 (m, 2H); LCMS m / z425.2 (M+H) +.
[0264] [step] [3] [:synthesis] [ , N , ] [ , 6 , ] [-[5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [base] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3,6-] [Diamine] [(8a)] The reaction was carried out in 2 batches. [8-2a] (105 g, 247.35 mmol) was added to a solution of ethylenediamine (93.17 g, 1.55 mol, 103.75 mL) in EtOH (2.6 L). The reaction was heated to 80 °C for 16 hours, then cooled to 25 °C, and a 2:1 mixture of water / EtOH (4.5 L) was added dropwise. The reaction mixture was stirred for 30 minutes, then filtered and washed with H 2 O (900 mL×2). The two batches of filter cake were dried in an oven at 50 °C for 18 hours to give the crude product. [8a] The crude solid was purified by silica gel column chromatography (0-85% EtOAc / DCM). The resulting material was suspended in MTBE (1.5 L) and stirred at 25 °C for 2 hours, then filtered, rinsed and dried to give 20% ethyl acetate as a yellow solid. [8a] (101.3 g, 55% yield). 1H NMR (400 MHz, CDCl 3) δ 7.81 (s, 1H), 6.94 (s, 1H), 6.74 (s, 1H), 5.68 (s, 1H), 5.48 (dd, J= 2.4, 10.0 Hz, 1H), 4.27 - 4.14 (m, 2H), 4.09 (br d, J= 11.4 Hz, 1H), 3.89 (s, 3H), 3.72 - 3.63 (m, 1H), 2.66 - 2.44 (m, 1H), 2.15 (br dd, J= 3.5, 9.1 Hz, 1H), 1.97 (br dd, J= 2.1, 13.5 Hz, 1H), 1.91 - 1.83 (m, 1H), 1.82 - 1.68 (m, 2H), 1.59 (br d, J= 11.5 Hz, 1H), 0.98 (dd, J= 2.0, 8.4 Hz, 2H), 0.86 - 0.76 (m, 1H), 0.69 - 0.58 (m, 1H); LCMS m / z370.2 (M+H) +.
[0265] [step] [4] [:synthesis] [4-] [bromine] [- , N , -(6-{[5- ] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [base] []] [Amine] [}-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-2,6-] [Dimethoxybenzene] [-1-] [Sulfonamide] [(8b)] At 25 °C under nitrogen, [8a] (40 g, 108.28 mmol) was dissolved in pyridine (200 mL) and added [Intermediate] [Db] (41.11 g, 130.26 mmol) and DMAP (1.59 g, 12.99 mmol). The reaction solution was stirred at 25°C for 16 hours. The crude reaction mixture was mixed with [4] The other crude reaction mixture of [8a] was combined. The two reaction mixtures were diluted with DCM (1.6 L) and washed with 1 M AcOH (2.8 L), then extracted with DCM (900 mL×3). The combined organic phases were washed with brine (500 mL×2), then dried over MgSO 4, filtered and concentrated. The crude residue was purified by silica gel column chromatography (0-8% EtOAc / DCM) to give [8b] (68.6 g, 87% yield). 1H NMR (400 MHz, DMSO- d 6) δ 11.12 (s, 1H), 8.38 - 8.08 (m, 2H), 7.53 - 7.31 (m, 1H), 6.99 (s, 2H), 5.77 (d, J= 8.8 Hz, 1H), 5.50 (dd, J= 2.3, 9.7 Hz, 1H), 3.93 (br d, J= 11.0 Hz, 1H), 3.89 (s, 3H), 3.79 (s, 6H), 3.70 - 3.53 (m, 1H), 2.41 - 2.26 (m, 1H), 2.10 - 2.01 (m, 1H), 1.95 - 1.89 (m, 2H), 1.80 - 1.64 (m, 1H), 1.63 - 1.46 (m, 2H), 0.97 (dd, J= 2.4, 8.3 Hz, 2H), 0.77 - 0.53 (m, 2H); LCMS m / z648.1, 650.1 (M+H) +.
[0266] [step] [5] [:synthesis] [ , N , ] [-(6-{[5-] [Cyclopropyl] [-1-(] [Oxyhexane] [-2-] [base] [)-1 , H , - ] [Pyrazole] [-3-] [base] []] [Amine] [}-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [)-2,6-] [Dimethoxy] [-4-(1,3-] [Zazoline] [-2-] [base] [)] [benzene] [-1-] [Sulfonamide] [(8c)] At 20°C under nitrogen, 4-bromo-N-(6-{[5-cyclopropyl-1-(oxan-2-yl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide was added. To a mixture of [8b] (280 mg, 0.43 mmol) in dioxane (6.0 mL) was added 1,3-oxadiazole (60 mg, 0.86 mmol), potassium tributylate (104 mg, 0.93 mmol), 2-dicyclohexylphosphino-2',4'6'-triisopropylbiphenyl (41 mg, 0.09 mmol) and tetrakis(triphenylphosphine)palladium(0) (75 mg, 0.06 mmol). The mixture was then stirred at 100° C. under nitrogen for 10 hours. LCMS of the crude reaction mixture showed that the starting material was consumed and the desired product mass was observed. The crude reaction mixture was combined with another batch (using 20 mg of aryl bromide) and the mixture was filtered. The filter cake was washed with EtOAc (2 x 30 mL) and purified by combi-flash (12 g silica gel, petroleum ether / EtOAc, 0-100%, then 0-20% methanol / DCM) to give N-(6-{[5-cyclopropyl-1-(oxan-2-yl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxy-4-(1,3-oxazol-2-yl)benzene-1-sulfonamide as a yellow gum. [8c](140 mg). LCMS m / z637 [M+H]+.
[0267] [step] [6] [:synthesis] [ , N , ] [-{6-[(3-] [Cyclopropyl] [-1 , H , - ] [Pyrazole] [-5-] [base] [)] [Amine] []-5-] [Methoxy] [-1,2-] [Benzoazole] [-3-] [base] [}-2,6-] [Dimethoxy] [-4-(1,3-] [Zazoline] [-2-] [base] [)] [benzene] [-1-] [Sulfonamide] [(] [Example] [8)] Stir at room temperature [8c] (140 mg, 0.22 mmol) in DCM (2.0 mL) and TFA (5.0 mL) was added for 3 h. LCMS showed the formation of the desired product. The crude reaction mixture was concentrated under reduced pressure to give the crude product (200 mg), which was dissolved in DMF (2 mL) and purified by C18 reverse phase chromatography to give the product as a white solid. [Example]
[08] (16 mg). LCMS m / z553.2 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.91 (br s, 1H), 11.17 (br s, 1H), 8.32 (s, 1H), 8.14 (s, 1H), 8.08 (br s, 1H), 7.46 (s, 1H), 7.40 (s, 1H), 7.26 (s, 2H), 5.78 (s, 1H), 3.89 (s, 3H), 3.87 (s, 6H), 1.90-1.79 (m, 1H), 0.96-0.87 (m, 2H), 0.70-0.63 (m, 2H).
[0268] According to the above [Example] [01-08] Methods AF described, using [Intermediate] [AN] or commercially available reagents to prepare the following [surface] The following examples were synthesized by making noncritical variations or substitutions of the exemplary procedures which will be apparent to those skilled in the art. [surface]
[18] [:] [Instance Number] [Structure / IUPAC] [name] [Analysis data] [method]
[09] 2-Methoxy-N-{4-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 416.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.20 (br s, 1H), 9.11 (s, 1H), 7.81 (d, J=6.8 Hz, 1H), 7.67-7.54 (m, 2H), 7.35 (s, 1H), 7.27 (s, 1H), 7.20 (d, J=8.5 Hz, 1H), 7.09 (t, J=7.5 Hz, 1H), 6.60 (s, 1H), 5.89 (s, 1H), 3.82 (s, 6H) [C]
[10] N-[6-(Cyclobutylamino)-4-methoxy-1,2-benzoxazol-3-yl]-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 434.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.49 (t, J=8.4 Hz, 1H), 6.81-6.75 (m, 3H), 6.05 (s, 1H), 5.95 (s, 1H), 3.90-3.81 (m, 4H), 3.78 (s, 6H), 2.40-2.29 (m, 2H), 1.88-1.65 (m, 4H) [A]
[11] 2,6-Dimethoxy-N-{4-methoxy-6-[(oxetan-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 436.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.06 (br s, 1H), 7.48 (t, J=8.5 Hz, 1H), 7.21 (br d, J=6.0 Hz, 1H), 6.77 (d, J=8.5 Hz, 2H), 6.08 (s, 1H), 5.94 (s, 1H), 4.86 (t, J=6.5 Hz, 2H), 4.63-4.55 (m, 1H), 4.40 (t, J=6.0 Hz, 2H), 3.85 (s, 3H), 3.78 (s, 6H) [A]
[12] N-[6-(Cyclopentylamino)-4-methoxy-1,2-benzoxazol-3-yl]-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 448.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.94 (br s, 1H), 7.46 (br t, J=7.7 Hz, 1H), 6.75 (br d, J=8.4 Hz, 2H), 6.42 (br s, 1H), 6.09 (s, 1H), 6.01 (s, 1H), 3.83 (s, 3H), 3.77 (s, 6H), 3.75-3.67 (m, 1H), 1.92 (qd, J=6.3, 12.3 Hz, 2H), 1.72-1.60 (m, 2H), 1.60-1.49 (m, 2H), 1.48-1.38 (m, 2H) [A]
[13] 2,6-Dimethoxy-N-(4-methoxy-6-{[(3R)-oxolan-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 450.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.49 (t, J=8.5 Hz, 1H), 6.77 (d, J=8.5 Hz, 2H), 6.71 (br d, J=6.3 Hz, 1H), 6.10 (d, J=15.8 Hz, 2H), 4.01 (br s, 1H), 3.89-3.85 (m, 1H), 3.84 (s, 3H), 3.80 (d, J=8.3 Hz, 1H), 3.78 (s, 6H), 3.71 (dt, J=5.5, 8.3 Hz, 1H), 3.52 (dd, J=3.4, 8.9 Hz, 1H), 2.24-2.13 (m, 1H), 1.80-1.70 (m, 1H) [A]
[14] 2,6-Dimethoxy-N-(4-methoxy-6-{[(3S)-oxolan-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 450.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.48 (t, J=8.5 Hz, 1H), 6.77 (d, J=8.6 Hz, 2H), 6.71 (d, J=6.4 Hz, 1H), 6.15-6.03 (m, 2H), 4.05-3.97 (m, 1H), 3.89-3.85 (m, 1H), 3.83 (s, 3H), 3.80 (d, J=8.1 Hz, 1H), 3.78 (s, 6H), 3.71 (dt, J=5.5, 8.2 Hz, 1H), 3.52 (dd, J=3.4, 8.9 Hz, 1H), 2.24-2.12 (m, 1H), 1.82-1.68 (m, 1H) [A]
[15] N-{6-[(1H-imidazol-2-yl)amino]-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 446.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.35 (br s, 1H), 7.48 (t, J=8.4 Hz, 1H), 7.37 (s, 1H), 6.79-6.67 (m, 5H), 3.86 (s, 3H), 3.77 (s, 6H) [A]
[16] 2,6-Dimethoxy-N-{4-methoxy-6-[(1,2-oxazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 447.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.80 (s, 1H), 8.69 (d, J=1.8 Hz, 1H), 7.50 (t, J=8.4 Hz, 1H), 7.34 (d, J=1.3 Hz, 1H), 6.78 (d, J=8.5 Hz, 2H), 6.72 (d, J=1.1 Hz, 1H), 6.29 (d, J=1.8 Hz, 1H), 3.91 (s, 3H), 3.78 (s, 6H) [A]
[17] 2,6-Dimethoxy-N-{4-methoxy-6-[(1,3-oxazol-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 447.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.69 (d, J=1.0 Hz, 1H), 7.44 (d, J=1.2 Hz, 1H), 7.35 (t, J=8.4 Hz, 1H), 7.04 (d, J=1.0 Hz, 1H), 6.83 (d, J=1.3 Hz, 1H), 6.68 (d, J=8.4 Hz, 2H), 3.86 (s, 3H), 3.68 (s, 6H) [A]
[18] 2,6-Dimethoxy-N-{4-methoxy-6-[(pyridin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 457.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.61 (s, 1H), 9.35 (s, 1H), 8.25 (br d, J=3.7 Hz, 1H), 7.98 (s, 1H), 7.70-7.62 (m, 1H), 7.50 (t, J=8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 6.88-6.83 (m, 2H), 6.78 (d, J=8.6 Hz, 2H), 3.92-3.90 (m, 3H), 3.79 (s, 6H) [A]
[19] 2,6-Dimethoxy-N-{4-methoxy-6-[(oxazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 458.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 9.80 (s, 1H), 8.76 (d, J=4.5 Hz, 1H), 8.02 (s, 1H), 7.55-7.44 (m, 2H), 7.22 (d, J=8.8 Hz, 1H), 6.90 (s, 1H), 6.78 (d, J=8.5 Hz, 2H), 3.91 (s, 3H), 3.78 (s, 6H) [A]
[20] 2,6-Dimethoxy-N-{4-methoxy-6-[(pyrimidin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 458.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.09 (s, 1H), 9.42 (br s, 1H), 8.59 (d, J=4.8 Hz, 2H), 7.96 (s, 1H), 7.51 (t, J=8.4 Hz, 1H), 7.13 (s, 1H), 6.97 (t, J=4.9 Hz, 1H), 6.79 (d, J=8.5 Hz, 2H), 3.90 (s, 3H), 3.79 (s, 6H) [A] [twenty one] N-{5-methoxy-6-[(1-methyl-1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzenesulfonamide LCMS m / z 400.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.28 (s, 1H), 8.18 (s, 1H), 7.95 (br d, J=7.4 Hz, 2H), 7.71-7.64 (m, 1H), 7.64-7.58 (m, 2H), 7.53 (d, J=2.1 Hz, 1H), 7.25 (s, 1H), 6.06 (d, J=2.3 Hz, 1H), 3.89 (s, 3H), 3.79 (s, 3H) [B] [twenty two] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 416.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 7.94 (dd, J=1.7, 7.8 Hz, 1H), 7.66 (br s, 1H), 7.58 (d, J=2.2 Hz, 1H), 7.55-7.48 (m, 1H), 7.29 (s, 1H), 7.11 (d, J=8.1 Hz, 1H), 7.06-6.96 (m, 1H), 6.13 (d, J=2.3 Hz, 1H), 3.99 (s, 3H), 3.87 (s, 3H) [C] [twenty three] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4-methylbenzene-1-sulfonamide LCMS m / z 430.0 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.77 (d, J=7.9 Hz, 1H), 7.70 (br s, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.30 (s, 1H), 6.97 (s, 1H), 6.87 (d, J=7.9 Hz, 1H), 6.13 (d, J=2.3 Hz, 1H), 4.00 (s, 3H), 3.88 (s, 3H), 2.38 (s, 3H) [C] [twenty four] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-5-methylbenzene-1-sulfonamide LCMS m / z 430.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (br s, 1H), 11.23 (br s, 1H), 8.27 (br s, 1H), 8.19 (br s, 1H), 7.67 (br s, 1H), 7.60 (br s, 1H), 7.46-7.35 (m, 2H), 7.08(br d, J=8.4 Hz, 1H), 6.12 (s, 1H), 3.91 (s, 3H), 3.79 (s, 3H), 2.30 (s, 3H) [C]
[25] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4,5-dimethylbenzene-1-sulfonamide LCMS m / z 444.1 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.72 (br s, 1H), 7.65 (s, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.29 (s, 1H), 6.94 (s, 1H), 6.13 (d, J=2.4 Hz, 1H), 4.00 (s, 3H), 3.86 (s, 3H), 2.30 (s, 3H), 2.23 (s, 3H) [C]
[26] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4-methyl-5-(propan-2-yl)benzene-1-sulfonamide LCMS m / z 472.0 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.73 (s, 1H), 7.71 (br s, 1H), 7.58 (d, J=2.5 Hz, 1H), 7.33 (s, 1H), 6.91 (s, 1H), 6.13 (d, J=2.5 Hz, 1H), 4.01 (s, 3H), 3.84 (s, 3H), 3.17-3.02 (m, 1H), 2.36 (s, 3H), 1.17 (d, J=7.0 Hz, 6H) [C]
[27] 4-Chloro-2-methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 450.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (br s, 1H), 11.45 (br s, 1H), 8.27 (s, 1H), 8.19 (s, 1H), 7.86 (d, J=8.5 Hz, 1H), 7.60 (s, 1H), 7.36-7.28 (m, 2H), 7.18 (dd, J=1.6, 8.5 Hz, 1H), 6.12 (s, 1H), 3.91 (s, 3H), 3.86 (s, 3H) [B]
[28] 2-Ethoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 430.0 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.93 (br d, J=7.9 Hz, 1H), 7.71 (br s, 1H), 7.61-7.51 (m, 2H), 7.27 (s, 1H), 7.12 (br d, J=8.4 Hz, 1H), 7.03 (br t, J=7.6 Hz, 1H), 6.11 (s, 1H), 4.59 (br s, 2H), 4.17 (q, J=7.0 Hz, 2H), 3.97 (s, 3H), 1.34 (br t, J=6.9 Hz, 3H) [C]
[29] 2-Ethoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4-methylbenzene-1-sulfonamide LCMS m / z 444.0 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.80 (d, J=8.1 Hz, 1H), 7.71 (s, 1H), 7.58 (d, J=2.3 Hz, 1H), 7.29 (s, 1H), 6.95 (s, 1H), 6.86 (d, J=8.1 Hz, 1H), 6.13 (d, J=2.3 Hz, 1H), 4.16 (q, J=7.0 Hz, 2H), 3.99 (s, 3H), 2.37 (s, 3H), 1.36 (t, J=7.0 Hz, 3H) [C]
[30] 2-Ethoxy-6-methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 460.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (s, 1H), 10.94 (s, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 7.62-7.58 (m, 1H), 7.45 (t, J=8.5 Hz, 1H), 7.41 (s, 1H), 6.75 (d, J=4.3 Hz, 1H), 6.72 (d, J=4.3 Hz, 1H), 6.12 (t, J=2.2 Hz, 1H), 4.06 (q, J=7.0 Hz, 2H), 3.88 (s, 3H), 3.76 (s, 3H), 1.21 (t, J=7.0 Hz, 3H) [B]
[31] 2-(2,2-difluoroethoxy)-6-methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z496.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.21 (s, 1H), 11.06 (s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.62 (t, J=1.9 Hz, 1H), 7.52 (t, J=8.5 Hz, 1H), 7.41 (s, 1H), 6.87 (d, J=8.1 Hz, 1H), 6.84 (br d, J=8.5 Hz, 1H), 6.38 (tt, J=3.8, 54.6, Hz 1H), 6.13 (t, J=2.1 Hz, 1H), 4.39 (dt, J=3.8, 14.1 Hz, 2H), 3.91 (s, 3H), 3.78 (s, 3H) 19F NMR (376MHz, DMSO-d 6) δ-124.71 (br s, 1F) [B] [3] [2] 2-Methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-6-[(propan-2-yl)oxy]benzene-1-sulfonamide LCMS m / z 474.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (s, 1H), 10.87 (s, 1H), 8.25 (s, 1H), 8.20 (s, 1H), 7.60 (s, 1H), 7.47-7.38 (m, 2H), 6.75 (d, J=8.1 Hz, 1H), 6.71 (br d, J=8.3 Hz, 1H), 6.12 (t, J=2.2 Hz, 1H), 4.65 (spt, J=6.1 Hz, 1H), 3.87 (s, 3H), 3.77 (s, 3H), 1.13 (d, J=6.0 Hz, 6H) [B]
[33] 2-(Cyclobutyloxy)-6-methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z486.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.17 (br s, 1H), 10.98 (br s, 1H), 8.22 (br s, 1H), 8.18 (s, 1H), 7.59 (s, 1H), 7.47-7.32 (m, 2H), 6.71 (d, J=8.5 Hz, 1H), 6.50 (br d, J=8.3 Hz, 1H), 6.10 (t, J=2.1 Hz, 1H), 4.66 (quintet, J=7.3 Hz, 1H), 3.86 (s, 3H), 3.76 (s, 3H), 2.21 (br s, 2H), 1.88 (quintet, J=9.7 Hz, 2H), 1.57-1.43 (m, 2H) [B]
[34] 2-(Cyclopropyloxy)-6-methoxy-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 472.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.19 (br s, 1H), 10.97 (s, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 7.60 (s, 1H), 7.49 (t, J=8.5 Hz, 1H), 7.39 (s, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.78 (d, J=8.4 Hz, 1H), 6.12 (s, 1H), 3.91-3.85 (m, 4H), 3.78 (s, 3H), 0.69-0.60 (m, 2H), 0.55-0.48 (m, 2H) [B]
[35] 2,6-Dimethoxy-N-{5-methoxy-6-[(1-methyl-1H-1,2,4-triazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide MS (flow injection mode) m / z460.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.09 (s, 1H), 8.31 (s, 1H), 8.19 (s, 1H), 8.10 (s, 1H), 7.51-7.44 (m, 2H), 6.75 (d, J=8.4 Hz, 2H), 3.90 (s, 3H), 3.83 (s, 3H), 3.76 (s, 6H) [B]
[36] 2,6-Dimethoxy-N-{5-methoxy-6-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide MS (flow injection mode) m / z 460.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.16 (br s, 1H), 11.14 (br s, 1H), 8.20 (br s, 1H), 7.91 (br s, 1H), 7.54-7.42 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 3.90 (s, 3H), 3.76 (s, 6H), 2.32 (br s, 3H) [B]
[37] 2,6-Dimethoxy-N-{5-methoxy-6-[(5-methyl-1,2,4-oxadiazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide MS (flow injection mode) m / z 483.9 [M+Na] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.18 (br s, 1H), 8.99 (s, 1H), 7.92 (s, 1H), 7.57 (s, 1H), 7.47 (t, J=8.5 Hz, 1H), 6.74 (d, J=8.5 Hz, 2H), 3.89 (s, 3H), 3.76 (s, 6H), 2.55 (s, 3H) [B]
[38] N-{6-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 474.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.01 (s, 1H), 7.82 (s, 1H), 7.50-7.44 (m, 2H), 6.74 (d, J=8.8 Hz, 2H), 6.44 (s, 1H), 5.94 (s, 1H), 3.89 (s, 3H), 3.77 (s, 6H), 3.52 (s, 3H), 2.13 (s, 3H) [B]
[39] N-{6-[(1-ethyl-1H-pyrazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide MS (flow injection mode) m / z 473.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.98 (s, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.58 (d, J=2.3 Hz, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.42 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.06 (d, J=2.3 Hz, 1H), 4.07 (q, J=7.3 Hz, 2H), 3.89 (s, 3H), 3.76 (s, 6H), 1.37 (t, J=7.3 Hz, 3H) [B]
[40] N-{6-[(5-ethyl-1H-1,2,4-triazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 475.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.18 (s, 1H), 11.06 (s, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.51-7.43 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 3.89 (s, 3H), 3.76 (s, 6H), 2.69 (q, J=7.5 Hz, 2H), 1.24 (t, J=7.7 Hz, 3H) [B]
[41] N-{6-[(1-ethyl-1H-1,2,4-triazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide MS (flow injection mode) m / z 475.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.07 (br s, 1H), 8.36 (s, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 7.53-7.41 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 4.15 (q, J=7.3 Hz, 2H), 3.89 (s, 3H), 3.75 (s, 6H), 1.41 (t, J=7.3 Hz, 3H) [B]
[42] N-{6-[(1-ethyl-1H-1,2,3-triazol-4-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 475.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.00 (br s, 1H), 8.30 (s, 1H), 7.88 (s, 1H), 7.66 (s, 1H), 7.54-7.39 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 4.36 (q, J=7.3 Hz, 2H), 3.88 (s, 3H), 3.75 (s, 6H), 1.44 (t, J=7.4 Hz, 3H) [B]
[43] N-{6-[(5-ethyl-1,2,4-oxadiazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide MS (flow injection mode) m / z 497.9 [M+Na] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.17 (br s, 1H), 9.02 (s, 1H), 7.93 (s, 1H), 7.57 (s, 1H), 7.47 (t, J=8.5 Hz, 1H), 6.75 (d, J=8.6 Hz, 2H), 3.88 (s, 3H), 3.76 (s, 6H), 2.90 (q, J=7.5 Hz, 2H), 1.30 (t, J=7.5 Hz, 3H) [B]
[44] 2,6-Dimethoxy-N-{5-methoxy-6-[(5-methoxy-1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide MS (flow injection mode) m / z 475.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.76 (br s, 0.5H), 11.30 (br s, 0.5H), 11.0-10.93 (m, 1H), 8.18 (s, 0.5H), 8.12 (s, 1H), 7.38-7.53 (m, 2H), 6.94 (br s, 0.5H), 6.73 (d, J=8.6 Hz, 2H), 5.65 (br s, 0.5H), 5.51 (br s, 0.5H), 3.87 (s, 3H), 3.82-3.71 (m, 9H) [mixture of tautomers] [B]
[45] N-{6-[(4-cyano-3-methyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 485.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.01 (br s, 1H), 11.09 (br s, 1H), 7.85 (br s, 2H), 7.52 (s, 1H), 7.47 (t, J=8.4 Hz, 1H), 6.74 (d, J=8.4 Hz, 2H), 3.92 (s, 3H), 3.76 (s, 6H), 2.36 (s, 3H) [B]
[46] N-{6-[(4-cyano-1,3-dimethyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z499.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.11 (s, 1H), 8.46 (s, 1H), 7.56 (s, 1H), 7.47 (t, J=8.5 Hz, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.64 (s, 1H), 3.91 (s, 3H), 3.76 (s, 6H), 3.60 (s, 3H), 2.24 (s, 3H) [B]
[47] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 486.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.91 (br s, 1H), 10.97 (s, 1H), 8.12 (br s, 1H), 8.06 (s, 1H), 7.46 (t, J=8.4 Hz, 1H), 7.40 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 5.79 (s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 1.91-1.81 (m, 1H), 0.96-0.87 (m, 2H), 0.70-0.62 (m, 2H) [B]
[48] N-{6-[(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z500.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.01 (br s, 1H), 7.79 (s, 1H), 7.51-7.43 (m, 2H), 6.74 (d, J=8.6 Hz, 2H), 6.44 (s, 1H), 5.88 (s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 3.51 (s, 3H), 1.86-1.75 (m, 1H), 0.86-0.77 (m, 2H), 0.68-0.60 (m, 2H) [B]
[49] 2,6-Dimethoxy-N-{5-methoxy-6-[(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z487.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.03 (br s, 1H), 7.95 (s, 1H), 7.41 (t, J=8.4 Hz, 1H), 7.35 (s, 1H), 6.71 (d, J=8.5 Hz, 1H), 3.98 (s, 2H), 3.90 (s, 2H), 3.86 (s, 3H), 3.72 (s, 6H) [B]
[50] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(propan-2-yl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z488.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.87 (br s, 1H), 8.10 (br s, 1H), 7.97 (s, 1H), 7.39 (t, J=8.4 Hz, 1H), 7.30 (s, 1H), 6.70 (d, J=8.4 Hz, 2H), 5.87 (s, 1H), 3.86 (s, 3H), 3.71 (s, 6H), 2.90 (td, J=6.8, 13.7 Hz, 1H), 1.21 (d, J=6.8 Hz, 6H) [B]
[51] 2,6-Dimethoxy-N-(5-methoxy-6-{[1-methyl-3-(propan-2-yl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z502.2 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.99 (br s, 1H), 7.79 (s, 1H), 7.52-7.41 (m, 2H), 6.72 (d, J=8.5 Hz, 2H), 6.43 (s, 1H), 5.99 (s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 3.54 (s, 3H), 2.82 (septet, J=6.9 Hz, 1H), 1.19 (d, J=6.9 Hz, 6H) [B]
[52] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z502.2 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.00 (br s, 1H), 7.78 (s, 1H), 7.50-7.43 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 6.29 (s, 1H), 5.89 (s, 1H), 4.32 (septet, J=6.6 Hz, 1H), 3.89 (s, 3H), 3.77 (s, 6H), 2.17 (s, 3H), 1.26 (d, J=6.8 Hz, 6H) [B]
[53] 2,6-Dimethoxy-N-(5-methoxy-6-{[1-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 487.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.98 (br s, 1H), 8.23 (s, 1H), 8.14 (s, 1H), 7.60 (d, J=2.5 Hz, 1H), 7.46 (t, J=8.5 Hz, 1H), 7.43 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.06 (d, J=2.3 Hz, 1H), 4.41 (septet, J=6.7 Hz, 1H), 3.89 (s, 3H), 3.76 (s, 6H), 1.42 (d, J=6.5 Hz, 6H) [B]
[54] 5-({3-[(2,6-dimethoxybenzene-1-sulfonyl)amino]-5-methoxy-1,2-benzoxazol-6-yl}amino)-1H-pyrazole-3-carboxylic acid LCMS m / z 490.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.19 (br s, 2H), 11.02 (br s, 1H), 8.48 (s, 1H), 8.16 (br s, 1H), 7.50-7.44 (m, 2H), 6.74 (d, J=8.6 Hz, 2H), 6.59 (s, 1H), 3.90 (s, 3H), 3.77 (s, 6H) [Example 55] [Ester hydrolysis]
[55] 5-({3-[(2,6-dimethoxybenzene-1-sulfonyl)amino]-5-methoxy-1,2-benzoxazol-6-yl}amino)-1H-pyrazole-3-carboxylic acid methyl ester LCMS m / z504.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.38 (br s, 1H), 11.03 (br s, 1H), 8.54 (s, 1H), 8.18 (s, 1H), 7.51-7.42 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 6.66 (s, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.76 (s, 6H) [B]
[56] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(piperidin-4-yl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z529.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.93 (br s, 1H), 8.05 (br s, 1H), 7.91 (s, 1H), 7.34 (br t, J=8.3 Hz, 1H), 7.24 (s, 1H), 6.67 (d, J=8.4 Hz, 2H), 5.89 (s, 1H), 3.83 (s, 3H), 3.66 (s, 6H), 3.15 (br d, J=12.1 Hz, 2H), 2.83-2.71 (m, 3H), 1.93 (br d, J=12.2 Hz, 2H), 1.61 (br d, J=12.7 Hz, 2H) [B]
[57] 5-({3-[(2,6-dimethoxybenzene-1-sulfonyl)amino]-5-methoxy-1,2-benzoxazol-6-yl}amino)-3-methyl-1H-pyrazole-4-carboxamide LCMS m / z 503.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.44 (br s, 1H), 11.07 (br s, 1H), 9.94 (br s, 1H), 8.33 (br s, 1H), 7.50 (br s, 2H), 6.99 (br s, 2H), 6.78 (br d, J=8.3 Hz, 2H), 3.94 (br s, 3H), 3.80 (br s, 6H), 2.49 (br s, 3H) [B]
[58] 5-({3-[(2,6-dimethoxybenzene-1-sulfonyl)amino]-5-methoxy-1,2-benzoxazol-6-yl}amino)-1,3-dimethyl-1H-pyrazole-4-carboxamide LCMS m / z 517.2 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.20 (s, 1H), 8.51 (s, 1H), 8.49 (s, 1H), 7.63 (s, 1H), 7.48 (t, J=8.5 Hz, 1H), 6.75 (d, J=8.5 Hz, 2H), 6.39 (s, 2H), 3.94 (s, 3H), 3.76 (s, 6H), 3.50 (s, 3H), 2.40 (s, 3H) [B]
[59] N-(6-{[1-(2-hydroxyethyl)-3-methyl-1H-pyrazol-5-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z504.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.09 (br s, 1H), 8.29 (s, 1H), 7.58-7.46 (m, 2H), 6.86 (s, 1H), 6.80 (d, J=8.4 Hz, 2H), 6.09 (s, 1H), 5.47 (br s, 1H), 4.06 (br t, J=4.6 Hz, 2H), 3.94 (s, 3H), 3.82 (s, 6H), 3.75 (br s, 2H), 2.21 (s, 3H) [B]
[60] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z504.1 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.03 (s, 1H), 7.90 (s, 1H), 7.52-7.43 (m, 2H), 6.74 (d, J=8.6 Hz, 2H), 6.43 (s, 1H), 6.14 (s, 1H), 4.29 (s, 2H), 3.89 (s, 3H), 3.77 (s, 6H), 3.58 (s, 3H), 3.26 (s, 3H) [B]
[61] 2,6-Dimethoxy-N-{5-methoxy-6-[(1H-1,2,4-triazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 447.0 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.08 (br s, 1H), 8.81-7.82 (m, 3H), 7.54-7.41 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 3.91 (s, 3H), 3.75 (s, 6H) [B]
[62] 2-(2,2-difluoroethoxy)-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)-4-methylbenzene-1-sulfonamide LCMS m / z 521.9 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 11.09 (br s, 1H), 8.16 (s, 1H), 8.11 (s, 1H), 7.86-7.65 (m, 1H), 7.38 (s, 1H), 6.99 (s, 1H), 6.88 (d, J=8.0 Hz, 1H), 5.88 (s, 1H), 4.22-3.99 (m, 2H), 3.93-3.83 (m, 3H), 2.94-2.87 (m, 1H), 2.33 (s, 3H) 1.26-1.17 (m, 9H) [B] [6] [3] 2-Ethoxy-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 472.4 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 11.21 (br s, 1H), 8.29-8.00 (m, 2H), 7.87 (dd, J=1.5, 7.8 Hz, 1H), 7.56 (br t, J=7.8 Hz, 1H), 7.35 (s, 1H), 7.16 (d, J=8.5 Hz, 1H), 7.07 (t, J=7.5 Hz, 1H), 5.87 (s, 1H), 4.12 (q, J=6.9 Hz, 2H), 3.88 (s, 3H), 2.93-1.86 (m, 1H), 1.32-1.11 (m, 9H) [B] [6] [4] 2-(2,2-Difluoroethoxy)-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4-methylbenzene-1-sulfonamide LCMS m / z 480 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.25 (s, 1H), 8.15 (br d, J=7.5 Hz, 1H), 7.77 (d, J=8.0 Hz, 1H), 7.59 (d, J=1.9 Hz, 1H), 7.33 (s, 1H), 7.13 (s, 1H), 6.98 (d, J=8.0 Hz, 1H), 6.60-6.26 (m, 1H), 6.11 (d, J=1.9 Hz, 1H), 4.42 (dt, J=3.8, 13.9 Hz, 2H), 3.90 (s, 3H), 2.34 (s, 3H) [B] [6] [5] 2-Methoxy-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 457.9 [M+H] +; 1H NMR (500 MHz, DMSO- d 6) δ 11.91 (br s, 1H), 11.29 (br s, 1H), 8.21-8.09 (m, 2H), 7.86 (dd, J=1.5, 7.9 Hz, 1H), 7.61 (t, J=7.9 Hz, 1H), 7.35 (s, 1H), 7.18 (d, J=8.2 Hz, 1H), 7.10 (t, J=7.6 Hz, 1H), 5.88 (s, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 2.92-2.85 (m, 1H), 1.21 (d, J=6.9 Hz, 6H) [B] 66 N-(6-{[3-(1,1-difluoroethyl)-1H-pyrazol-5-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 510 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 13.10-12.74 (m, 1 H), 10.96 (s, 1H), 8.33 (br s, 1H), 7.96-8.22 (m, 1H), 7.50-7.42 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 6.37 (s, 1H), 3.89 (s, 3H), 3.76 (s, 6H), 2.00 (t, J=18.8 Hz, 3H) [B] 67 N-(6-{[5-(difluoromethoxy)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 511 [M+H] +; 1H NMR (600 MHz, DMSO- d 6) δ 11.92 (s, 1H), 11.02 (br s, 1H), 8.39-8.17 (m, 1H), 7.50 (s, 1H) 7.46 (t, J=8.4 Hz, 1H), 7.26 (t, J=73.8 Hz, 1H), 6.96 (s, 1H), 6.74 (d, J=8.4 Hz, 2H), 5.94 (d, J=1.4 Hz, 1H), 3.89 (s, 3H), 3.76 (s, 6H) [B] [6] [8] N-(6-{[5-(2,2-difluorocyclopropyl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide or1=Unknown single mirror image isomer absolute stereochemistry SFC MS m / z522 [M+H] +; [α] D 22= +18.3° (C 0.1, MeOH); 1H NMR (600 MHz, DMSO- d 6) δ 12.21 (br s, 1H), 10.94 (s, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 7.46 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.01 (br s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 3.03-2.87 (m, 1H), 2.14-1.99 (m, 1H), 1.89-1.76 (m, 1H). Column: Chiralpak ®AD SFC (20 × 250 mm; 10 μm); Mobile phase: A: CO 2; Mobile phase: B: isopropanol + 10 mM NH 3; 50% B isocratic, 100 bar, 80 mL / min; R t = 3.96 min [B] [6] [9] N-(6-{[5-(2,2-difluorocyclopropyl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide or1 = unknown single mirror isomer absolute stereochemistry SFC MS m / z522 [M+H] +; [α] D 22= -10.1° (C 0.1, MeOH); 1H NMR (600 MHz, DMSO- d 6) δ 12.21 (br s, 1H), 10.94 (s, 1H), 8.18 (s, 1H), 8.12 (s, 1H), 7.46 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 6.01 (s, 1H), 3.88 (s, 3H), 3.76 (s, 6H), 3.01-2.88 (m, 1H), 2.12-2.01 (m, 1H), 1.90-1.78 (m, 1H). Column: Chiralpak ®AD SFC (20 × 250 mm; 10 μm); Mobile phase: A: CO 2; Mobile phase: B: isopropanol + 10 mM NH 3; 50% B isocratic, 100 bar, 80 mL / min; R t = 7.97 min [B]
[70] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-2-ethoxy-5-fluoro-4-methylbenzene-1-sulfonamide LCMS m / z 520 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.61 (d, J=8.9 Hz, 1H), 7.42 (br s, 1H), 7.02 (d, J=5.8 Hz, 1H), 5.72 (s, 1H), 4.20-4.08 (m, 5H), 2.30 (d, J=1.8 Hz, 3H), 1.93-1.85 (m, 1H), 1.36 (t, J=7.0 Hz, 3H), 1.01-0.94 (m, 2H), 0.76-0.69 (m, 2H) [B] [7] [1] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 504 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.98 (br s, 1H), 9.74 (br s, 1H), 8.73 (br s, 1H), 7.90 (br d, J=4.7 Hz, 1H), 7.48 (br t, J=8.5 Hz, 1H), 6.77 (d, J=8.4 Hz, 2H), 5.73 (s, 1H), 4.05 (d, J=2.6 Hz, 3H), 3.77 (s, 6H), 1.92-1.82 (m, 1H), 0.95-0.87 (m, 2H), 0.71-0.64 (m, 2H) [B] [7] [2] N-{6-[(3-ethyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 492 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.97 (br s, 1H), 8.77 (br s, 1H), 7.94 (br s, 1H), 7.49 (br d, J=4.7 Hz, 1H), 6.78 (br dd, J=8.3, 4.5 Hz, 2H), 5.84 (br s, 1H), 4.05 (br s, 3H), 3.78 (br d, J=4.3 Hz, 6H), 2.61-2.55 (m, 2H), 1.24-1.14 (m, 3H) [B]
[73] N-{6-[(5-ethyl-1-methyl-1H-pyrazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 488 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.96 (br s, 1H), 8.18-8.10 (m, 2H), 7.46 (t, J=8.4 Hz, 1H), 7.39 (s, 1H), 6.74 (d, J=8.4 Hz, 2H), 5.89 (s, 1 H), 3.87 (s, 3H), 3.75 (s, 6H), 3.66 (s, 3H), 2.60-2.55 (m, 2H), 1.17 (t, J=7.5 Hz, 3H) [B]
[74] N-{6-[(1-ethyl-5-methyl-1H-pyrazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 488 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.95 (br s, 1H), 8.15-8.09 (m, 2H), 7.45 (t, J=8.4 Hz, 1H), 7.40 (s, 1H), 6.73 (d, J=8.5 Hz, 2H), 5.86 (s, 1H), 3.97 (d, J=7.1 Hz, 2H), 3.87 (s, 3H), 3.75 (s, 6H), 2.21 (s, 3H), 1.29 (t, J=7.1 Hz, 3H) [B]
[75] N-{6-[(1-ethyl-1H-imidazol-4-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 474 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 8.11 (br s, 1H), 7.44 (s, 1H), 7.39 (t, J=8.4 Hz, 1H), 7.34 (s, 1H), 7.03 (s, 1H), 6.96 (s, 1H), 6.76 (s, 1H), 6.60 (d, J=8.5 Hz, 2H), 4.03-3.98 (m, 2H), 3.97 (s, 3H), 3.92 (s, 6H), 1.50 (t, J=7.3 Hz, 3H) [B]
[76] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-2-ethoxy-4-fluorobenzene-1-sulfonamide LCMS m / z 506 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 8.00 (dd, J=8.9, 6.4 Hz, 1H), 7.41 (br s, 1H), 6.95 (dd, J=10.9, 2.2 Hz, 1H), 6.83 (td, J=8.4, 2.2 Hz, 1H), 5.72 (s, 1H), 4.20-4.11 (m, 5H), 1.93-1.84 (m, 1H), 1.38 (t, J=7.0 Hz, 3H), 1.01-0.94 (m, 2H), 0.76-0.69 (m, 2H) [B]
[77] 2-Ethoxy-5-fluoro-N-{5-methoxy-6-[(1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}-4-methylbenzene-1-sulfonamide LCMS m / z 462 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.18 (br s, 1H), 11.33 (br s, 1H), 8.26 (s, 1H), 8.19 (s, 1H), 7.59 (s, 1H), 7.55 (d, J=9.0 Hz, 1H), 7.38 (s, 1H), 7.13 (d, J=5.9 Hz, 1H), 6.11 (s, 1H), 4.09 (q, J=6.9 Hz, 2H), 3.90 (s, 3H), 2.26 (s, 3H), 1.21 (t, J=6.9 Hz, 3 H) [B]
[78] 2-Ethoxy-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)-4-methylbenzene-1-sulfonamide LCMS m / z 486 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.89 (br s, 1H), 11.08 (br s, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 7.74 (d, J=8.1 Hz, 1H), 7.38 (s, 1H), 6.98 (s, 1H), 6.87 (br d, J=8.1 Hz, 1H), 5.87 (s, 1H), 4.15-4.04 (m, 2H), 3.88 (s, 3H) 2.94-2.84 (m, 1H), 2.32 (s, 3H), 1.26-1.17 (m, 9H) [B]
[79] 2-Ethoxy-5-fluoro-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)-4-methylbenzene-1-sulfonamide LCMS m / z 504 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 11.33 (br s, 1H), 8.16 (br s, 1H), 8.12 (br s, 1H), 7.55 (d, J=9.0 Hz, 1H), 7.36 (s, 1H), 7.13 (br d, J=5.8 Hz, 1H), 5.87 (s, 1H), 4.08 (q, J=7.0 Hz, 2H), 3.88 (s, 3 H), 2.93-2.86 (m, 1H), 2.26 (d, J=1.3 Hz, 3H), 1.23-1.18 (m, 9H) [B]
[80] 2-(Cyclopropyloxy)-N-{6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-6-methoxybenzene-1-sulfonamide LCMS m / z 530 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 7.46-7.34 (m, 2H), 7.01-6.92 (m, 1H), 6.65-6.57 (m, 1H), 6.50-6.39 (m, 1H), 5.75-5.64 (m, 1H), 4.30-4.17 (m, 3H), 3.97-3.86 (m, 3H), 3.84-3.76 (m, 1H), 1.92-1.82 (m, 1H), 1.05-0.97 (m, 2H), 0.90-0.84 (m, 2H), 0.80 (br s, 4H) [B]
[81] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-2-fluoro-6-methoxybenzene-1-sulfonamide LCMS m / z 492 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.49-7.41 (m, 1H), 7.39-7.31 (m, 1H), 6.90 (d, J=8.3 Hz, 1H), 6.77 (dd, J=10.2, 8.6 Hz, 1H), 5.72 (s, 1H), 4.13 (d, J=2.3 Hz, 3H), 3.81 (s, 3H), 1.92-1.87 (m, 1H), 1.00-0.92 (m, 2H), 0.77-0.69 (m, 2H) [B]
[82] 3-Methoxy-N-{5-methoxy-6-[(3-methyl-1H-pyrazol-5-yl)amino]-1,2-benzoxazol-3-yl}-5,6,7,8-tetrahydronaphthalene-2-sulfonamide LCMS m / z 484 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.63-7.58 (m, 1H), 7.56 (s, 1H), 7.27-7.22 (m, 1H), 6.78 (s, 1H), 5.88 (s, 1H), 3.99-3.92 (m, 3H), 3.84-3.78 (m,3H), 2.76 (br s, 2H), 2.72-2.63 (m, 2H), 2.30-2.24 (m, 3H), 1.75 (br t, J=3.0 Hz, 4H) [D]
[83] 2-Ethoxy-6-methoxy-N-(5-methoxy-6-{[5-(propan-2-yl)-1H-pyrazol-3-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 502 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (s, 1H), 10.92 (br s, 1H), 8.16 (s, 1H), 8.09 (s, 1H), 7.43 (t, J=8.3 Hz,1H), 7.38 (s, 1H), 6.72 (dd, J=8.5, 4.0 Hz, 2H), 5.87 (s, 1H), 4.05 (q, J=7.0 Hz, 2H), 3.86 (s, 3H), 3.75 (s, 3H), 2.91-2.87 (m, 1H), 1.22-1.17 (m, 9H) [B]
[84] 2,6-Dimethoxy-N-{5-methoxy-6-[(3-methyl-1H-pyrazol-5-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 460 [M+H] +; 1H NMR (500 MHz, methanol-d 4) δ 7.60 (br s, 1H), 7.46 (t, J=8.5 Hz, 1H), 7.31 (s, 1H), 6.72 (d, J=8.5 Hz, 2H), 5.88 (s, 1H), 3.95 (s, 3H), 3.84 (s, 6H), 2.28 (s, 3H) [D]
[85] N-{6-[(3-cyclopentyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 514 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.88 (s, 1H), 10.91 (s, 1H), 8.14 (br s, 1H), 8.04 (s, 1H), 7.46 (t, J=8.5 Hz, 1H), 7.39 (s, 1H), 6.74 (d, J=8.5 Hz, 2H), 5.83 (s, 1H), 3.87 (s, 3H), 3.76 (s, 6H), 3.11-2.92 (m, 1H), 2.14-1.88 (m, 2H), 1.75-1.66 (m, 2H), 1.63-1.51 (m, 4H) [B]
[86] N-(6-{[3-(1-hydroxyethyl)-1H-pyrazol-5-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide or1=Unknown single mirror image isomer absolute stereochemistry SFC MS m / z490 [M+H] +; [α] D 22= -14.2° (C 0.1, CHCl 3); 1H NMR (400 MHz, DMSO-d 6) δ 12.01 (s, 1H), 10.98 (br s, 1H), 8.20-8.14 (m, 2H), 7.52-7.45 (m, 1H), 6.80 (s, 1H), 6.77 (d, J=8.6 Hz, 2H), 6.01 (s, 1H), 5.33 (br d, J=4.9 Hz, 1H), 4.80-4.79 (m, 1H), 3.93 (s, 3H), 3.81 (s, 6H), 1.43 (d, J=6.5 Hz, 3H) Column:ChiralPak ®AD (100 × 4.6 mm, 3 μm) Mobile phase: A: CO 2 Mobile phase: B: methanol containing 10 mM NH 3; 30% B isocratic, 160 bar, 4.0 mL / min; R t = 6.65 min [B]
[87] N-(6-{[3-(1-hydroxyethyl)-1H-pyrazol-5-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide or1 = unknown single mirror isomer absolute stereochemistry SFC MS m / z490 [M+H] +; [α] D 22= +33.8° (C 0.1, CHCl 3); 1H NMR (400 MHz, DMSO-d 6) δ 11.99 (s, 1H), 10.94 (br s, 1H), 8.35-8.06 (m, 2H), 7.46 (t, J=8.5 Hz, 1 H), 7.07 (s, 1H), 6.77 (d, J=8.6 Hz, 2H), 6.00 (s, 1H), 5.33 (br d, J=4.9 Hz, 1H), 4.80-4.76 (m, 1H), 3.92 (s, 3H), 3.78 (s, 6H), 1.43 (d, J=6.5 Hz, 3H) Column:ChiralPak ®AD (100 × 4.6 mm, 3 μm) Mobile phase: A: CO 2 Mobile phase: B: methanol containing 10 mM NH 3; 30% B isocratic, 160 bar, 4.0 mL / min; R t = 8.87 min [B]
[88] N-(6-{[5-(4-hydroxybutan-2-yl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 518 [M+H] +; 1H NMR (600 MHz, DMSO- d 6) δ 7.23 (t, J=8.3 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.60 (d, J=8.4 Hz, 2H), 5.48 (s, 1H), 3.78 (s, 3H) 3.61 (s, 7H), 3.39 (q, J=6.6 Hz, 3H), 2.80-2.69 (m, 1H), 1.72-1.53 (m, 2H), 1.11 (br d, J=6.9 Hz, 3H). This is the H-NMR of the sodium salt. [B]
[89] 2,6-Dimethoxy-N-(5-methoxy-6-{[4-methyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide or1 = unknown single mirror isomer absolute stereochemistry LCMS m / z500 [M+H] + 1H NMR (400 MHz, DMSO- d 6) δ 10.93 (s, 1H), 8.07 (br s, 2H), 7.40 (br t, J=8.2 Hz, 1H), 7.32 (br s, 1H), 6.71 (d, J=8.4 Hz, 2H), 5.83 (s, 1H), 4.12-4.05 (m, 1H), 3.99-3.93 (m, 1H), 3.86 (s, 3H), 3.72 (s, 6H), 3.26-3.16 (m, 1H), 2.71-2.63 (m, 1H), 2.07-2.00 (m, 1H), 1.23 (d, J=7.0 Hz, 3H) Separation of PMB-protected enantiomers by chiral SFC: Column: Chiralcel OJ-H SFC (21 × 250 mm, 5 μm); Mobile phase: A: CO 2; Mobile phase: B: methanol + 10 mM NH 3; 22% B isocratic, 120 bar, 80 mL / min; Peak 2. [α] D 22= -10.4° (C 0.1, MeOH) [B]
[90] 2,6-Dimethoxy-N-(5-methoxy-6-{[4-methyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide or1 = unknown single mirror isomer absolute stereochemistry LCMS m / z500 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.93 (br s, 1H), 8.08 (s, 2H), 7.41 (br t, J=8.4 Hz, 1H), 7.33 (br s, 1H), 6.71 (d, J=8.4 Hz, 2H), 5.84 (s, 1H), 4.13-4.05 (m, 1H), 4.01-3.90 (m, 1H), 3.87 (s, 3H), 3.72 (s, 6H), 3.27-3.16 (m, 1H), 2.71-2.63 (m, 1H) 2.07-2.00 (m, 1H), 1.23 (d, J=6.8 Hz, 3H) Separation of PMB-protected enantiomers by chiral SFC: Column: Chiralcel OJ-H SFC (21 × 250 mm, 5 μm); Mobile phase: A: CO 2; Mobile phase: B: methanol + 10 mM NH 3; 22% B isocratic, 120 bar, 80 mL / min; Peak 1. [α] D 22= +6.9° (C 0.1, MeOH) [B]
[91] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(methoxymethyl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 490 [M+H] +; 1H NMR (400 MHz, CDCl 3) δ 7.70 (s, 1H), 7.41 (s, 1H), 7.33 (t, J=8.5 Hz, 1H), 7.07 (br s, 1H), 6.58 (d, J=8.6 Hz, 2H), 5.99 (br s, 1H), 4.45 (s, 2H), 3.92 (s, 3H), 3.85 (s, 6H), 3.36 (s, 3H) [B]
[92] N-{6-[(3-chloro-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 480 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.99 (s, 1H), 8.31 (s, 1H), 7.51-7.47 (m, 2H), 6.74 (d, J=8.5 Hz, 2H), 6.23 (s, 1H), 5.25 (s, 1H), 3.89 (s, 3H), 3.77 (s, 6H) [B]
[93] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(trifluoromethyl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 514 [M+H] +; 1H NMR (600 MHz, DMSO- d 6) δ 12.04 (br s, 2H), 7.43 (s, 1H), 7.38 (t, J=8.4 Hz, 1H), 6.66 (d, J=8.4 Hz, 2H), 6.53 (s, 1H), 5.45 (s, 2H), 3.82 (s, 3H), 3.68 (s, 6H) [B]
[94] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(1-methylcyclopropyl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z500 [M+H] +; 1H NMR (600 MHz, DMSO- d 6) δ 10.94 (s, 1H), 8.08 (br s, 1H), 8.06 (s, 1H), 7.45 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.73 (d, J=8.5 Hz, 2H), 5.87 (br s, 1H), 3.87 (s, 3H), 3.76 (s, 6H), 1.37 (s, 3H), 0.90-0.86 (m, 2H), 0.77-0.73 (m, 2H) [B]
[95] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-3-methoxynaphthalene-2-sulfonamide LCMS m / z 506 [M+H] +; 1H NMR (600 MHz, DMSO- d 6) δ 11.02 (s, 1H), 8.53 (s, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.94 (s, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.74 (br s, 1H), 7.61 (t, J=7.7 Hz, 1H), 7.51 (s, 1H), 7.46 (t, J=7.7 Hz, 1H), 7.32 (s, 1H), 5.76 (s, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 1.88-1.83 (m, 1H), 0.92-0.89 (m, 2H), 0.68-0.65 (m, 2H) [B]
[96] N-(5-aminopentyl)-4-({6-[(3-ethyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}sulfonylamine)-3-methoxybenzamide LCMS m / z 572 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 8.01 (d, J=7.9 Hz, 1H), 7.53 (s, 1H), 7.47 (s, 1H), 7.39 (d, J=9.2 Hz, 1H), 7.25 (s, 1H), 5.90 (s, 1H), 3.97 (s, 3H), 3.90 (s, 3H), 3.42-3.38 (m, 2H), 2.94-2.88 (m, 2H), 2.65 (q, J=7.6 Hz, 2H), 1.73-1.62 (m, 4H), 1.45 (br d, J=6.6 Hz, 2H), 1.29-1.25 (m, 3H) [D]
[97] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-4-fluoro-2-methoxybenzene-1-sulfonamide LCMS m / z 492 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.97 (dd, J=8.8, 6.5 Hz, 1H), 7.49-7.39 (m, 1H), 6.98 (dd, J=10.9, 2.3 Hz, 1H), 6.83 (td, J=8.5, 2.3 Hz, 1H), 5.72 (s, 1H), 4.16 (d, J=3.6 Hz, 3H), 3.89 (s, 3H), 1.94-1.83 (m, 1H), 1.04-0.91 (m, 2 H) 0.78-0.63 (m, 2H) [B]
[98] 2-(Cyclobutyloxy)-N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-6-methoxybenzene-1-sulfonamide LCMS m / z 544 [M+H] +; 1H NMR (400 MHz, chloroform- d) δ 7.46 (d, J=5.5 Hz, 1H), 7.34 (t, J=8.4 Hz, 1H), 6.59 (d, J=8.4 Hz, 1H), 6.50 (d, J=4.5 Hz, 1H), 6.41 (d, J=8.4 Hz, 1H), 5.70 (s, 1H), 4.71 (quintet, J=7.2 Hz, 1H), 4.23 (d, J=3.9 Hz, 3H), 3.90 (s, 3H), 2.46-2.36 (m, 2H), 2.30-2.15 (m, 2H), 1.94-1.79 (m, 3H), 1.73-1.58 (m, 2H), 1.05-0.98 (m, 2H), 0.77 - 0.71 (m, 2H) [B]
[99] 2-Ethoxy-6-methoxy-N-{5-methoxy-6-[(5-methyl-1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 474 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.86 (s, 1H), 10.93 (s, 1H), 8.17 (s, 1H), 8.11 (s, 1H), 7.44 (t, J=8.4 Hz, 1H), 7.39 (s, 1H), 6.73 (dd, J=8.4, 4.1 Hz, 2H), 5.87 (s, 1H), 4.06 (q, J=6.9 Hz, 2H), 3.87 (s, 3H), 3.76 (s, 3H), 2.19 (s, 3H), 1.20 (t, J=7.0 Hz, 3H) [B]
[0100] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-4,5-difluoro-2-methoxybenzene-1-sulfonamide LCMS m / z 510 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 7.86 (t, J=9.4 Hz, 1H), 7.46-7.33 (m, 1H), 7.14 (dd, J= 12.1, 6.1 Hz, 1H), 5.72 (s, 1H), 4.15 (d, J=2.9 Hz, 3H), 3.85 (s, 3H), 1.93-1.85 (m, 1H), 1.02-0.93 (m, 2H), 0.77-0.68 (m, 2H) [B]
[0101] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoro-4-methoxy-1,2-benzoxazol-3-yl}-4-(difluoromethyl)-2-ethoxybenzene-1-sulfonamide LCMS m / z538.2 [M+H] +; 1H NMR (400 MHz, chloroform-d) δ 8.14 (d, J=8.1 Hz, 1H), 7.29 (d, J=5.5 Hz, 1H), 7.12 (d, J=7.9 Hz, 1H), 7.03 (s, 1H), 6.71-6.36 (m, 2H), 5.63 (s, 1H), 4.20-4.11 (m, 5H), 1.81-1.73 (m, 1H), 1.44 (t, J=6.9 Hz, 3H), 0.96-0.90 (m, 2H), 0.68-0.62 (m, 2H) [B]
[0102] 2,6-Dimethoxy-N-{5-methoxy-6-[(pyrimidin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 458 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.64 (s, 1H), 8.61 (d, J=4.8 Hz, 2H), 8.29 (s, 1H), 7.55 (t, J=8.5 Hz, 1H), 7.32 (d, J=8.6 Hz, 2H), 7.16 (s, 1H), 7.03 (t, J=4.8 Hz, 1H), 6.85-6.89 (m, 2H), 6.80 (d, J=8.5 Hz, 2H), 3.84 (s, 3H), 3.75 (s, 6H), 3.70 (s, 3H) [B]
[0103] N-{6-[(5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z500 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.93 (s, 1H), 8.09 (s, 1H), 8.02 (s, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.39 (s, 1H), 6.75 (d, J=8.5 Hz, 2H), 5.70 (s, 1H), 3.87 (s, 3H), 3.77 (s, 3H), 3.76 (s, 6H), 1.90-1.82 (m, 1H), 0.98-0.92 (m, 2H), 0.61-0.56 (m, 2H) [B]
[0104] 2,6-Dimethoxy-N-{5-methoxy-6-[(5-methoxy-1-methyl-1H-pyrazol-3-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 490 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.95 (s, 1H), 8.17 (s, 1H), 8.13 (s, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.75 (d, J=8.5 Hz, 2H), 5.55 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.77 (s, 6H) [B]
[0105] 2,6-Dimethoxy-N-{5-methoxy-6-[(4-methylpyrimidin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 472 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.12 (s, 1H), 8.66 (br s, 1H), 8.46 (d, J=5.1 Hz, 1H), 8.15 (s, 1H), 7.56 (br s, 1H), 7.46 (br t, J=8.4 Hz, 1H), 6.91 (d, J=5.1 Hz, 1H), 6.74 (d, J=8.3 Hz, 2H), 3.93 (s, 3H), 3.75 (s, 6H), 2.43 (s, 3H) [B]
[0106] N-{6-[(4-ethylpyrimidin-2-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 486 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 8.62 (s, 1H), 8.47 (d, J=5.1 Hz, 1H), 8.10 (s, 1H), 7.48 (br s, 1H), 7.39 (br t, J=8.3 Hz, 1H), 6.91 (d, J=5.1 Hz, 1H), 6.70 (d, J=8.5 Hz, 2H), 3.92 (s, 3H), 3.71 (s, 6H), 2.71 (q, J=7.6 Hz, 2H), 1.92 (s, 1H), 1.26 (t, J=7.6 Hz, 3H) [B]
[0107] N-{6-[(5-ethylpyrimidin-2-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 486 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.12 (br s, 1H), 8.57 (br d, J=2.5 Hz, 1H), 8.50 (s, 2H), 8.13 (br s, 1H), 7.45-7.55 (m, 1H), 7.44-7.34 (m, 1H), 6.71 (br d, J=8.0 Hz, 2H), 3.92 (s, 3H), 3.71 (br s, 6H), 2.59-2.53 (m, 2H), 1.20 (t, J=7.6 Hz, 3H) [B]
[0108] N-{6-[(4,6-dimethylpyrimidin-2-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 486 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.14 (s, 1H), 8.64 (br s, 1H), 8.00 (br s, 1H), 7.45 (br s, 1H), 7.38 (t, J=1.0 Hz, 1H), 6.78 (s, 1H), 6.70 (br d, J=8.4 Hz, 2H), 3.92 (s, 3H), 3.70 (br s, 6H), 2.38 (s, 6H) [B]
[0109] N-{6-[(3-Benzyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 536 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.04 (s, 1H), 10.93 (s, 1H), 8.17 (s, 1H), 8.13 (s, 1H), 7.47 (t, J=8.5 Hz, 1H), 7.40 (s, 1H), 7.34-7.19 (m, 5H), 6.74 (d, J=8.5 Hz, 2H), 5.86 (d, J=1.8 Hz, 1H), 3.92 (s, 2H), 3.86 (s, 3H), 3.76 (s, 6H) [B]
[0110] 2,6-Dimethoxy-N-{5-methoxy-6-[(5-methylpyrimidin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 472 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.04 (br s, 1H), 8.52 (br s, 1H), 8.40 (s, 2H), 8.07 (s, 1H), 7.47 (br s, 1H), 7.37 (br t, J=8.4 Hz, 1H), 6.66 (d, J=8.4 Hz, 2H), 3.85 (s, 3H), 3.67 (s, 6H), 2.12 (s, 3H) [B]
[0111] 2,6-Dimethoxy-N-{5-methoxy-6-[(pyridin-2-yl)amino]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide LCMS m / z 457 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.05 (br s, 1H), 8.75 (br s, 1H), 8.51 (br s, 1H), 8.27 (br d, J=4.5 Hz, 1H), 7.67-7.60 (m, 1H), 7.46 (br d, J=13.1 Hz, 1H), 7.27 (br d, J=7.5 Hz, 1H), 6.87 (br t, J=5.2 Hz, 1H), 6.73 (br d, J=8.3 Hz, 2H), 3.91 (s, 3H), 3.75 (br s, 6H) [B]
[0112] N-{6-[(5',6'-dihydrospiro[cyclopropane-1,4'-pyrrolo[1,2- b]pyrazole]-2'-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 512 [M+H] +; 1H NMR (600 MHz, CD 3OD) δ 7.68 (s, 1H), 7.45 (br t, J=8.3 Hz, 1H), 7.30 (s, 1H), 6.72 (br d, J=8.4 Hz, 2H), 4.19 (br t, J=7.1 Hz, 2H), 3.94 (s, 3H), 3.84 (s, 6H), 2.56 (br t, J=7.1 Hz, 2H), 1.03 (br d, J=12.2 Hz, 4H) [B]
[0113] N-{6-[(5-cyclopropyl-1-ethyl-1H-pyrazol-3-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 514 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 10.89 (s, 1H), 7.64 (s, 1H), 7.41-7.37 (m, 1H), 6.66 (d, J=8.5 Hz, 2H), 6.28 (s, 1H), 5.76 (s, 1H), 3.80 (s, 3H), 3.76 (q, J=7.3 Hz, 2H), 3.69 (s, 6H), 1.79-1.74 (m, 1H), 1.12 (t, J=7.2 Hz, 3H), 0.78-0.72 (m, 2H), 0.59-0.54 (m, 2H) [B]
[0114] 2,6-Dimethoxy-N-(5-methoxy-6-{[3-(2-methylpropyl)-1H-pyrazol-5-yl]amino}-1,2-benzoxazol-3-yl)benzene-1-sulfonamide LCMS m / z 502 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.86 (br s, 1H), 10.93 (s, 1H), 8.15 (br s, 1H), 8.08 (s, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.41 (s, 1H), 6.75 (d, J=8.6 Hz, 2H), 5.88 (s, 1H), 3.88 (s, 3H), 3.77 (s, 6H), 1.94-1.81 (m, 1H), 0.90 (d, J=6.6 Hz, 6H) [B]
[0115] N-(6-{[3-(Difluoromethyl)-1H-pyrazol-5-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 496 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 12.88 (s, 1H), 10.89 (br s, 1H), 8.11 (s, 1H), 7.45-7.36 (m, 2H), 7.07 (br t, J=54.3 Hz, 1H), 6.67 (d, J=8.5 Hz, 2H), 6.34 (s, 1H), 3.83 (s, 3H), 3.69 (s, 6H) [B]
[0116] N-{6-[(3-tributyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 502 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 10.93 (s, 1H), 8.16 (s, 1H), 8.06 (s, 1H), 7.47 (t, J=8.5 Hz, 1H), 7.40 (s, 1H), 6.75 (d, J=8.5 Hz, 2H), 5.88 (s, 1H), 3.88 (s, 3H), 3.77 (s, 6H), 1.27 (s, 9H) [B]
[0117] N-(6-{[5-(3,3-difluorocyclobutyl)-1H-pyrazol-3-yl]amino}-5-methoxy-1,2-benzoxazol-3-yl)-2,6-dimethoxybenzene-1-sulfonamide LCMS m / z 536 [M+H] +; 1H NMR (DMSO- d 6, 400 MHz) δ 12.11 (s, 1H), 10.94 (s, 1H), 8.14 (s, 1H), 7.47 (t, J=8.4 Hz, 1H), 7.42 (s, 1H), 6.75 (d, J=8.5 Hz, 2H), 6.06 (s, 1H), 3.89 (s, 3H), 3.77 (s, 6H), 3.07-2.94 (m, 2H), 2.78-2.67 (m, 3H), 2.34-2.33 (m, 1H) [B]
[0118] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-(pyridin-2-yl)benzene-1-sulfonamide LCMS m / z 563 [M+H] +; 1H NMR (400 MHz, methanol-d 4) δ 8.67-8.63 (m, 1H), 8.00-7.91 (m, 2H), 7.66 (br s, 1H), 7.47-7.42 (m, 1H), 7.38-7.31 (m, 3H), 5.77 (s, 1H), 4.00-3.96 (m, 9H), 1.96-1.86 (m, 1H), 1.02-0.96 (m, 2H), 0.79-0.72 (m, 2H) [E]
[0119] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-3,5-dimethoxy[1,1'-biphenyl]-4-sulfonamide LCMS m / z 562 [M+H] +; 1H NMR (400 MHz, CD 3OD) δ 7.62 (d, J=7.3 Hz, 2H), 7.55-7.49 (m, 1H), 7.46-7.41 (m, 2H), 7.40-7.35 (m, 1H), 7.29 (s, 1H), 6.87 (s, 2H), 5.75 (s, 1H), 3.93 (s, 3H), 3.84 (s, 6H), 1.92-1.85 (m, 1H), 0.99-0.93 (m, 2H), 0.75-0.71 (m, 2H) [E]
[0120] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-(pyridin-4-yl)benzene-1-sulfonamide LCMS m / z 563 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.89 (s, 1H), 11.09 (s, 1H), 8.70-8.65 (m, 2H), 8.13 (s, 1H), 8.06 (s, 1H), 7.82-7.79 (m, 2H), 7.42 (s, 1H), 7.08 (s, 2H), 5.78 (s, 1H), 3.89 (s, 9H), 1.90-1.79 (m, 1H), 0.94-0.86 (m, 2H), 0.69-0.62 (m, 2H) [E]
[0121] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-(1,3-thiazol-4-yl)benzene-1-sulfonamide LCMS m / z 569 [M+H] +; 1H NMR (400 MHz, DMSO- d 6) δ 11.90 (br s, 1H), 11.02 (s, 1H), 9.22 (d, J=1.8 Hz, 1H), 8.49 (d, J=1.9 Hz, 1H), 8.12 (br s, 1H), 8.09-8.01 (m, 1H), 7.43(s, 1H), 7.33 (s, 2H), 5.77 (d, J=7.5 Hz, 1H), 3.90-3.84 (m, 9H), 1.85 (ddd, J=4.9, 8.4, 13.4 Hz, 1H), 0.98-0.90 (m, 2H), 0.71-0.63 (m, 2H) [E]
[0122] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-(1-methyl-1H-pyrazol-3-yl)benzene-1-sulfonamide LCMS m / z 566 [M+H] +; 1H NMR (400 MHz, CDCl 3) δ 7.68 (s, 1H), 7.46 (s, 1H), 7.38 (d, J=2.3 Hz, 1H), 7.01 (s, 3H), 6.53 (d, J=2.4 Hz, 1H), 5.70 (s, 1H), 3.97 (s, 6H), 3.95 (s, 6H), 1.87-1.80 (m, 1H), 1.00-0.95 (m, 2H), 0.75-0.71 (m, 2H) [E]
[0123] N-{6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-5-methoxy-1,2-benzoxazol-3-yl}-2,6-dimethoxy-4-(1-methyl-1H-pyrazol-4-yl)benzene-1-sulfonamide LCMS m / z 566 [M+H] +; 1H NMR (400 MHz, CDCl 3) δ 7.74 (d, J=9.4 Hz, 2H), 7.63 (s, 1H), 7.46 (s, 1H), 6.98 (s, 1H), 6.63 (s, 2H), 5.69 (s, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.93 (s, 6H), 1.90-1.82 (m, 1H), 1.02-0.96 (m, 2H), 0.75-0.70 (m, 2H) [E]
[0269] [intermediate] [O] [:] [5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H, - ] [Pyrazole] [-3-] [amine]
[0270] [ , N , ] ['-(5-] [Ethyl] [-1 , H , - ] [Pyrazole] [-3-] [base] [)- , N , , , N , - ] [Dimethylformamidine] [(O1)] [:] A solution of 5-ethyl-1H-pyrazol-3-amine in DMF-DMA was heated at 90 °C for 15 h, after which the reaction was cooled, concentrated and purified by silica gel chromatography (eluting with 0-10% methanol in DCM) to give [O1](4.2 g,94%). LCMS m / z167 [M+H]+.
[0271] [ , N , ] ['-(5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H , - ] [Pyrazole] [-3-] [base] [)- , N , , , N , - ] [Dimethylformamidine] [(O2)] [:] Sodium hydride (3.3 g, 81.6 mmol, 60% dispersion in mineral oil) was added portionwise to N'-(5-ethyl-1H-pyrazol-3-yl)-N,N-dimethylformamidine (
[01] ) (11.3 g, 67.9 mmol) in anhydrous THF (100 mL) was added to a stirred solution of [2-(chloromethoxy)ethyl](trimethyl)silane (17.0 g, 18.0 mL, 102 mmol) and the reaction was stirred at room temperature for two hours. LCMS indicated that most of the starting material was consumed, and the reaction was diluted with EtOAc (100 mL) and washed with saturated aqueous ammonium chloride (100 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated to give 2-(chloromethoxy)ethyl)-(trimethyl)silane as a brown oil. [O2](18.7 g,93%). LCMS m / z297.1 [M+H]+.
[0272] [5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H , - ] [Pyrazole] [-3-] [amine] [(] [Intermediate] [O)] [:] Solid NaHCO 3 (17.1 g, 204 mmol) was added to a stirred solution of hydrazine hydrochloride (14.0 g, 204 mmol) in a mixture of methanol (140 mL) / H 2 O (10 mL), and the reaction was stirred at room temperature for 10 minutes. Next, N'-(5-ethyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)-N,N-dimethylformamidine (
[02] ) (20.2 g, 68.0 mmol) and acetic acid (4.1 g, 3.9 mL, 68.0 mmol) were added and the reaction was stirred at 50°C for seven hours. LCMS indicated that the starting material was consumed, and the reaction was concentrated, diluted with EtOAc (200 mL), washed with saturated aqueous NaHCO 3 solution (100 mL) and brine (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give a residue, which was purified by silica gel chromatography (eluting with 0-50% EtOAc in petroleum ether) to give 4-(4-(4-oxo-1-yl)-4-nitropropene as a yellow oil. [Intermediate] [O](5.3 g,32%). LCMS m / z242 [M+H] +; 1H NMR (400 MHz, chloroform- d) δ 5.49 (s, 1H), 5.20 (s, 2H), 3.60-3.53 (m, 2H), 2.61 (q, J=7.4 Hz, 2H), 1.24 (t, J=7.6 Hz, 3H), 0.93-0.86 (m, 2H, -0.01 (s, 9H).
[0273] [Intermediate] [P] [:] [ , N , ] [ , 6 , ] [-(5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H , - ] [Pyrazole] [-3-] [base] [)-5-] [Methoxy] [-1,2-] [Benzoazole] [-3,6-] [Diamine]
[0274] [4-] [bromine] [-2-] [fluorine] [-5-] [Methoxybenzaldehyde] [(P1)] [:] To a cooled (0 °C) solution of 2-fluoro-5-methoxybenzaldehyde (25.0 g, 162.2 mmol) in chloroform (500 mL) was added bromine (51.8 g, 16.6 mL, 324.0 mmol) dropwise under a dry nitrogen atmosphere. After the addition was complete, the black solution was warmed to room temperature and stirred for 5 days. At this time, the red solution was poured into saturated aqueous NaHCO 3 solution (200 mL) and extracted with DCM (3×200 mL). The combined organic layers were washed with H 2 O (100 mL), dried over sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (eluting with 0-10% EtOAc in petroleum ether) to give 24 g of solid material, which was confirmed to be 4-bromo-2-fluoro-5-methoxybenzaldehyde ( [P1]) and a 2:1 mixture of 2-fluoro-5-methoxybenzaldehyde. Triturate with petroleum ether (50 mL) and filter to obtain a light yellow solid. [P1](6.40 g,17%). 1H NMR (400 MHz, chloroform- d) δ 10.39 (s, 1H), 7.23-6.95 (m, 2H), 3.95 (s, 3H).
[0275] [ , N , ] [-[( , E , )-(4- ] [bromine] [-2-] [fluorine] [-5-] [Methoxyphenyl] [)] [Methylene] []] [Hydroxyamine] [(P2)] [:] to 4-bromo-2-fluoro-5-methoxybenzaldehyde ( [P1]) (6.4 g, 27.5 mmol) and potassium acetate (5.4 g, 54.9 mmol) in acetic acid (40 mL) was added hydroxylamine hydrochloride (3.8 g, 54.9 mmol). The reaction was then refluxed at 120 °C for 4 hours after which LCMS indicated that the starting material was consumed and two new products were detected. The reaction was cooled, concentrated and diluted with saturated aqueous NaHCO 3 solution (200 mL). The mixture was extracted with EtOAc (3×50 mL) and the organic extracts were dried over sodium sulfate, filtered, concentrated and purified by silica gel chromatography (eluting with 0-10% EtOAc in petroleum ether) to give 4-bromo-2-fluoro-5-methoxybenzonitrile ( [P3], 2.0 g, 32%) (for analytical data see the following experiment), followed by a more polar white solid [P2](4.0 g,59%). [P2], 1H NMR (400 MHz, chloroform- d ) δ 8.24 (s, 1H), 7.27 (d, J=9.1 Hz, 1H), 7.22-7.16 (m, 1H), 3.84 (s, 3H).
[0276] [4-] [bromine] [-2-] [fluorine] [-5-] [Methoxybenzonitrile] [(P3)] [:] N-[(E)-(4-bromo-2-fluoro-5-methoxyphenyl)methylene]hydroxylamine ( To a solution of [P2]) (3.5 g, 14.1 mmol) in ACN (70 mL) was added TEA (1.43 g, 14.1 mmol) followed by dimethyl acetylenedicarboxylate (DMAD, 4.1 g, 28.2 mmol). The resulting crude reaction mixture was stirred at room temperature for 25 hours after which TLC (petroleum ether: EtOAc 3 / 1) indicated that the starting material was consumed and a less polar product was formed. The reaction was concentrated and purified by silica gel chromatography (eluting with 0-30% EtOAc in petroleum ether) to give [P3](3.0 g,81%). 1H NMR (400 MHz, chloroform- d) δ 7.48 (d, J=7.9 Hz, 1H), 7.03 (d, J=5.3 Hz, 1H), 3.92 (s, 3H).
[0277] [4-[(5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H , - ] [Pyrazole] [-3-] [base] [)] [Amine] []-2-] [fluorine] [-5-] [Methoxybenzonitrile] [(P4)] [:] Argon was bubbled through 4-bromo-2-fluoro-5-methoxybenzonitrile ( [P3]) (2.0 g, 8.7 mmol), 5-ethyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-amine (2.5 g, 10.3 mmol, [intermediate] [0]) and cesium carbonate (8.4 g, 25.8 mmol) in dioxane (40 mL) were added for 1 min, followed by the addition of Pd 2 (dba) 3 (0.79 g, 0.86 mmol) and Xantphos (1.5 g, 2.6 mmol). The resulting mixture was heated at 80 °C for 18 h, after which LCMS showed that the starting material was consumed. The reaction was cooled and diluted with EtOAc (200 mL), filtered and concentrated to give a brown gum, which was purified by silica gel chromatography (eluting with 0-10% EtOAc in petroleum ether) to give [P4](3.5 g,74%). LCMS m / z391 [M+H]+.
[0278] [ , N , ] [ , 6 , ] [-(5-] [Ethyl] [-1-{[2-(] [Trimethylsilyl] [)] [Ethoxy] []] [methyl] [}-1 , H , - ] [Pyrazole] [-3-] [base] [)-5-] [Methoxy] [-1,2-] [Benzoazole] [-3,6-] [Diamine] [(] [Intermediate] [P)] [:] A solution of acetohydroxamic acid (2.3 g, 30.1 mmol) and potassium tributylate (3.4 g, 30.1 mmol) in anhydrous DMF (60 mL) was stirred under nitrogen for 30 minutes. To the resulting white mixture was added 4-[(5-ethyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)amino]-2-fluoro-5-methoxybenzonitrile ( [P4]) (3.9 g, 10.0 mmol) in anhydrous DMF (20 mL). After addition, the crude reaction mixture was stirred at 80 °C for 16 h. LCMS indicated about 35% of the desired product was formed and starting material was still present. The reaction was cooled to room temperature before acetohydroxamic acid (2.3 g, 30.1 mmol) and potassium tert-butoxide (3.4 g, 30.1 mmol) were added again. After purging with nitrogen, the reaction was stirred at 80 °C for 40 h. LCMS indicated about 55% of the desired product was formed and starting material was still present. The reaction was cooled to room temperature before acetohydroxamic acid (2.3 g, 30.1 mmol) and potassium tert-butoxide (3.4 g, 30.1 mmol) were added again. After purging with nitrogen, the reaction was stirred at 80 °C for 16 h and LCMS indicated about 80% of the desired product was formed. The reaction was stopped, cooled to room temperature, and concentrated in vacuo to remove DMF and give a residue, which was dissolved in EtOAc (250 mL). This...
Claims
1. A compound of formula (V) or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or a hydrate of any of the foregoing, wherein: R3 is hydrogen, halogen, C1-C4 alkyl, -CH2OCH3, methoxy, -C(O)OH, -C(O)OCH3, C3-C5 cycloalkyl, 4-6 heterocyclic alkyl, or benzyl, wherein the C1-C4 alkyl is substituted with -OH or one, two, or three fluorine atoms as appropriate, the methoxy is substituted with one, two, or three fluorine atoms as appropriate, and the C3-C5 cycloalkyl is substituted with methyl or one or two fluorine atoms as appropriate; R4 is hydrogen or a C1-C3 alkyl substituted with -OH as appropriate; R5 is hydrogen, halogen, cyano, C1-C3 alkyl, or -C(O)NH2; R6 is hydrogen, halogen, C1-C4 alkyl, -O-(C1-C4 alkyl) or -O-(C3-C5 cycloalkyl), wherein the -O-(C1-C4 alkyl) is substituted with one, two, or three fluorine atoms as appropriate; R7 is hydrogen, C1-C4 alkyl, or methoxy; R8 is -(CHR11)n-4-8-membered heterocyclic alkyl, 5-8-membered heteroaryl, or 9-10-membered heteroaryl, wherein the -(CHR11)n-4-8-membered heterocyclic alkyl is optionally substituted by one, two, or three independently selected substituents from the following: syloxy group, one or two methyl substituents, ethyl group, -CHF2, -CF3, -CH2CHF2, -CH2CF3, methoxy group, 4-6-membered heterocyclic alkyl, and one or two fluorine atoms, wherein the 5-8-membered heteroaryl is optionally substituted by the following: syloxy group, cyano group, methyl group, -[CH(R16)]p[N(CH3)2], or a 6-membered heterocyclic alkyl group optionally substituted with methyl, wherein the 9-10-membered heteroaryl is optionally substituted with methyl, R10 is hydrogen or C1-3 alkyl; R11 is hydrogen or methyl; R16 is hydrogen or methyl; n is 0 or 1; and p is 0 or 1.
2. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R3 is hydrogen, chlorine, C1-C4 alkyl, -CHF2, -CF3, -CF2CH3, -CH2-CF3, -CH2OCH3, methoxy, -O-CHF2, -C(O)OH, -C(O)OCH3, bicyclo[1.1.1]pent-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, piperidinyl, or benzyl, wherein the C1-C4 alkyl group is substituted with -OH as appropriate, and wherein the cyclopropyl group is substituted with methyl or two fluorine atoms as appropriate.
3. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R3 is cyclopropyl.
4. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R4 is hydrogen, methyl, ethyl, or isopropyl.
5. The compound of claim 4 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R4 is hydrogen.
6. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R5 is hydrogen, fluorine, cyano, methyl, ethyl, or -C(O)NH2.
7. The compound of claim 6 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R5 is hydrogen.
8. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R3 is cyclopropyl, R4 is hydrogen, and R5 is hydrogen.
9. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R6 is hydrogen, bromine, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, -O-isopropyl, -O-CH2CHF2, -O-CF3, -O-cyclobutyl, or -O-cyclopropyl.
10. The compound of claim 9 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R6 is a methoxy group.
11. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R7 is hydrogen, methyl, ethyl, or methoxy.
12. The compound of claim 11 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R7 is a methoxy group.
13. The compound of claim 11 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R7 is hydrogen.
14. The compound of claim 1 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein R8 is azirrobutyl, oxacyclobutyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropiperanyl, piperidinyl, dioxacyclohexyl, pyriminyl, -CH(CH3)-azirrobutyl, -CH2-pyrrolidinyl, -CH(CH3)-pyriminyl, azispiro[3.4]octyl, imidazolyl, pyrazolyl, triazolyl, acezolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrimidinyl, pyridinyl, 6,7-dihydro-4H-pyrazolo[5,1-c][1,4]acezolyl, or hexahydropyridolo[3,4-d]pyrimidinyl. The aziridine group is optionally substituted with a methoxy, fluorine, or tetrahydrofuran group; the pyrrolidyl group is optionally substituted with one substituent selected from oxy, methyl, ethyl, -CH2CHF2, methoxy, tetrahydrofuran, and fluorine, or with two or three independently selected substituents selected from oxy, methyl, and fluorine; the dioxanecyclohexyl group is optionally substituted with two methyl substituents; the piperidinyl group is optionally substituted with one substituent selected from methyl, ethyl, -CH2CHF2, -CH2CF3, aziridine, and tetrahydrofuran, or with two or three substituents selected from methyl and one or two fluorine atoms; the piperidinyl group is optionally substituted with methyl or two substituents selected from oxy and methyl; the aziridine group is optionally substituted with methyl or ethyl; the -CH2-aziridine group is optionally substituted with methyl or one or two fluorine atoms; and the -CH(CH3)-aziridine group is optionally substituted with one fluorine atom. The -CH2-pyrrolidyl group is optionally substituted with -CHF2, -CF3, two methyl substituents, or one or two fluorine atoms; the -CH2-piperidinyl group is optionally substituted with methyl, methoxy, or one or two fluorine atoms; the pyrazolyl group is optionally substituted with methyl; the triazolyl group is optionally substituted with methyl; the imidazoleyl group is optionally substituted with methyl; the pyridinyl group is optionally substituted with one or two substituents selected from methyl and oxy groups; the pyridyl group is optionally substituted with methyl or -N(CH3)2; the pyrimidinyl group is optionally substituted with methyl, cyano, -CH2[N(CH3)2], -N(CH3)2, -CH(CH3)[N(CH3)2], or a methyl-substituted piperyl; the pyridyl group is optionally substituted with oxy or methyl; and the hexahydropyrido[3,4-d]pyrimidinyl group is optionally substituted with methyl.
15. A compound or its tautomer or stereoisomer, or a pharmaceutically acceptable salt of the compound or its tautomer or stereoisomer, or a hydrate of any of the foregoing, wherein the compound is selected from the group consisting of:
16. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
17. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
18. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
19. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
20. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers or a hydrate of any of the foregoing, wherein the compound is:
21. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
22. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
23. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers, or a hydrate of any of the foregoing, wherein the compound is:
24. The compound of claim 15 or its tautomers or stereoisomers, or a pharmaceutically acceptable salt of the compound or its tautomers or stereoisomers or a hydrate of any of the foregoing, wherein the compound is:
Citation Information
Patent Citations
Fused isoxazolyl compounds as KAT6a inhibitors
WO2022243983A1
